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CHAPTER I
INTRODUCTION
Methamphetamine (Meth) is a potent, widely-used stimulant and its use is
met with high rates of relapse without an effective, FDA-approved
pharmacotherapy (Brecht et al. 2000;Elkashef et al. 2008;United Nations Office
on Drugs and crime 2009). One factor that contributes to craving and relapse is
exposure to environmental or contextual cues associated with previous Meth use
(Hartz et al. 2001;O'Brien et al. 1992;Tolliver et al. 2010). With repeated Meth
use, the rewarding properties of the drug become associated with the
environmental cues in which they are taken. These contextual cues then become
extremely salient to the Meth user. This associative learning can be studied in
the laboratory with humans and rodents using conditioned place preference
(CPP), which employs classical conditioning to measure the rewarding properties
of abused drugs (Childs and deWit H. 2009;Tzschentke 1998;Tzschentke 2007).
Another way to assess Meth-induced brain adaptations following repeated Meth
use is the enhanced motor activity (termed motor sensitization) that is elicited
with subsequent drug injections. This behavior endures for long periods of time
after cessation from drug administration (McDaid et al. 2007). It is hypothesized
that the neuronal adaptations associated with this motor sensitization model
aspects of the brain changes that reflect drug craving (Robinson and Berridge
1993).
1
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The current dissertation project utilizes Meth-induced CPP and motor
sensitization to elucidate the neuronal underpinnings of addiction.
Repeated drug stimuli are hypothesized to “hijack” normal neuronal mechanisms
of learning and memory processes, resulting in abnormal, addictive behaviors
(Kelley 2004). The glutamate transmitter system is an important player for
learning and memory processing as well as stimulant addiction. Glutamate
activates both ionotropic and metabotropic receptors. Ionotropic receptors
rapidly increase neuronal spiking, whereas metabotropic glutamatergic receptors
(mGluRs) modulate and fine tune neuronal excitability. mGluRs are divided into
three groups based on pharmacology, sequence homology and associated
signaling mechanisms (Conn and Pin 1997). The group I subtype 5 receptor
(mGluR5) is highly expressed in brain regions important for stimulant reward
(Lu et al. 1999;Testa et al. 1995). The mGluR5 is important for several phases of
behaviors induced by amphetamines, including Meth, such as acquisition
(Miyatake et al. 2005;Osborne and Olive 2008) and expression (Gass et al.
2009;Herzig et al. 2005) of associative learning. However, the role of these
receptors in the maintenance of Meth-induced reward remains unknown. This is
an important clinical issue, as treatment strategies need to be effective following
the molecular adaptations and behavioral changes have occurred. Withdrawal
time after the last drug administration influences drug-induced behaviors as well
as underlying molecular adaptations. For example, rodent models of addiction
including opiate-induced conditioned place preference and stimulant- induced
self-administration demonstrate that cue-induced drug seeking can “incubate”
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over a time frame of two weeks to three months after the cessation of drug
treatment (Li et al. 2008;Lu et al. 2004a;Lu et al. 2004b). Furthermore, the
glutamate receptor systems, including the mGluR5, also are up-regulated in
reward-related brain regions following extended (but not short term) withdrawal
from cocaine administration (Ghasemzadeh et al. 2009a;Ghasemzadeh et al.
2009b). Therefore, we sought to determine if the mGluR5 was important for
long-term maintenance of Meth-induced associative learning.
Substance use disorders occur with a higher frequency in the
schizophrenia patient population than in the general United States population
(Compton et al. 2005). Moreover, the use of amphetamines exacerbates
psychosis in schizophrenia patients (Angrist et al. 1980;Janowsky and Davis
1976). Developmental rodent models of schizophrenia (e.g., isolation rearing and
neonatal ventral hippocampal lesions) demonstrate an enhanced sensitivity to
stimulant-induced motor sensitization (Chambers and Taylor 2004;Dai et al.
2004) and self-administration (Brady et al. 2008;Chambers and Self 2002), but a
deficit in stimulant-induced associative learning that are likely due to cognitive
deficits incurred with this disorder (Le et al. 2002;Wongwitdecha and Marsden
1995). These observations likely reflect the fact that the neurocircuitry
implicated in schizophrenia overlaps with that targeted by stimulants (Pierce and
Kalivas 1997;Swerdlow et al. 2001). Therefore, we hypothesized that deficits
associated with schizophrenia, such as sensorimotor gating, would negatively
correlate with that of Meth-induced associative learning (i.e., greater deficits in
sensorimotor gating would correlate with less preference for the context
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associated with the rewarding properties of Meth). Thus, we used both
pharmacological and developmental (i.e. isolation rearing) models of
schizophrenia in conjunction with Meth-induced CPP to model the co-morbid
condition of the schizophrenia individual with stimulant use disorder. We
further sought to determine the effects of augmenting mGluR5 signaling on the
different phases of Meth-induced CPP and motor sensitization in isolation reared
rats (i.e., development and expression).
The overall goal of this dissertation is to expand our knowledge of the
role of the mGluR5 system in Meth addiction and in the co-morbidity of
schizophrenia and Meth substance use disorder. This project is subdivided into
two major parts with individual, yet related hypotheses. Part 1 was designed to
determine if the mGluR5 is necessary for the maintenance of Meth-induced
associative learning, and if this was associated with an up-regulation of these
receptors in reward-related brain regions. Part 2 was designed to ascertain if
deficits associated with schizophrenia are directly correlated with Meth-induced
associative learning and if mGluR5 receptor activation enhances Meth-induced
CPP in a developmental rodent model of schizophrenia.

CHAPTER II
LITERATURE REVIEW

Methamphetamine substance use disorder and rodent behavioral
models
Methamphetamine (Meth) was given the title “America’s most dangerous
drug” by Newsweek Magazine in August 2005 by David J. Jefferson. In the same
year, it was estimated that Meth use resulted in 900 deaths and the loss of
44,000 quality of life years (Nicosia et al. 2009). The estimated total cost to the
United States in 2005, including factors such as drug treatment, criminal justice,
and child endangerment reached $23.5 billion (Nicosia et al. 2009). Though
there has been a decline in prevalence of Meth use since 2005, Meth remains the
third most widely abused drug in the world (United Nations Office on Drugs and
crime 2009). Meth use is a problem of grave concern with high health, social,
and economic costs that merit scientific investigation.

5
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Meth is a powerfully rewarding substance due to its ability to greatly
increase brain monoamines. Meth and other amphetamines act as a substrate
for plasma membrane monoamine transporters including dopamine (DAT),
serotonin (SERT) and norepinephrine (NET), thereby inhibiting the reuptake of
these transmitters (Bonisch 1984;Fleckenstein et al. 1999;Han and Gu
2006;Haughey et al. 2000;Jones et al. 1998;Liang and Rutledge 1982;Zaczek et
al. 1991). Amphetamines bind to vesicle monoamine transporters (VMAT)
located on the monoamine containing synaptic vesicles (Partilla et al. 2006;Peter
et al. 1994). VMATs use secondary active transport via a coupled proton pump to
transport monoamine transmitters into the vesicle (Schuldiner et al. 1998).
Amphetamines are weak bases, and upon entering the vesicle amphetamines
increase the vesicular pH and reduce the vesicular/cytoplamic pH gradient, thus
reducing the energy barrier for sequestered transmitter to be released into the
cytosol (Sulzer et al. 1993;Sulzer et al. 1995;Sulzer and Rayport 1990). This
results in a decrease in monoamine transmitter in the vesicle, an increase in
transmitter in the cytosol, and, through reverse transport at the monoamine
transporters, an increase in transmitter release to the extracellular synaptic cleft
(Sulzer et al. 1995). Amphetamines also act as competitive monoamine oxidase
inhibitors, which are yet another means of increasing monoamine concentration
within the cell by hindering catabolism (Mantle et al. 1976;Scorza et al. 1997).
Thus, through its action at monoamine transporters, VMATs, and monoamine
oxidase, Meth acts to increase monoamine neurotransmitters released into the
synaptic cleft.
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Meth (international union of pure and applied chemistry (IUPAC)
nomenclature = N-methyl-1-phenyl-propan-2-amine) differentiates itself from
amphetamine (Amph, IUPAC nomenclature = (±)-1-phenyl-propan-2-amine) in
having an additional methyl group that allows for greater brain penetration and
more persistent effects (NIDA Research Report Methamphetamine Abuse and
Addiction 2006). Moreover, the rates of illicit Meth use are reported to be higher
than that of Amph (Colliver 2006). In humans, the half life of Meth is
approximately 10 hr (Cook et al. 1993;Harris et al. 2003;Newton et al. 2005) and
the subjective “high” occurs rapidly after approximately 10min (Perez-Reyes et al.
1991). The subjective effects of Meth in humans include arousal, euphoria,
relaxation, anxiety, talkativeness, paranoia, and hallucinations (Bell 1973;Martin
et al. 1971). Meth is a sympathomimetic that produces physiological effects
including increases in heart rate, blood pressure, and respiration rate (Ho et al.
2009;Martin et al. 1971) and a propensity for stroke (Perez, Jr. et al.
1999;Rothrock et al. 1988).
The laboratory rat is often used to model human Meth addiction, and the
pharmacodynamics of Meth in the rat emulates the human; however, the
pharmacokinetics of Meth is quite different. In the rat, the half life is of Meth is
70min after an intravenous administration (Cho et al. 2001;Riviere et al. 1999).
After intraperitoneal (i.p.) administration, peak locomotor activity following an
acute, low dose of Meth (1-2mg/kg) occurs at approximately 30min (Shoblock et
al. 2003). The Napier laboratory reports similar peak motor effects for an acute
dose of subcutaneously (s.c.) administered Meth (1mg/kg) and that this motor
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activity is enhanced following repeated treatment (2.5mg/kg, s.c. per day for 5
days) (McDaid et al. 2007). These pharmacokinetic factors must be considered
in experimental design using rodent models of addiction.
The rewarding subjective effects of Meth can be associated with the
context in which they are administered. Presentation of cues associated with
drugs, such as pictures of people taking drugs or drug paraphernalia produce an
enhanced subjective and physiological state similar to that experienced with drug
taking (Carter and Tiffany 1999;Tolliver et al. 2010). Moreover, human imaging
data demonstrate that exposure to drug-related cues can enhance activity in
reward-related brain regions of stimulant addicts (Breiter et al. 1997;Childress et
al. 1999;Grant et al. 1996;Kilts et al. 2004;Maas et al. 1998), and lead to craving
and relapse in the withdrawn addict. Newton and colleagues recently reported
that 15% of Meth-dependent individuals surveyed relapse due to cravings and
44% stated that they relapsed because they wanted “to get high” (Newton et al.
2009). Though drug craving may not be the only factor contributing to relapse,
craving in Meth-dependent individuals has been shown to predict Meth use
(Hartz et al. 2001). The presentation of drug cues to stimulant withdrawn
addicts increases measures of craving and drug-taking behavior in a clinical
laboratory setting (Hogarth et al. 2010;Mucha et al. 1998;Panlilio et al.
2005;Tolliver et al. 2010). Cues associated with stimulant use produce a strong
psychological and physiological response in stimulant abusers that can lead to
craving and relapse. Therefore, uncoupling these contextual drug cues with the
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rewarding properties of Meth may provide an important means of relapse
prevention in stimulant use disorders.
A behavioral model that measures the association between drug-paired
cues and the rewarding effects of abused drugs is conditioned place preference
(CPP). CPP implements classical or Pavlovian conditioning (Pavlov 1927). In
this paradigm, the unconditioned stimulus (UCS; e.g., Meth) is paired with a
neutral environmental context, termed the conditioned stimulus (CS), during a
process called conditioning. After conditioning, the subject demonstrates that
the enhanced salient properties of the UCS are transferred to the CS, and in CPP
this process is demonstrated by the subject preferring the drug-paired context in
the absence of the UCS. This is termed expression of CPP. CPP is reliably used to
measure the rewarding effects of Meth as well as Amph and other abused
substances in laboratory rodents (Spyraki et al. 1982;Tzschentke
1998;Tzschentke 2007). Recently, Childs and deWit report that this behavioral
paradigm can be directly tested in humans using Amph as the UCS (Childs and
deWit H. 2009). Therefore, the CPP behavioral model provides a means for
assessing the association between rewarding effects of drugs and conditioned
contextual cues that is relevant in humans.
Another index of brain plasticity that occurs with repeated drug
administration, aside from CPP, is the progressive enhancement in motor
activity, termed motor sensitization. Neuronal structures upon which
psychostimulants and other drugs of abuse act adapt to produce an enhanced
response with repeated exposure to the drug stimulus (Stewart and Badiani
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1993). It is hypothesized that the neuronal adaptations associated with motor
sensitization may model certain aspects of the brain changes that are associated
with Meth abuse in humans (Robinson and Berridge 1993;Stewart and Badiani
1993). The sensitizing effect of Amph, for example, is so powerful that a single
administration of the drug can enhance responding to subsequent Amph
administration, and these sensitized behaviors evoked by Amph become more
pronounced even after long periods of withdrawal from repeated exposure (e.g., 3
weeks) (Vanderschuren et al. 1999). Sensitization to the effects of Amph also
occur in humans after repeated, intermittent administration including
enhancements in Amph-induced euphoria, energy level, and talkativeness
(Strakowski et al. 1996;Strakowski et al. 2001;Strakowski and Sax 1998).
Repeated Amph and Meth induce psychotic effects similar to those reported in
schizophrenia (Angrist and Gershon 1970;Bell 1973;Griffith et al. 1972) which
also demonstrates persistent sensitization-like properties (Robinson and Becker
1986;Schmidt and Beninger 2006;Yui et al. 1999). Our laboratory and others
have demonstrated that Meth and Amph can differentially induce CPP and motor
sensitization behaviors in rodents depending on factors such as drug dosage
(Itzhak et al. 2002;Shen et al. 2006), rodent age (Belluzzi et al. 2004), and rodent
strain (Kosten et al. 1994). These reports suggest that the two behaviors may
model different aspects of human drug addiction.
Relapse rates for Meth addicts undergoing behavioral/cognitive recovery
programs reach approximately 50-60% (Brecht et al. 2000;McLellan et al. 2000),
and there is currently no FDA-approved pharmacotherapy for Meth use disorders

11
(Elkashef et al. 2008). Therefore, the treatment of Meth use disorders represents
an unmet need for which the development of more effective pharmacotherapy
merits investigation. The current studies implemented CPP and motor
sensitization in order to identify potential therapeutic targets for addiction
therapy.

Dual diagnosis of substance use disorders and schizophrenia: clinical
scenario and rodent behavioral models

A recent clinical assessment determined that 25% of schizophrenia
patients also meet criteria for psychostimulant abuse or dependence (Compton et
al. 2005), a frequency that is considerably higher than the 5% of the general
United States population reported to have used or abused Meth in 2004
(http://www.drugabusestatistics.samhsa.gov/2k5/meth/meth.htm). Dual
diagnosis schizophrenia patients show an increased incidence of violence
(Buckley et al. 2004), as well as greater housing, economic, and health care
access problems (Compton et al. 2005). Case studies demonstrate that the
atypical antidepressant, olanzapine, can reduce psychotic symptoms induced by
Meth abuse, but it remains unclear if this treatment reduces relapse to Meth
abuse in the stimulant abstinent co-morbid patient (Misra et al. 2000). Fifty-five
percent of schizophrenia patients who are medicated with antipsychotics are
substance abusers (Swofford et al. 2000), indicating that blocking dopamine
transmission is insufficient to alter stimulant abuse. There clearly is an unmet
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need for an effective pharmacotherapy for the dual diagnosis patient. This
project is predicated on the concept that a better understanding of the behavioral
profile of dual diagnosis will shed light on the neurobiological underpinnings that
overlap between stimulant use disorders and schizophrenia.
Schizophrenia is described by the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) as a mixture of characteristic positive
and negative “signs and symptoms associated with marked social or occupational
dysfunction.” Positive symptoms include “distortions in thought content
(delusions), perception (hallucinations), language and thought process
(disorganized speech), and self-monitoring of behavior (grossly disorganized or
catatonic behavior)” while negative symptoms include “restrictions in the range
and intensity of emotional expression (affective flattening), in the fluency and
productivity of thought and speech (alogia), and in the initiation of goal-directed
behavior (avolition)” (American Psychiatric Association 2000). As stated in the
previous section, repeated use of amphetamines results in psychotic symptoms
akin to schizophrenia in humans, including cognitive dysfunction, delusions, and
hallucinations (Harris and Batki 2000;McKetin et al. 2006;Scott et al. 2007).
Though the DSM-IV classifies substance-induced psychotic disorders separately,
there is evidence to suggest that use of amphetamines results in an augmentation
of symptoms in schizophrenia patients (Angrist et al. 1980;Janowsky and Davis
1976). The striking similarity between clinical presentations of schizophrenia
and psychosis induced by amphetamines lends credence to the idea that there is
an overlapping neurobiological function between the two disorders. One
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behavioral feature that occurs with both schizophrenia patients and
administration of amphetamines is a sensorimotor gating deficit that indicates
cognitive fragmentation (Braff et al. 1978;Grillon et al. 1992). This can be
measured in both humans and rodents with the prepulse inhibition (PPI) deficits
of the acoustic startle response (Braff et al. 2001;Swerdlow and Geyer 1998). PPI
is defined as the natural inhibitory response that occurs when a startling stimulus
is preceded by a weaker stimulus (Graham 1975;Hoffman and Searle 1968;Ison et
al. 1973;Swerdlow and Geyer 1998)(Fig. 1). Recent studies report that sensitizing
treatment regimens of Amph disrupt PPI and Amph-induced PPI deficits in
laboratory rats can model of aspects of human schizophrenia (Peleg-Raibstein et
al. 2008;Tenn et al. 2005). Assays of brain chemistry and anatomy in Amphtreated rats demonstrate further similarities to the schizophrenia brain state such
as a decrease in the enzyme glutamic acid decarboxylase 67 (GAD67) in the
prefrontal cortex, hippocampus and thalamus (Akbarian et al. 1995;Heckers et al.
2002;Peleg-Raibstein et al. 2008;Perry et al. 1979;Volk et al. 2000). Therefore,
further study into the behavioral outcomes induced by repeated Amph such as
sensorimotor gating deficits and reward-mediated behaviors will help elucidate
neurobiological underpennings of, and identify therapeutic targets for, the dually
diagnosed patient.
Early stressors in development of laboratory rodents such as maternal and
social deprivation (termed isolation rearing), produce behavioral, neurochemical,
and morphological adaptations that result in a phenotype that resembles aspects
of schizophrenia. In this model, rats are separated from their mother
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approximately one day post-weaning (post-natal day 21) and housed individually
until adulthood with minimal handling by the experimenter (Einon and Morgan
1977;Varty et al. 1999). Sensorimotor gating deficits are observed in isolationreared rats (Geyer et al. 1993). Isolation rearing-induced PPI deficits are
reversed by antipsychotic medications used to treat symptoms in schizophrenia
patients, giving predictive validity of isolation rearing as a model for
schizophrenia (Bakshi et al. 1998). Furthermore, there is evidence of decreases
in volume of the frontal cortex in both isolation reared rodents (Day-Wilson et al.
2006) and schizophrenia patients (Benes et al. 1991), which indicates similar
morphological alterations. Isolation rearing provides an ideal nonpharmacological means of assessing sensorimotor gating deficits associated with
schizophrenia in the adult rat.
Other rodent models of schizophrenia demonstrate enhanced sensitivity to
psychostimulants; a phenomenon that is known to occur in humans (Angrist et
al. 1980;Janowsky and Davis 1976). The model predominantly used in these
studies is the neonatal ventral hippocampal lesion (NVHL). In this model,
bilateral excitotoxic lesions are produced in the ventral hippocampus on post
natal day seven which disrupts the hippocampal connection to the prefrontal
cortex. This results in behavioral and neurochemical properties in rats that are
similar to features presented by human patients with schizophrenia (Lipska et al.
1993;Lipska et al. 1995). The NVHL rodents show enhanced motor sensitization
to nicotine and cocaine compared to sham lesioned counterparts. The acquisition
of both cocaine (Chambers and Self 2002) and Meth self-administration (Brady
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et al. 2008) is also enhanced in NVHL rats. Furthermore, NVHL lesioned
rodents displayed enhanced motivation to work for Meth administration when
the schedule of reinforcement was altered to a progressive ratio in the selfadministration paradigm (Brady et al. 2008). Like the NVHL rats, isolationreared rodents also demonstrate enhanced motor sensitization to Meth (Dai et al.
2004), cocaine and amphetamine (Lipska et al. 1993) as well as enhanced
responding in a progressive ratio for both cocaine and amphetamine (Smith et al.
1997). Taken together, motor sensitization and self-administration studies
indicate that the NVHL and isolation rearing rodent models of schizophrenia are
more sensitive to the locomotor stimulating and reinforcing effects of stimulants,
which may reflect positive symptoms associated with schizophrenia. However,
these developmental rodent schizophrenia models demonstrate a diminished
response to the rewarding properties of stimulant drugs, which could reflect
negative symptoms associated with schizophrenia such as anhedonia and
cognitive dysfunction. For example, in CPP paradigms, isolation reared rats fail
to demonstrate a significant preference for environmental context associated
with Amph (Wongwitdecha and Marsden 1995) and the opiate morphine
(Wongwitdecha and Marsden 1996). Rats with the NVHL lesion also showed
blunted CPP induced by Amph or the natural reward saccharin (Le et al. 2002).
Overall, in developmental rodent models of schizophrenia there is a disparity in
the rewarding vs. reinforcing properties of stimulants. Therefore, one objective
of the current dissertation project was to investigate how sensorimotor gating

16
deficits associated with different rodent models of schizophrenia correlate with
rewarding and incentive motivational properties of Meth.

Glutamate transmission in addiction and schizophrenia

The reinforcing properties of abused stimulants and the neuropathology of
schizophrenia are both associated with hyperactivity of the mesolimbic dopamine
system (see reviews (Carlsson 1988;Wise and Rompre 1989)). Most abused
drugs increase extracellular dopamine concentrations in the nucleus accumbens
(NAc) (Di Chiara and Imperato 1988), which receives dopaminergic input from
the ventral tegmental area (VTA) (Swanson 1982). Amphetamines also increase
extracellular glutamate concentrations in the NAc and other regions where VTA
dopamine projections terminate such as the mPFC and ventral pallidum (VP)
(Chen et al. 2001;Shoblock et al. 2003;Xue et al. 1996). The mPFC provides
glutamatergic innervations to both the NAc and VP (Christie et al. 1985;Fuller et
al. 1987;Sesack et al. 1989) as well as the VTA (Sesack and Pickel 1992). The VP
and NAc have reciprocal GABAergic connections (Jones and Mogenson
1980;Mogenson et al. 1983;Walaas and Fonnum 1979;Zahm et al. 1985). The
NAc receives glutamatergic projections from the hippocampus and amygdala
(McDonald 1991;Meredith et al. 1990). The amygdala also sends a glutamatergic
projection to the VP (Carnes et al. 1990;Fuller et al. 1987;Russchen and Price
1984). The current literature review will focus on the mPFC, NAc and VP as these
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regions are critical players in stimulant-induced motor sensitization, conditioned
reward, schizophrenia and sensorimotor gating (see Fig. 2 for circuitry diagram).

Glutamate alterations specific to motor sensitization
Rodent studies demonstrate that mPFC, NAc and VP brain structures are
involved in different phases of motor sensitization. Initial studies revealed that
lesions of the mPFC reduce induction of Amph-induced motor sensitization
(Bjijou et al. 2002;Cador et al. 1999;Wolf et al. 1995;Wolf and Xue 1999) but not
the expression of this behavior (Li and Wolf 1997). Tzschentke later revealed,
however, that mPFC lesions do not affect the development of Amph-induced
motor sensitization (Tzschentke and Schmidt 1999;Tzschentke and Schmidt
2000). These disparate findings may be due to differences in environmental
conditions associated with Amph administration and lesion extent. However, the
literature is in agreement that mPFC lesions disrupt both the development and
expression of cocaine-induced motor sensitization (Li et al. 1999;Pierce et al.
1998;Tzschentke and Schmidt 1999;Tzschentke and Schmidt 2000). To date,
there is no study employing lesions of the mPFC to determine its effects on Methinduced motor sensitization. It is known that extracellular glutamate levels in the
mPFC are differentially altered by systemic administration of Amph vs. Meth.
That is, there is an increase in mPFC glutamate levels after Meth (2mg/kg)
injections peaking approximately 100min post-injection but no changes occur in
mPFC glutamate levels after Amph (2mg/kg) administration (Shoblock et al.
2003). Preliminary work from the Szumlinski laboratory demonstrated a
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reduction in mPFC extracellular glutamate levels three weeks after repeated Meth
(Lominac and Szumlinski 2008). However, direct infusion of Amph into the
mPFC results in a dose-dependent increase in glutamate levels in the same brain
region (Del Arco et al. 1998). The neuronal firing response of mPFC neurons to
local, microiontophoretic application of glutamate is also enhanced in Amphsensitized rats (Peterson et al. 2000). These studies implicate the mPFC as an
important structure in the development of stimulant-induced motor sensitization
and that neurons of this region are hyper-responsive to glutamate during
withdrawal from repeated exposure to stimulants.
The NAc is a brain region classically considered important for the
expression of stimulant-induced motor sensitization (see reviews (Pierce and
Kalivas 1997;Vanderschuren and Kalivas 2000). Glutamate neurotransmission is
important in this role, since local injection of NMDA receptor antagonist (AP-5)
into the core region of the NAc blocks cocaine-induced motor sensitization
(Pulvirenti et al. 1994). Furthermore, increases in extracellular glutamate occur
in the NAc only in rats sensitized to cocaine subsequent to an additional cocaine
injection, and this effect is specific to the core subregion of the NAc (Pierce et al.
1996). Pierce and Kalivas also demonstrated that local injection of AMPA into
the core but not the shell subregion of the NAc enhanced locomotor effects in
cocaine-sensitized rats (Pierce et al. 1996). However, NAc neurons are less
sensitive to locally applied glutamate three days after administration of a
sensitizing regimen of cocaine or Amph, perhaps due to a shorter withdrawal
period (White et al. 1995). These findings converge to show the importance of
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glutamate in the NAc core to the expression of stimulant-induced motor
sensitization.
An output structure of the NAc, the VP, may play a role in the development
and expression of stimulant-induced motor sensitization. Local injection of
Amph into the VP increases motor activity but to a lesser extent than local NAc
application (Fletcher et al. 1998). Blockade of AMPA/kainate receptors in the VP
also reduces acute Amph-induced hyperactivity (Willins et al. 1992). The
expression, however, of Amph-induced motor sensitization is reduced by intraVP administration of NMDA receptor antagonists (Chen et al. 2001).
Furthermore, a challenge administration of Amph given 10-14 days after repeated
Amph treatments increases extracellular glutamate levels in the VP (Chen et al.
2001). Our lab has demonstrated that the there is an increase in neuronal
response of VP neurons three days following repeated, sensitizing cocaine
administration (McDaid et al. 2005). These studies demonstrate that the VP
glutamate system is involved in the acute hyper-motoric effects of stimulants as
well as in the expression of stimulant-induced motor sensitization.

Neuronal activation and glutamatergic alterations following
stimulant-induced associative learning
The complex neuronal processes involved with addiction are thought to
involve hijacking normal components of learning and memory. The PFC,
important for executive function and control of memory maintenance (Goldstein
and Volkow 2002;MacDonald, III et al. 2000), has decreased activation in Meth-
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addicted humans performing cognitive tasks (Paulus et al. 2003;Salo et al. 2009).
However, the PFC becomes highly activated with the presentation of stimulantrelated cues in subjects with stimulant use disorders (Grant et al. 1996;Hester
and Garavan 2009;Maas et al. 1998). Meth conditioned rats given a priming
injection of Meth and re-exposed to Meth-cues demonstrate enhanced
extracellular mPFC glutamate levels compared to rats that were not primed with
Meth (Qi et al. 2009). These data indicate that the mPFC is sensitive to Meth and
Meth-related cues. The mPFC projects to the NAc, and recently both of these
regions were proven to be critical for cue- and Meth-induced reinstatement of
drug-seeking behavior in rodents (Rocha and Kalivas 2010). The NAc is a central
component of the reinforcing, rewarding and hyper-motoric effects of stimulants
(Bozarth and Wise 1981;Swerdlow et al. 1986;Wise and Bozarth 1985). While the
NAc is a central mediator of the reinforcing effects of stimulants, it may not be as
critical to the learning or craving associated with the drug and drug cues, since
cortical regions but not subcortical structures such as the NAc are metabolically
activated in the presence of cocaine cues (Grant et al. 1996) but also see (Breiter
et al. 1997). In rodent studies of cellular activation, there is an increase in fos
expression after Meth administration in the NAc (Lee et al. 2000). However,
there is an increase in fos expression in the mPFC but not in the NAc in rodents
responding to cocaine cues (Brown et al. 1992;Mattson and Morrell 2005).
However, Rhodes et al. found an increase in c-Fos expression in the NAc shell as
well as in the PFC in response to Meth-associated cues (Rhodes et al. 2005).
Based on behavioral and cellular activity data, the mPFC and NAc play important
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roles in response to stimulant cues. While imaging data suggests that the mPFC
might be more sensitive to drug-related cues, the resolution of these procedures
may make discerning activation in the NAc or VP more difficult.
The VP plays a critical role in integration of neuronal signaling to produce
motivated motor behavior (Mogenson and Yang 1991). VP neurons encode
information relevant to incentive properties of cues that predict reward, which is
enhanced subsequent to Amph sensitization (Tindell et al. 2005). NMDA
receptors in the VP are necessary for the development but not expression of
amphetamine-induced CPP (Hiroi and White 1993). Work conducted in the
Napier lab revealed an increase in the stable form of the FosB immediate early
gene family, ΔFosB, that persists following a sensitizing regimen of Meth in the
VP (McDaid et al. 2006b). Biochemical and electrophysiological data suggest
that VP neurons are activated by stimulants and related cues.
In summary, the mPFC, NAc, and VP all demonstrate cellular or region
activation in response to stimulant administration, and these responses are
enhanced following repeated exposure. The mPFC is hyper-activated in response
to the presentation of stimulant-related cues in human addicts.

Glutamate alterations associated with schizophrenia and
sensorimotor gating deficits
The glutamate hypothesis of schizophrenia was born out of clinical
evidence that individuals taking phencyclidine (PCP), the ionotropic glutamate
NMDA receptor open channel blocker, experienced a psychotic state similar to

22
that of schizophrenia (Allen and Young 1978;Fauman et al. 1976;Rainey, Jr. and
Crowder 1975), and that PCP exacerbated illness in schizophrenia patients (Itil et
al. 1967). PCP can also induce sensorimotor gating deficits in rodents and nonhuman primates (Linn and Javitt 2001;Martinez et al. 1999) that are reversed by
antipsychotic medications (Bakshi et al. 1994;Bakshi and Geyer 1995;Linn et al.
2003). Levels of glutamate are lower in the cerebral spinal fluid (CSF) of
schizophrenia patients than in individuals without the illness (Kim et al. 1980).
There is pre-clinical and clinical evidence that schizophrenia is not merely a
disorder of a hyperactive dopamine system but also involves glutamatergic
dysregulation.
Limbic circuitry associated with reward innervates the brain stem circuitry
that mediates the acoustic startle response. Briefly, auditory stimuli are
received by the inferior colliculus (IC) via the cochlear nucleus (Coch) and
relayed to the superior colliculus (SC) and pedunculopontine tegmental nucleus
(PPTg). The PPTg sends descending cholinergic projections to the nucleus
reticularis pontis (PnC) of the primary startle pathway as well as sending
excitatory ascending projections to the thalamus and dopaminergic nuclei of the
reward pathway such as the VTA. The PnC can also be directly activated by
auditory stimuli and sends projections to spinal motor neurons eliciting a startle
response (see Fig. 2, and reviews, (Davis et al. 1982;Fendt et al. 2001;Swerdlow et
al. 1992). The limbic reward circuitry (discussed above) modulates the PPI
circuit predominantly at the level of the PPTg via GABAergic projections from the
VP and NAc (Chivileva and Gorbachevskaya 2008;Haber et al. 1990). I will limit
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my review of brain regions involved with the modulation of PPI to those
discussed previously, the mPFC, NAc and VP (see Fig. 2 for diagram of circuitry).
Post-mortem morphological studies identify a decreased neuronal density
in the mPFC of schizophrenia patients (Benes et al. 1986). It was further
determined that this lower density was due to a loss of small, likely GABAergic
interneurons and that levels of larger pyramidal neurons were generally
unaltered (Benes et al. 1991). This morphological alteration may contribute to
the sensorimotor gating deficits in schizophrenia patients since intra-mPFC
administration of picrotoxin, the GABAA receptor antagonist, disrupts PPI in
rodents (Japha and Koch 1999). A reduction in GABAergic inhibition in the
mPFC would result in an increase in glutamate release in the VTA leading to an
increase in dopamine release in the NAc (see Fig. 2 for circuitry). The
mechanism by which PPI is disrupted in the mPFC is likely associated with a loss
of dopaminergic inhibition of glutamate neurons since lesions of dopamine
terminals reduce PPI and this effect is reversed by administration of the
antipsychotic haloperidol that has a high affinity for dopamine D2 receptors
(Bubser and Koch 1994;Koch and Bubser 1994). The deficits in PPI induced by
local injections of picrotoxin into the mPFC are also reversed by haloperidol,
further substantiating this claim (Japha and Koch 1999). Therefore a loss of
inhibition of in the mPFC via both GABAergic and dopaminergic means may lead
to an increase in NAc dopamine resulting in PPI deficits associated with
schizophrenia. Isolation-reared rodents that displayed PPI deficits have reduced
mPFC volume (neuronal number was unaltered), which further validates the role
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of mPFC in sensorimotor gating deficits associated with schizophrenia as well as
the utility of the isolation-rearing model (Day-Wilson et al. 2006). Other studies
reveal a disconnection in PFC neurons (Bagorda et al. 2006;Witte et al. 2007)
and a reduction in metabotropic glutamate receptors in isolation reared rodents
(Melendez et al. 2004). Therefore, the mPFC is key in sensorimotor gating
deficits associated with schizophrenia.
The NAc receives glutamatergic projections from the mPFC, hippocampus,
amygdala, and dopaminergic innervation from the VTA. The NAc, thus, is an
important site for glutamate and dopamine transmitter interaction. Zhang and
colleagues report a close correlation between Amph-induced deficits in
sensorimotor gating and increases in extracellular dopamine levels in the NAc
(Zhang et al. 2000). Local injection of Amph into the NAc disrupts PPI
(Swerdlow et al. 2007;Wan and Swerdlow 1996), an effect that is reduced by the
co-administration of ionotropic AMPA receptor antagonist, CNQX (Wan and
Swerdlow 1996). Furthermore, intra-NAc administration of AMPA or NMDA
alone decreases PPI (Reijmers et al. 1995;Wan et al. 1995). Lesions of dopamine
terminals in the NAc and administration of haloperidol reverse AMPA-induced
disruptions of PPI (Wan et al. 1995). Clearly, the NAc is a region critical for the
dopamine-induced effects on sensorimotor gating that are also affected by
glutamatergic transmission.
The NAc and VP are connected via reciprocal GABAergic projections and
both regions innervate the PPTg (Haber et al. 1990;Heimer et al. 1991;Parent et
al. 1999). Volume loss in the VP is reported in post-mortem brain tissue from
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schizophrenia patients (Bogerts et al. 1985). Lesions of the VP as well as GABA
agonist application in this region reveal that it is a critical mediator in the
sensorimotor gating deficits associated with excess dopamine in the NAc
(Kretschmer and Koch 1998;Swerdlow et al. 1990). Further evidence for the role
of VP GABA transmission in regulation of dopamine induced PPI is
demonstrated by dopamine receptor (D3/D2) agonist quinelorane inducing
increased extracellular GABA levels in the VP as well as reducing PPI in rodents
(Qu et al. 2008). The VP works to integrate dopamine- and GABA-mediated
signaling to modulate sensorimotor gating behavior.

Involvement of the metabotropic glutamate receptor group I, subtype
5 (mGluR5) in reward-mediated behaviors

Glutamate activates ionotropic glutamate receptors and metabotropic
glutamate receptors. Metabotropic glutamate receptors (mGluRs) are classified
into three different groups based on sequence homology, pharmacology and
associated signaling cascades with which they are coupled (Nakanishi 1992). The
mGluRs have seven transmembrane domains, a large extracellular aminoterminus, an intracellular carboxy-terminus, and are members of the family 3/C
G-protein coupled receptors (GPCRs) (see for review (Conn and Pin
1997;Hermans and Challiss 2001;Pin et al. 2003)). The group I subtype 1
receptor (mGluR1) was the first cloned mGluR (Houamed et al. 1991;Masu et al.
1991) and subsequent cloning of group I subtype 5 metabotropic glutamate
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receptor (mGluR5) determined that the two receptors share approximately 87%
sequence homology (Abe et al. 1992). The mGluR5 also exists in a covalent,
disulfide-linked homodimer in non-reducing conditions (Romano et al. 1996) but
also see evidence for non-covalent dimerization (Romano et al. 2001). The
extracellular amino-terminal region of the group I mGluR homodimer forms a
venus-flytrap-shaped region where agonist binding occurs (Kunishima et al.
2000). Also, mGluR5 demonstrates constitutive activity, and both the
extracellular amino terminal (Muhlemann et al. 2005) and the seventransmembrane domain play roles in this receptor behavior (Goudet et al. 2004).
The mGluR5 are coupled to guanine nucleotide binding Gq proteins and upon
activation stimulate phosphoinositide (PI) hydrolysis resulting in an increase in
intracellular calcium concentrations (Abe et al. 1992). Splice variants of both
mGluR1 (mGluR1a-c; (Pin et al. 1992;Tanabe et al. 1992) and mGluR5 exist
(mGluR5a and mGluR5b; (Abe et al. 1992;Joly et al. 1995;Minakami et al. 1993))
and mGluR1a, mGluR5a, and mGluR5b all function to induce PI hydrolysis in a
similar manner (Joly et al. 1995). The activation of group I mGluRs (mGluR1 and
mGluR5) modulates neuronal excitability and increases intracellular calcium
levels, which makes these receptors important modulators of neuronal plasticity.
The mGlu5 receptor is of special interest since these receptors are located
within reward-related brain regions. Studies using in situ hybridization to detect
mRNA levels of subtype-specific mGluRs have demonstrated that expression
levels of mGluR5 are high in the rat basal ganglia, including the NAc,
caudate/putamen, hippocampus and frontal cortex (Kerner et al. 1997;Lu et al.
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1999;Testa et al. 1994a), and these results were confirmed by receptor protein
detection (Romano et al. 1995). Deposition of Fluoro-Gold retrograde dye into
the VP, a region of moderate mGluR5 expression, reveals that approximately 82%
of mGluR5 mRNA containing neurons in the NAc project to this region (Lu et al.
1999). The mGlu5 receptor is located primarily post-synaptically. Indeed,
electron microscopy reveals the predominant expression of mGluR5 protein in
the cortex, hippocampus and NAc is on dendritic spines, though slight expression
of mGluR5 on pre-synaptic axon terminals occurs in these brain regions (Mitrano
and Smith 2007;Romano et al. 1995). The localization of mGluR5 on postsynaptic neurons within the limbic brain regions makes them a suitable target for
study on stimulant-induced reward.
Subtype-selective mGluR5 allosteric modulator ligands have unique
characteristics that gives them potential for novel substance use disorder
pharmacotherapy. These ligands do not bind to the orthosteric
agonist/antagonist binding site but instead bind non-competitively to a specific
site located within the seven transmembrane-domain region of the receptor.
Most allosteric modulators are active only when endogenous agonist is bound to
the receptor in order to physiologically potentiate or decrease effects of the
agonist itself. Through this mechanism of action, the use of allosteric
modulators decreases the likelihood of unwanted side effects that occur with
traditional agonist/antagonist therapies that are often plagued with
compensatory effects subsequent to receptor over/under-activation (see for
review (Wang et al. 2009)). The ligand 2-methyl-6-(phenylethynyl)-pyridine
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(MPEP) binds to specific residues within the seven-transmembrane spanning
region in order to negatively modulate mGluR5 (Malherbe et al. 2003). MPEP is
found to specifically decrease agonist-induced activity of mGluR5 and is
systemically active (Gasparini et al. 1999). However, MPEP is also shown to have
inverse agonist activities in reducing the constitutive activity of mGluR5 (Goudet
et al. 2004;Muhlemann et al. 2005;Pagano et al. 2000). The ligand 3-[(2methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) acts at the same allosteric site
as MPEP but has greater potency and selectivity for the mGluR5 (Cosford et al.
2003). Both MPEP and MTEP are useful, systemically active, pharmacological
tools for determining the functional role of mGluR5 in vivo.
The use of allosteric modulators demonstrates the functional importance
of mGluR5 in stimulant-mediated behaviors. When MPEP (50mg/kg, i.p.) is
given after the acquisition of amphetamine-induced associative learning on the
test day, it blunts the expression of Meth-induced CPP in rats (Herzig et al.
2005). Additionally, MPEP (100nmol, intracerebroventricular) given prior to
Meth pairing in a specific context hinders the development of the Meth-induced
place conditioning in mice (Miyatake et al. 2005). Therefore, the use of MPEP
demonstrates the importance of mGluR5 activation during both the development
and expression phases of stimulant-induced associative learning processes.
Another mGluR5 NAM, MTEP, has been used in operant tasks to demonstrate
the reinforcing properties of stimulants. Administration of MTEP dosedependently (at 1 and 3mg/kg) reduces the self-administration of Meth without
altering operant responding for a natural food reinforcer (Osborne and Olive
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2008). Furthermore, MTEP (3mg/kg, i.p.) reduces the total number of lever
responses in a progressive ratio paradigm of Meth self-administrations, as well as
the total number of Meth infusion reinforcers earned (Gass et al. 2009).
Moreover, after stable self-administration is acquired and the association
between the lever and Meth infusion is extinguished, a pre-treatment of MTEP (1
and 3mg/kg, i.p.) reduces cue and Meth-primed reinstatement of drug-seeking
behavior. Throughout these studies, responding for food remains unaltered by
MTEP treatments up to the highest dose tested, 3mg/kg (Gass et al. 2009). This
collective evidence suggests that mGluR5 activation is needed for the acquisition
and retrieval of cue- and Meth-primed drug-seeking behaviors. An area that
remains to be explored, however, is the role of mGluR5 in the maintenance of
stimulant-associated memories. This is a critical gap for the treatment of
substance use disorders and therapeutic intervention at this time period would
aid relapse prevention in the drug-withdrawn substance abuser.
The expression and cellular localization of glutamate receptor proteins,
including mGluR5, can be altered by stimulant administration. Much of the
literature to date reports the consequences of cocaine administration on
glutamate receptor protein levels; less is known about the effects of Meth or
Amph. Studies utilizing synaptosomal fractionation procedures determined that
21 days after a sensitizing course of cocaine administration there are enhanced
expression levels of mGluR5 as well as AMPA and NMDA receptor subunits in
the membrane fraction of mPFC (Ghasemzadeh et al. 2009b) and NAc tissue
(Ghasemzadeh et al. 2009a). These effects are not observed one day after the end
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of cocaine treatment (Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b).
The Wolf laboratory also demonstrated an increase the surface expression of
AMPA receptor subunits, GluR1 and GluR2/3 at 21 days, and GluR1 and GluR2 in
the NAc at 14 days, but not one day, following cocaine-induced sensitization
(Boudreau et al. 2007;Boudreau and Wolf 2005). Furthermore, one day after an
acute challenge administration of cocaine eliciting expression of motor
sensitization, surface expression levels of GluR1 and GluR2 AMPA receptor
subunits decreased in the NAc (Boudreau et al. 2007). However, 21 days
following a repeated Amph treatment course that induced motor sensitization,
GluR1 and GluR2 membrane surface expression levels remain unchanged in the
NAc (Nelson et al. 2009). Metabotropic glutamate receptor mRNA levels are
altered following Amph-induced sensitization in the NAc. Three hours after
repeated Amph, mGluR1 levels are increased and mGluR5 levels are decreased in
this brain region. While the alterations in mGluR1 are transient, mGluR5 levels
remain decreased up to at least 28 days after the last Amph treatment (Mao and
Wang 2001). Similar results are reported using synaptosomal fragmentation
subsequent to a single, acute injection of Amph in the striatum (Shaffer et al.
2010). That is, one hr after Amph administration, mGluR5 membrane fraction
levels are decreased, but the decreases are transient since they normalize by five
hrs post-Amph (Shaffer et al. 2010). Shaffer and colleagues also observe a
transient increase in mGluR5 levels in the mPFC one hr after Amph that is also
normalized by five hr, while no alterations in mGluR1 expression were found in
the striatum or mPFC subsequent to Amph treatment (Shaffer et al. 2010). These
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collective results demonstrate that glutamate receptor redistribution following
cocaine sensitization enhances over the course of time. However, glutamate
receptor trafficking is differentially regulated by stimulants cocaine and Amph.
Therefore, investigation into the effects of the stimulant Meth on changes in
glutamate receptor profiles in reward-related brain regions will fill a gap in our
understanding of the literature.
The mGlu5 receptors influence neuronal plasticity through the modulation
of ionotoropic glutamate receptors. The activation of group I mGluRs (mGluR1
and mGluR5) in hippocampal neurons gives rise to NMDA and AMPA receptor
internalization, which results in a loss of electrophysiological function
determined by a decrease in excitatory post synaptic potentials (Snyder et al.
2001). Zhang and colleagues show a mechanism by which mGluR1/5-induced
internalization of AMPA receptor subunits occurs. Internalization and dephosphorylation of GluR1 and GluR2 subunits induced by mGluR1/5 activation
was reversed by inhibition of the striatal enriched protein tyrosine phosphatase
(STEP) and this effect is specific to mGluR5. Furthermore, activation of
mGluR1/5 results in an increase in synaptic fragments of STEP61 isoform in
hippocampal tissue (Zhang et al. 2008). The STEP61 isoform occurs as a result of
alternative splicing and is named for its molecular weight of 61kDa (Sharma et al.
1995). This specific STEP isoform is associated with membranes and localized to
the endoplasmic reticulum of neurons (Bult et al. 1996). The inhibition of STEP
activity in the striatum results in blockade of Amph-induced motor sensitization,
which illustrates that the function of STEP is behaviorally relevant to stimulant-
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mediated behaviors (Tashev et al. 2009). Specific activation of mGluR5 results in
dephosphorylation and subsequent internalization of AMPA receptor subunits
via STEP61 activity which may be a necessary component of Amph-induced motor
sensitization.

Significance

The goal of the current dissertation was to expand our knowledge of the
role of the mGluR5 system in Meth addiction and in the co-morbidity of
schizophrenia and Meth use disorders. First, we sought to determine the role of
mGluR5 in the maintenance of Meth-induced associative learning and we further
characterized cellular adaptations of mGluR5 in reward-related brain regions at
two behaviorally relevant time points. From the literature review, it can be seen
that advanced biochemical assays are being utilized to determine the cellular
adaptations of the glutamate system including mGluR5 subsequent to cocaine
administration. However, the dynamics of mGluR5 following Meth-induced
motor sensitization and associative learning remain unknown. Our findings will
help guide the field of psychostimulant addiction and determine if mGluR5 could
be considered as a potential target for future pharmacotherapies. Our second
focus was the effects of Meth exposure in pharmacological and developmental
rodent models of schizophrenia. Since the neurocircuitry of stimulant addiction
and schizophrenia show clear overlap, we sought to determine how behavioral
outcomes of each might be correlated in individual rodents. Rodent models of
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schizophrenia demonstrate sensitivity to the effects of stimulant. We reveal here
a direct correlation between sensorimotor gating deficits associated with
schizophrenia and Meth-induced sensitization and associative learning. We
determined that augmenting mGluR5 signaling also increase Meth-induced
associative learning in a developmental rodent model of schizophrenia. These
novel findings will add to the knowledge of behavioral dysfunction associated
with the co-occurrence of Meth abuse and schizophrenia.
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Figure 1. Schematic of the prepulse inhibition (PPI) of the acoustic
startle response in rodents. When a strong acoustic stimulus (PULSE) of
120dB(A) is presented alone a large startle response subsequently occurs. When
a weaker acoustic stimulus (PRE PULSE) between 68-77dB(A), for example, is
presented before the strong, startling PULSE stimulus, the startle response is
diminished. The average startle magnitude that is measured is a result of the
force the rat exerts on the enclosure in the PPI apparatus that is coupled to a
sensor that transmits the information to the PC computer. Figure is modified
from Swerdlow & Geyer 1998 Schizophrenia Bulletin 24(2):285-301 and includes
original data traces of average startle magnitude obtained by A. Herrold in saline
treated male Sprague-Dawley rats.
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Figure 2. Neurocircuitry of reward and sensorimotor gating. Pictured
here are the brain structures which are involved in stimulant-induced behaviors
which also modulate the primary circuitry responsible for mediating the acoustic
startle response. Glutamate (Glu) projections are depicted in green,
dopaminergic (DA) in blue and GABAergic (GABA) in red. mPFC, medial
prefrontal cortex; NAc, nucleus accumbens; VP, ventral pallidum; Hipp,
hippocampus; MDT, medial dorsal thalamus; Amg, amygdala; VTA, ventral
tegmental area; PPTg, pedunculopontine nucleus; PnC, nucleus reticularis pontis
caudalis; SC, superior colliculus, IC, inferior colliculus; Coch, cochlear nucleus.

CHAPTER III
RATIONALE FOR METHODOLOGY AND PRELIMINARY STUDIES

Methamphetamine conditioned place preference dose determination
To determine the dose of Meth to be used with repeated conditioning
sessions in the CPP task to induce a reliable and persistent preference of the
Meth-paired context, a Meth dose-response study (0.1, 0.3, and 1.0mg/kg, in the
volume of 1ml/kg (i.p.)) was conducted using 36 male Sprague-Dawley rats. The
CPP experiment consisted of three phases during which activity and time spent in
each compartment was monitored: pre-test, conditioning, and CPP tests. For the
pre-test, rats were given access to the entire CPP box (see Fig. 3B) in a drug-free
state for 30min. The CPP box consists of two large chambers with distinct yet
neutral cues separated by sliding Plexiglas doors from a smaller center chamber
with a smooth white floor and white sides (Fig.3C&D). Rats were then assigned
to Meth and saline paired chambers in a counter-balanced manner. That is, half
of the rats were paired with Meth in the chamber of the CPP box where they
spent the least amount of time on the pre-test and the other half were paired with
saline in the chamber where they spent the greatest amount of time on the pretest. Also, the time spent in each of the large chambers during the pre-test was
balanced so that there was no statistical difference between the sides for which
they were paired for each group.
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Rats were then administered Meth at a dose of 0.1, 0.3, or 1.0mg/kg, i.p. on days
1, 3, and 5 and then immediately placed in the assigned, Meth-paired chamber for
45min. On days 2, 4, and 6, rats were administered saline (1ml/kg, i.p.) and then
immediately placed in the opposite compartment for 45min. Three days later,
rats were tested for conditioned preference (CPP Test 1) in a drug-free state.
Then rats were repeatedly tested for persistence of preference weekly up to CPP
Test 3 (see Fig. 4A for experimental timeline). A two-way repeated measures
ANOVA statistical analysis with a post hoc Newman Keuls test for multiple
comparisons was conducted to determine preference; preference was defined as a
significantly greater amount of time being spent in the Meth-paired compared to
the saline-paired chamber. Rats that spent greater than two standard deviations
above or below the mean in any chamber on any test day were removed from
statistical analysis. Rats conditioned with Meth at a dose of 0.1mg/kg (n=10)
demonstrated a significant preference for the Meth-paired chamber on CPP Tests
1 and 2 (post hoc Newman Keuls, p<0.01; effect of Chamber F(1,18)=27.917,
p<0.0001; effect of CPP Test Day F(2,36)=0.008, p=0.992; Interaction
F(2,36)=3.670, p=0.0035, Fig.4B). Rats conditioned with Meth at a dose of
0.3mg/kg (n=10) significantly preferred the Meth-paired chamber over the
saline-paired chamber on CPP Tests 1 and 2 (post hoc Newman Keuls, p<0.01;
effect of Chamber F(1,18)=10.542, p=0.004; effect of CPP Test Day F(2,36)=0.034,
p=0.967; Interaction F(2,36)=10.998, p=0.002, Fig. 4C). Rats conditioned with
Meth at a dose of 1.0mg/kg (n=10) demonstrated a significant preference for the
Meth- compared to the saline-paired chamber on CPP Tests 1, 2, and 3 (post hoc
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Newman Keuls, p<0.01; effect of Chamber F(1,18)=31.451, p<0.0001; effect of CPP
Test Day F(2,36)=0.023, p=0.977; Interaction F(2,36)=2.271, p=0.118, Fig. 4D).
Therefore, the 1.0mg/kg Meth dose appeared to provide the most consistent and
enduring preference in this conditioning paradigm, thus it was chosen for the
completion of the current dissertation work. For future studies that will
determine antagonism (Chapter IV) and correlation of CPP with other behavioral
outcomes (Chapter VII), a different experimental design was used in which the
rats are paired with Meth on the side where they spent the least amount of time
on the pre-test. Pairing rats with a drug on the side in which they spent the least
amount of time on the pre-test raises some concern as to whether reward or
anxiolytic properties of the drug are being assessed. However, studies in our lab
were conducted in order to determine the anxiolytic properties of the Meth
dosing regimen chosen using an elevated plus maze. Work completed by Robin
Voigt in the Napier lab has determined that neither acute nor repeated treatment
of Meth (1mg/kg, i.p.) produced anxiolytic or anxiogenic properties compared to
saline (1ml/kg, i.p.) treatment. Studies in the published literature have employed
the method of pairing rodents with a rewarding stimulant on the side in which
the least amount of time was spent in the pre-test during conditioning (Li et al.
2001;Nomikos and Spyraki 1988). Thus, we felt comfortable moving forward
with this behavioral treatment paradigm with Meth CPP.
Motor activity was also assessed at each conditioning session (after the
initial 10min where animals are settling down from initial injection). Rats were
removed from motor assessments for an individual activity parameter if activity

39
counts for Day 1 or Day 5 were greater than two standard deviations above or
below the mean. A two-way repeated measures ANOVA with post hoc Newman
Keuls test for multiple comparisons was utilized to determine the effects of each
dose of Meth on motor activity on the first (Day 1) and last (Day 5) day of
administration and to compare acute effects of each dose. Rats administered
Meth at a dose of 1.0mg/kg demonstrated increased horizontal activity (Fig. 5A)
and time spent in stereotypy (i.e., repetitive movements; Fig. 5C) on conditioning
Day 1 compared to rats administered 0.3 or 0.1mg/kg Meth (two-way repeated
measures ANOVA with post hoc Newman Keuls test, p<0.01). However, Meth
administration in this paradigm at any dose tested failed to develop motor
sensitization (i.e., there was not an increase in motor activity on Day 1 compared
to Day 5 for any motor parameter at any Meth dose tested). Statistical results
for each motor parameter: Horizontal activity; Dose F(2,31)=27.134, p<0.0001,
Test Day F(1,31)=1.846, p=0.184, Interaction F(2,31)=4.144, p=0.025. Vertical
activity; Dose F(2,30)=14.278, p<0.0001, Test Day F(1,30)=0.0005, p=0.983,
Interaction F(2,30)=3.793, p=0.034. Stereotypy time; Dose F(2,31)=21.424,
p<0.0001, Test Day F(1,31)=2.480, p=0.125, Interaction F(2,31)=2.874, p=0.072. We
have found in the Napier laboratory that while this treatment course of Meth
reliably induces CPP, motor sensitization does not always occur. This could be
due to the Meth dose or treatment interval, since Meth administered daily for five
days at a dose of 2.5mg/kg (s.c.) has induced motor sensitization in the Napier
laboratory. These data also demonstrate that CPP and motor sensitization can be
dissociated and likely model different aspects of the addiction phenomenon.
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Figure 3. Behavioral testing apparatus. A total of 16 test boxes were used
for the completion of the current dissertation acquired from Accuscan
Instruments, Inc., Columbus, OH. A) The CPP box consists of two larger
chambers (25cm x 30cm x 30cm) separated with sliding Plexiglas doors by a
smaller center chamber (13cm x 30cm x 30cm) equipped with two banks of
photobeams attached to the metal frame (24 horizontal and 12 vertical
photobeams). At the start of the pre-test or CPP test, the doors placed inside the
box. The rat is then placed in the small center chamber enclosed by the sliding
doors. B) Immediately after the rat is placed in the center chamber, the sliding
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doors are removed to allow the rat free access to the entire CPP box during the
pre-test or CPP test for 30min. C) During conditioning sessions, rats are placed
in an assigned chamber separated by one sliding door for 45min. Each larger
chamber has distinct, yet neutral visual and tactile cues. Pictured here is the
white, opaque patterned floor with an over-turned paint dish glued to the center
with epoxy. The visual cues are the vertical stripes on the surrounding walls of
the chamber. D) Pictured here is an alternative chamber configuration with
the grid floor and Plexiglas rectangular insert glued with epoxy to the center of
the floor. The visual cues are horizontal stripes on the surrounding walls of the
chamber. The floors are removable and floor type is randomized with visual cues
in the CPP box during the assignment of chamber for conditioning.
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Figure 4. Methamphetamine dose response CPP study. A) Timeline for
behavioral experimentation. Rats were pre-tested in a drug free state on day -2.
Three days later, rats were given Meth at a dose of 0.1mg/kg (N=10), 0.3mg/kg
(N=10), or 1.0mg/kg (N=10) on days 1, 3, and 5 and placed in their assigned
chamber. All rats were administered saline (1ml/kg, i.p.) and placed in the
opposite chamber on days 2, 4, and 6. Rats were then tested for initial preference
on day 9 (CPP Test 1) in a drug-free state. Rats were then repeatedly tested for
persistence of preference in a drug-free state on day 12 (CPP Test 2) and day 23
(CPP Test 3). Solid lines with filled squares represent time spent on the Methpaired chamber. Dotted lines with empty squares represent time spent on the
saline-paired chamber. Solid lines with filled triangles represent time spent in
the center chamber (center chamber not included in statistical measures, only
used for visual comparison). B) Rats conditioned with Meth at a dose of
0.1mg/kg (i.p.) only expressed a significant preference for the Meth-paired
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chamber on CPP Tests 1 and 2. C) Rats conditioned with Meth at a dose of
0.3m/kg (i.p.) spent significantly more time in the Meth-paired chamber on CPP
Tests 1 and 2. D) Rats conditioned with Meth at a dose of 1.0mg/kg (i.p.)
expressed a significant preference for the Meth-paired chamber on CPP Tests 1 to
3. Two-way repeated measures ANOVA with post-hoc Newman Keuls, **p<0.01.
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Figure 5. Motor activity induced by Meth during conditioning. Motor
activity was assessed on conditioning Day 1 and Day 5 (Fig. 4A) for all doses of
Meth (0.1, 0.3, and 1.0mg/kg, see key) for the last 35min of the conditioning
session. Sample size is represented within bars (n). A) Rats treated with
1.0mg/kg Meth demonstrated increased horizontal activity on Day 1 and Day 5
compared to rats treated with 0.3 or 0.1mg/kg Meth during conditioning.
However, rats treated with 0.1, 0.3 or 1.0mg/kg Meth did not demonstrate an
increase in horizontal activity on Day 5 compared to Day 1. B) There was an
increase in vertical activity in rats treated with 1mg/kg Meth compared to rats
treated with 0.1 or 0.3mg/kg on Day 5. C) Rats treated with 1.0mg/kg Meth
demonstrated increased stereotypy time on Day 1 and Day 5 compared to rats
treated with 0.3 or 0.1mg/kg Meth during conditioning. However, there was no
difference in stereotypy time between Days 1 and 5 for any Meth dose tested.
Two-way repeated measures ANOVA with post hoc Newman Keuls test for
multiple comparisons, **p<0.01.
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mGluR 1/5 allosteric modulator selection

MPEP, 2-methyl-6-(phenyl-ethynyl)-pyridine, mGluR5 NAM
The mGluR5 NAM, MPEP, is systemically active and is mGluR subtype
selective (Gasparini et al. 1999). However, this ligand does display some offtarget activity at the ionotropic NMDA receptor at high concentrations (NMDAR
IC50=18µM; Table 1) (Cosford et al. 2003). The use of MPEP at a dose of
30mg/kg, i.p. has been shown to blunt the development and expression of
morphine-induced CPP (Herzig and Schmidt 2004), which has been validated in
our lab (Herrold et al. 2005). This dose of MPEP does not produce rewarding
effects on its own as assessed in a CPP paradigm (McGeehan and Olive 2003).
However, preliminary data from our lab suggests that it blunts motor activity.
Because administration of MPEP at a dose of 30mg/kg, i.p. did not blunt the
preference for cocaine, and a dose of 50mg/kg, i.p. did not affect preference for
ecstasy using CPP, we felt that 30mg/kg, i.p. of MPEP should not disrupt the
ability of rats to perform the CPP task. We also determined in preliminary
studies that MPEP (30mg/kg, i.p.) given after Meth conditioning but prior to the
CPP test (Fig. 6A) failed to disrupt the expression of Meth-induced CPP. These
results demonstrated that MPEP at 30mg/kg, i.p. failed to disrupt the
maintenance of the Meth-associated context (Fig. 6B&C). These results could be
due to the time period at which the mGluR5 NAM was administered, the number
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of administrations, or the dose given. In Chapter IV the variable of time period at
which mGluR5 is critical for the maintenance of CPP is further addressed.

MTEP, 3-[(2-methyl-1,3-thiazol-4-ul)ethynyl]pyridine, mGluR5 NAM
The novel mGluR5 NAM, MTEP, demonstrates increased selectivity and
potency over MPEP (Cosford et al. 2003) (Table 1.); thus, studies included in
Chapter IV and VI of the current dissertation project were carried out with this
ligand. In vitro selectivity data for MTEP demonstrate IC50 (half maximal
inhibitory concentration) greater than 100µM for the group I subtype 1
metabotropic glutamate receptor (mGluR1) and greater than 300µM over the
ionotropic NMDA receptor subunit NR2B (Cosford et al. 2003). Furthermore,
full receptor occupancy occurs after a 10mg/kg, i.p., dose of MTEP in rat
hippocampal brain tissue (Busse et al. 2004).
The dose of MTEP selected to test the effects of mGluR5 blockade on the
maintenance of Meth-induced CPP (Chapter IV) was 3mg/kg, i.p. This dose is
the maximal effective dose shown to reduce self-administration of Meth without
affecting self administration of food reward (Gass et al. 2009;Osborne and Olive
2008). Furthermore, MTEP at 3mg/kg, i.p. reduced cue- and Meth-induced
reinstatement of Meth self administration behavior (Gass et al. 2009). In order
to determine if blockade of mGluR5 could block the development of Methinduced motor sensitization (Chapter VI), a 5mg/kg, i.p., dose of MTEP was used.
This dose of MTEP (5mg/kg, i.p.) was chosen since it reduces the expression of
cocaine-induced rearing activity, a motor parameter more frequently seen to be
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augmented by repeated Meth treatment in our laboratory, without affecting
vertical activity in saline pre-treated rats (Dravolina et al. 2006).

JNJ16259685, (3,4-dihydro-2H-pyranol[2,3]b quinolin-7-yl)(cis-4methoxycylohexyl)methanone, mGluR1 NAM
The mGluR1 NAM, JNJ16259685, is selective, systemically active, and
highly potent drug (Table 1). In vivo potency data reveal an ED50 (half maximal
effective dose) equal to 0.04mg/kg, s.c. in the rat cerebellum and 0.014mg/kg, s.c
(Lavreysen et al. 2004). Furthermore, in vitro data demonstrate JNJ16259685
to be a selective ligand without non-specific effects on other mGluRs up to
concentrations of 10µM (Lavreysen et al. 2004). A dose of 0.3mg/kg
JNJ16259685 was used for the current dissertation project (Chapter IV) since it
reduces self-administration of ethanol in alcohol preferring rats without effecting
responding for sucrose reward (Besheer et al. 2008).

CDPPB, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide, mGluR5 PAM
The mGluR5 positive allosteric modulator, PAM, CDPPB, is shown to be
systemically active and selective. In vitro selectivity data for CDPPB demonstrate
an IC50 greater than 9.7µM for other metabotropic glutamate receptors
(mGluR17-4,8). In vivo potency data demonstrate an EC50 (half maximal
effective concentration) of 20nM (Lindsley et al. 2004) (Table 1).
In order to determine if augmenting mGluR5 could enhance Meth-induced
place preference in isolation-reared rats (Chapter VII), a 3mg/kg, s.c., dose of
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CDPPB was used. This dose of CDPBB (3mg/kg, s.c.) was chosen since it was
most effective in facilitating the extinction of cocaine-induced CPP (Gass and
Olive 2009). Doses of CDPPB that could be rewarding on their own were also
avoided, since this mGluR5 PAM was to be given prior to Meth conditioning in
the CPP paradigm. The 3mg/kg CDPPB dose had no effect on Amph-induced
motor activity (Kinney et al. 2005). Furthermore, a higher dose of CDPPB
(10mg/kg, s.c.) had no effect on extracellular dopamine concentrations in the
NAc or mPFC (Lecourtier et al. 2007). Therefore, we felt that a dose of 3mg/kg,
s.c. of CDPPB would selectively enhance signaling through mGluR5.
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mGluR Compound

Chemical
Name

Selectivity

Potency
(rat receptor)

MPEP: mGluR5 NAM

2-methyl-6(pheylethynyl)
pyridine

mGluR1 IC50>100µM
NR2B IC50=18µM

ED50=2.1mg/kg, i.p.
Hippocampal brain
concentration after
3mg/kg =
0.83±0.05µM

MTEP: mGluR5 NAM

3-([2-methyl-1,3thiazol-4ul)ethynyl]pyridine

mGluR1 IC50>100µM
NR2B IC50>300µM

ED50=1mg/kg, i.p.
Hippocampal brain
concentration after
3mg/kg = 1.4±0.2µM

JNJ16259685: mGluR1 NAM

(3,4-dihydro-2H-

mGluR5
IC50=1.31±0.39µM,
no activity on
mGluR3-4,6 up to
10µM

ED50=0.014mg/kg,
s.c. (thalamus)
ED50=0.040mg/kg,
s.c. (cerebellum)

mGluR1-4, 8
IC50=9.7µM

EC50=20nM

pyrano[2,3]b
quinolin-7-yl)(cis-4methoxycylohexyl)
methanone

CDPPB: mGluR5 PAM

3-cyano-N-(1,3diphenyl-1Hpyrazol-5yl)benzamide

Table 1. mGluR ligands used for the current dissertation project. All mGluR ligands
used are group and sub-type selective. Please refer to text for citations.
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Figure 6. Effects of MPEP (30mg/kg) on maintenance of Methinduced CPP. A) Timeline of behavioral experiment. Rats were given access to
the entire test box on the pre-test (protocol day -2). All rats were then
administered Meth (1mg/kg, i.p.) and then placed in the chamber where they
spent the least amount of time on the pre-test on days 1, 3, and 5. On days 2, 4,
and 6 rats were injected with saline (sal, 1ml/kg, i.p.) and placed in the opposite
chamber. Rats were given injections of saline vehicle (3ml/kg, i.p.) or MPEP
(30mg/kg, i.p.) in their home cage on days 7 and 8. Conditioning sessions lasted
for 45min. Twenty-four hours later, rats were given access to the entire CPP box
in a drug-free state on day 9 for 30min. A total of 24 rats were used for the
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following comparisons. Eight rats from the Meth/Sal group (conditioned with
Meth and given saline on days 7 and 8) were rats used in the Meth dose response
study that were paired on the side in which they spent the least amount of time
on the pre-test. The remaining 16 rats were tested in a separate behavioral run
where 4 were added to the Meth/Sal group, and 12 were administered Meth
during conditioning and MPEP on days 7 and 8 (Meth/MPEP group). Rats were
removed as outliers if time spent in any chamber on the pre-test or CPP test was
greater than two standard deviations above or below the mean. Both the B)
Meth/Sal group (t(10)=5.237, p=0.0004) and the C) Meth/MPEP group
(t(9)=3.846, p=0.004) expressed a significant preference for the Meth-paired
chamber after conditioning (CPP Test) compared to the initial preference (Pre
Test). Paired t-test, **p<0.01, ***p<0.001.
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Selection of Rodent Schizophrenia Models
In order to investigate the converging neuropathologies of schizophrenia
and stimulant use disorders, we chose to use pharmacological and developmental
models of schizophrenia that both exhibit deficits in sensorimotor gating of the
acoustic startle response measured by PPI. Deficits in PPI are a well-established
behavioral outcome that occurs in schizophrenia patients (Braff et al. 2001) and
are easily assessed with high construct validity. Deficits in PPI are induced by
Amph administration in both humans and rodents (Swerdlow et al. 2003).
Recently, two separate laboratories have published repeated, escalating
treatment courses of Amph administration that produce robust deficits in PPI
that chronically persist (Peleg-Raibstein et al. 2008;Tenn et al. 2005). This was
an important outcome measure, as behavioral assessments of reward were
designed to follow and emulate a co-morbid schizophrenia and stimulant
addiction brain state. The study conducted by Tenn and colleagues demonstrates
that PCP does not produce persistent PPI deficits, which ruled out its use in our
behavioral paradigm (Tenn et al. 2005). The Amph treatment course employed
by Peleg-Raibstein was utilized in Chapter VII since it allowed for rapid induction
(six days as opposed to three weeks as in the Tenn et al. 2005 study) of an
enduring brain state that is biochemically similar to that of the schizophrenia
neuropathology as described in the Literature Review (Chapter II)(PelegRaibstein et al. 2008). However, because the use of two such similar stimulants
to model separate behavioral outcomes presents itself as a potential confound, we
chose to validate our results obtained from the repeated Amph treatment
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paradigm with the use of a developmental rodent model of schizophrenia. The
early stressor of maternal separation and isolation rearing following weaning is
another means of inducing PPI deficits in rodents (Geyer et al. 1993). Unlike the
neonatal ventral hippocampal lesion model, isolation rearing is easily executed
and does not employ additional surgical techniques. In summary, repeated
escalating Amph and isolation rearing are two behavioral models of
schizophrenia with high construct validity that allow for sensorimotor gating
assessments in a chronic treatment paradigm.

CHAPTER IV
mGluR5 BUT NOT mGluR1 IS NECESSARY FOR MAINTENANCE OF
METHAMPHETAMINE-INDUCED ASSOCIATIVE LEARNING

Abstract
Conditioned place preference (CPP) reflects the significance of contextual
cues that are repeatedly associated with rewarding effects of abused drugs like
methamphetamine (Meth).

Glutamate neurotransmission is augmented in

response to exposure to stimulants and cues associated with their use. Activation
of group I metabotropic glutamate receptors (mGluR) is critical for the
acquisition and expression of behavioral tasks mediated by stimulants.

We

hypothesized that the maintenance of Meth-induced behaviors would also
require activated mGluR, and that the role of mGluR1 versus mGluR5 may differ.
Negative allosteric modulators (NAMs) of these receptors were evaluated, since
this class of drugs have the advantage of acting only on agonist- (i.e., glutamate)
occupied receptors and thus provide a more targeted action. Conditioning with
Meth every other day for six days resulted in significant preference for the Methpaired compartment.
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Two daily injections of the mGluR1 NAM, JNJ16259685 (0.3mg/kg, i.p.) or its
vehicle on days 13 and 14 after Meth-conditioning did not influence the
maintenance of Meth-induced CPP; however, administration of the mGluR5
NAMs MTEP (3mg/kg, i.p.) and MPEP (30mg/kg, i.p.) inhibited maintenance
processes necessary for CPP to be expressed. These findings demonstrate a
subtype-specific role of mGluR5 receptors in the maintenance of place preference
memory and potential of mGluR5 NAMs as a useful target for addiction therapy.
Introduction
Methamphetamine (Meth) addiction is a problem of global health concern
for which there is no FDA-approved pharmacotherapy (Elkashef et al. 2008).
Even after protracted abstinence, Meth-addicted individuals are prone to cueelicited relapse (Hartz et al. 2001). One aspect of addiction that makes it such a
persistent phenomenon is the strength of learned associations between the
rewarding effects of drugs and the context in which drugs are administered
(O'Brien et al. 1992). Drug-induced associative learning can be studied in
rodents and humans using conditioned place preference (CPP) (Childs and deWit
H. 2009;Tzschentke 2007).
Withdrawal from stimulant treatment results in dynamic changes within
the cortico-striatal glutamate transmitter system. At early time points after
stimulant administration, small transient changes in glutamate receptor proteins
occur, perhaps as a compensatory response to drug-induced glutamate
transmitter levels in brain regions such as the nucleus accumbens (NAc) and
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medial prefrontal cortex (mPFC) (Ghasemzadeh et al. 2009a;Ghasemzadeh et al.
2009b;Shaffer et al. 2010;Shoblock et al. 2003). During extended withdrawal
from long-term cocaine abuse, the frontal cortex of humans is hypoactive (Bolla
et al. 2004;Goldstein and Volkow 2002). In rats withdrawal from repeated
stimulant exposure reduces glutamate levels in NAc and mPFC (Baker et al.
2003;Lominac and Szumlinski 2008), and ionotropic and metabotropic
glutamate receptors are increased in these brain regions (Ary and Szumlinski
2007;Boudreau and Wolf 2005;Ghasemzadeh et al. 2009a;Ghasemzadeh et al.
2009b). After an extended withdrawal in human stimulant abusers, the FC
becomes hyper-responsive to drug-associated cues (Childress et al. 1999;Grant et
al. 1996). In stimulant-withdrawn rodents, re-exposure to drug or drugassociated cues increases limbic glutamate levels beyond that seen in rats without
a stimulant treatment history (Chen et al. 2001;Pierce et al. 1996;Qi et al. 2009).
Drug cues hinder abstinence in addiction; therefore, there should be great
therapeutic value in normalizing the glutamatergic responses to drug-associated
cues.
Glutamate acts on both ionotropic and metabotropic receptors. Group I
mGluRs include both metabotropic glutamate receptor subtype 1 (mGluR1) and 5
(mGluR5), which are located primarily post-synaptically (Conn and Pin 1997).
Because of the localization of group I mGluRs within the brain systems important
for stimulant-mediated behavior, negative allosteric modulators (NAMs) of
mGluR1 and 5 may provide an important avenue to normalize the hyperresponsive glutamate system after repeated stimulant administration (Lu et al.
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1999;Romano et al. 1995;Testa et al. 1994a). Binding to sites that are remote
from the orthostatic position, allosteric modulators alter the efficacy of
endogenous agonists (Pin et al. 2003;Wang et al. 2009). Allosteric modulators
also avoid many of the unwanted side effects that can occur with direct acting
agonists/antagonists, where compensatory effects and widespread action are
prevalent (Wang et al. 2009). Group I mGluR NAMs have recently been used in
rodent models of addiction (Carroll 2008;Olive 2009). The mGluR5 NAM 3-[(2methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) decreases self-administration
of Meth, as well as cue- and Meth-primed reinstatement of Meth selfadministration (Gass et al. 2009;Osborne and Olive 2008). Likewise, the related
NAM, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), reduces the development
and expression of Meth- and amphetamine-induced associative learning,
respectively (Herzig et al. 2005;Miyatake et al. 2005). The mGluR1 NAM,
JNJ16259685, decreases ethanol self-administration (Besheer et al. 2008), and
another mGluR1 NAM, EMQMCM, reduces cocaine-induced motor activity
(Dravolina et al. 2006) as well as cue- and drug-induced reinstatement of
nicotine self administration in rodents (Dravolina et al. 2007). While negative
modulation of mGluR1 and mGluR5 decreases reward-mediated behaviors,
evidence suggests that these receptor subtypes may play different roles in
acquisition, consolidation and retention of memory (Salinska 2006;Simonyi et al.
2007;Steckler et al. 2005). For example, the mGluR1 receptor is important for
the acquisition, while the mGluR5 receptor may be more critical for the retention,
of spatial memories (Steckler et al. 2005). What remains unknown is the role of
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these receptors, and potential subtype-specific effects, in the maintenance of
stimulant-associated memories.
The maintenance of drug memories underlies relapse; therefore, a better
understanding of the role of group I mGluRs in this relationship may aid relapse
reduction. We hypothesize that post-conditioning administration of mGluR5
NAMs will disrupt the Meth – context memory association and thus decrease the
subsequent expression of Meth-induced CPP. We chose to administer
therapeutic interventions at 13 and 14 days post-conditioning, a time frame when
extracellular limbic glutamate is increased (Chen et al. 2001), and our lab has
shown neuronal changes subsequent to repeated Meth administration (McDaid
et al. 2006b), and when there is evidence of persistent up-regulation in glutamate
receptors (Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b). Comparison
of the mGluR1 and mGluR5 NAMs will allow us to differentiate between the
involvements of the mGluR subtypes in this Meth-mediated behavior.

Materials and Methods
Animals
Eighty male, 225-250g, Sprague-Dawley rats were used. Rats were treated
in accordance with NIH Guide for the care and use of laboratory animals and the
Rush University Institutional Animal Care and Use Committee. Rats were
allowed to habituate to the environmentally controlled vivarium (23-25ºC;
7:00AM/7:00PM light dark cycle) at least one week prior to the start of
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behavioral testing and given food and water ad libitum. All studies were
conducted during the light phase.
Drugs
(+)Methamphetamine hydrochloride (Meth, Sigma-Aldrich, St. Louis,
MO) in 0.9% NaCl sterile saline was given at a dose of 1mg/kg as the base. Our
lab and others have used this dose to successfully induce Meth CPP in rats
(Herrold et al. 2009;Kitanaka et al. 2010;Li et al. 2002;Schindler et al. 2002).
The mGluR1 NAM, JNJ16259685 (Tocris Bioscience, Ellisville, MO) was
administered at a dose of 0.3mg/kg, which reduces ethanol self-administration
without reducing natural rewards (Besheer et al. 2008). The mGluR5 NAM, 3[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP, Tocris Bioscience) was
administered at a dose of 3mg/kg, which reduces Meth self-administration
(Osborne and Olive 2008) as well as cue- and drug-induced reinstatement of
Meth self-administration (Gass et al. 2009). The mGluR5 NAM 2-methyl-6(phenyl-ethynyl)-pyridine (MPEP; a gift from Novartis Institutes for BioMedical
Research; Basel, Switzerland) was administered at a dose of 30mg/kg, which
reduces the development and expression of morphine-induced CPP (Herzig and
Schmidt 2004). All NAMs were dissolved in 10% w/v (2-hydroxypropyl)-γcyclodextrin in sterile water solution (termed vehicle, Sigma-Aldrich). All drugs
and their vehicles were given via intraperitoneal (i.p.) injection in a volume of
1ml/kg.
Conditioned Place Preference (CPP)
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CPP boxes (Accuscan Instruments, Inc., Columbus, OH) used for the study
are described in a previous publication from our laboratory (Shen et al. 2006).
Rats were transported to the behavioral testing room at least 30min prior to
experimentation. Timeline of the behavioral paradigm is illustrated in Fig. 7A.
All rats were given a pretest that demonstrated no significant group preferences
for either chamber. Some individual rats tended to prefer one chamber over the
other; thus, rats were paired with Meth in the chamber in which they spent the
least amount of time during the pretest. Rats were treated with Meth on days 1, 3
and 5, and saline on days 2, 4 and 6 and then immediately placed in the
appropriate chamber for 45min. On day 9, untreated rats were tested for
chamber preference (CPP Test 1) by giving them free access to the entire box for
30min. Following the procedures employed by Paolone and colleagues (Paolone
et al. 2009), if the difference between pretest and CPP Test 1 was at least a 10%
(>180s), the rats were used for assessing the effects NAMs. This helped assure a
sufficient ‘signal’ was used to ascertain the antagonism capacity of mGluR1/5
NAMs (54 out of 80 rats met this criterion). On days 10-17, all rats were given
once daily vehicle (1ml/kg) injections in their home cage. On days 18 and 19, rats
were given in their home cage a once-daily injection of either vehicle (1ml/kg),
JNJ16259685 (0.3mg/kg), MTEP (3mg/kg), or MPEP (30mg/kg). On day 22,
rats were tested for preference and motor activity was assessed (CPP Test 2) as
described previously for CPP Test 1 in a drug-free state.
Statistics
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Differences in time spent per chamber between pretest and CPP Test 1 was
determined via a paired t-test. Preference was determined based on a significant
increase in amount of time spent on the Meth- vs. saline-paired chamber on CPP
Test 1 and 2 via a two- way repeated measure (rm) ANOVA with post hoc
Newman Keuls test with α=0.05 for all tests. Statistical outliers for a given
measure were removed if data fell outside 2 standard deviations from the mean.
Data are represented as the mean + standard error of the mean (SEM).

Results
The time spent in the two large chambers was not different during the
pretest for all rats tested (846.3±42.9sec vs. 813.1±42.6sec; t(79)=0.391, p=0.697,
N=80). Three days after conditioning, rats demonstrated a robust preference for
the Meth- (930.3±32.0sec) vs. the saline-paired chamber (694.1±31.6sec,
t(79)=3.732, p<0.001, n=80) as a whole. Rats that showed more than a 10%
change in preference on the pretest vs. CPP Test 1 (n=47), spent 1097.7±28.4sec
in the Meth-paired chamber and 539.7±28.2sec in the saline-paired chamber
during CPP Test 1 (t(46)=9.913, p<0.001). Thus, the culling procedure does not
drastically alter behavioral outcomes.
Rats given post-conditioning vehicle (Fig. 7B, n=11) or JNJ16259685 (Fig.
7C, n=12) spent significantly more time in the Meth- vs. saline-paired chamber
on both CPP Test 1 and 2 (two-way rmANOVA with post hoc Newman Keuls,
p<0.01). Thus, the conditioning protocol induced place preference that persisted
for at least 16 days and was not diminished by repeated testing or post-
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conditioning injections of vehicle or the mGluR1 NAM. However, rats treated on
days 18 and 19 with the mGluR5 NAMs, MTEP (Fig. 7D, n=15) or MPEP (Fig. 7E,
n=9), failed to maintain a preference for the Meth-paired chamber on CPP Test 2
(two-way rmANOVA with post hoc Newman Keuls, p>0.05). There were no
between group differences on CPP Test 2 in horizontal beam breaks (vehicle
3814±27, JNJ16259685 3250±22, MTEP 3640±24, and MPEP 3086±29;
F(3)=1.601, p=0.203) or vertical beam breaks (vehicle 693±82, JNJ16259685
607±61, MTEP 547+38, MPEP 523+74; F(3)=1.394, p=0.257). These data
indicate that mGluR1/5 NAM treatment history did not affect spontaneous motor
activity on the subsequent CPP test day.

Discussion
Previous studies have implicated the mGluR1 and 5 in drug-mediated
behaviors, but none to-date have determined the role of these receptors in the
maintenance of stimulant-associated contextual memories. Acquisition of spatial
learning is impaired by administration of JNJ16259685 prior to training on the
Morris water maze (Steckler et al. 2005). Yet, mGluR1 NAM treatment after
training on the Morris water maze only partially impairs performance on a
subsequent test of spatial memory retention (Steckler et al. 2005). Retention of
passive avoidance learning is also spared following mGluR1 NAM treatment
(Gravius et al. 2005). Though mGluR1 is important for drug reinforcement
behaviors, it may not be as critical for the maintenance of spatial memories which
play a role in CPP behavior. The current study provided the first evaluation of
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mGluR1 NAMs on previously acquired drug-context associations induced by
repeated Meth administration. In this paradigm, the mGluR1 NAM
JNJ16259685 did not alter subsequent expression of place preference. This
outcome may reflect the delayed post-conditioning time of the NAM
administration, and it is possible that its administration sooner after place
conditioning might result in a disruption of the drug-context association.
Supporting this possibility, mGluR1 NAM administration 3 days after repeated
cocaine blunted the expression of cocaine-induced motor sensitization (Dravolina
et al. 2006). Future studies with chronic or early post-conditioning treatment of
JNJ16259685 would further elucidate the involvement of mGluR1 system in
maintenance of Meth-associated memories.
Our results suggest that activation of mGluR5 at 13-14 days postconditioning is necessary for the maintenance of Meth-induced CPP, since rats
that were treated with the mGluR5 NAMs MTEP or MPEP failed to demonstrate
preference for the Meth-paired context. The use of two mGluR5 NAMs, MTEP
and MPEP, (as well as the comparison to the mGluR1 NAM, JNJ16259685)
strongly imply that this is an mGluR5-specific phenomenon. The postconditioning time of mGluR5 modulation may also be important, since pilot data
from our lab suggest that an early post-conditioning administration (2 and 3 days
after Meth injection) of MPEP does not alter subsequent expression of Methinduced CPP (i.e., CPP remained statistically significant (t(11)=3.292, p=0.007)
when tested one day after two daily home cage injections of MPEP (30mg/kg,
i.p.)). In Meth self-administering rats that have undergone extinction training,
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MTEP pre-treatment reduces cue-induced reinstatement (Gass et al. 2009).
Thus, mGluR5 appear to be important for several aspects of Meth rewardmediated behaviors (CPP and self administration) as well as multiple phases of
Meth-induced associative learning (expression and maintenance).
Since NAMs act on agonist-bound receptors, results from the current
study indicate the importance of glutamate acting on mGluR5 receptors two
weeks after acquisition of CPP to sustain the conditioned Meth memory.
Therefore, brain regions that highly express mGluR5, such as the NAc, may be
key mediators in this behavioral phenomenon (Testa et al. 1994a). Though the
literature on glutamate transmitter effects subsequent to Meth administration is
limited, increases in NAc glutamate have been shown to occur 3 weeks after
repeated Meth (Lominac and Szumlinski 2008). Another possibility is that areas
of modest mGluR5 expression, such as the VP, may be characterized by excessive
glutamate release following Meth conditioning, resulting in a proportionally large
number of agonist-occupied mGluR5. For example, following 14 days after
repeated amphetamine, increases in glutamate occur to an acute challenge of the
drug in the VP (Chen et al. 2001). Our laboratory has shown that withdrawal
from repeated treatment of cocaine results in enhanced response of VP neurons
to glutamate (McDaid et al. 2005) and an up-regulation of mGluR5 in the VP
following 14 days of withdrawal from Meth (unpublished results). The current
study suggests that adaptations in the mGluR5 system occurred approximately
two weeks after the acquisition of Meth-induced associative learning.
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Cue-elicited relapse is a significant obstacle to abstinence for Meth addicts
(Hartz et al. 2001); thus, a pharmacotherapy that can inhibit the maintenance of
associative processes should aide in reducing cue evoked drug-seeking. This
study has identified a critical time-frame at which negative modulation of
mGluR5 receptors is sufficient to disrupt the maintenance of Meth-induced
context associations. These novel findings add to current understanding of the
neurobiological underpinnings of Meth associated memories and indicate that
mGluR5 NAMs deserve further exploration as potential pharmacotherapy for the
Meth-withdrawn human addict.
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Figure 7. The mGluR5 NAMs MTEP and MPEP, but not the mGluR1
NAM JNJ1625985, inhibit the expression of Meth-CPP. A) Timeline
of treatment and testing. Rats were pre-tested for initial bias on day -2 and
subsequently paired with Meth (1mg/kg, i.p.) on days 1, 3, and 5 and saline
(1ml/kg, i.p.) on days 2, 4, and 6 for 45min. Chamber preference was assessed on
day 9, (CPP Test 1), in a drug-free state in order to verify that the preference
developed.

On days 18 and 19, rats were given either vehicle (1ml/kg),

JNJ1625985 (0.3mg/kg), MTEP (3mg/kg), or MPEP (30mg/kg).

Rats were

tested for preference three days later (protocol day 22, CPP Test 2) in a drug-free
state. B) Rats treated with vehicle (n=11) demonstrated a significant difference
in amount of time spent in the Meth- vs. saline-paired chamber during CPP Test
1 and 2 (significant main effect of chamber F(1,20)=23.075, p=0.0001, a nonsignificant main effect of test F(1,20)=0.054, p=0.818, and a significant chambertest interaction F(1,20)=9.099, p=0.007). C) Likewise, rats treated with the
mGluR1 NAM JNJ1625985 (n=12) spent more time in the Meth- compared to the
saline-paired chamber on CPP Tests 1 and 2 (a significant main effect of chamber
F(1,22)=95.531, p<0.0001, a non-significant main effect of test F(1,22)=0.0002,
p=0.987, and a non-significant chamber-test interaction F(1,22)=0.911, p=0.350).
In contrast to these effects, administration of mGluR5 NAMs disrupted the
maintenance of Meth-induced CPP. D) Rats treated with the mGluR5 NAM
MTEP (n=15) demonstrated a significant preference for the Meth-paired
chamber during CPP Test 1 but the preference was not observed during CPP Test
2 (a significant main effect of chamber F(1,28)=14.686, p=0.001, a non-significant
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main effect of test F(1,28)=0.088, p=0.769, and a significant chamber-test
interaction F(1,28)=7.048, p=0.013). E) Likewise, rats treated with MPEP (n=9)
did not maintain the significant preference for the Meth-paired chamber
observed during CPP Test 1 after the day 17 & 18 intervening NAM treatments (a
significant main effect of chamber F(1,16)=22.785, p=0.0002, a non-significant
main effect of test F(1,16)=0.024, p=0.879, and a significant chamber-test
interaction F(1,16)=14.930, p=0.001). CPP data are represented as time spent in
the Meth-paired chamber (black solid square with solid black line), saline-paired
chamber (white square with dotted black line), or center chamber (black solid
triangle with solid black line, not included in statistics but illustrated for
qualitative purposes) on CPP Test 1 (left set of data points / column labeled under
graph) and CPP Test 2 (right set of data points / column labeled under graph).
Data points represent the mean + SEM. Repeated measure ANOVA with posthoc Newman Keuls test for multiple comparisons, **p<0.01

CHAPTER V
NOVEL SURFACE EXPRESSION TECHNIQUES FOR ex vivo
ASSESSMENT OF METABOTROPIC RECEPTORS IN THE
MAMMALIAN BRAIN: UTILITY IN MEASURING mGlu5
RECEPTORS AFTER METHAMPHETAMINEINDUCED ASSOCIATIVE LEARNING
Abstract
Altered expression of receptors and their distribution between the cell
membrane surface and the cytoplasm is a means by which psychomotor
stimulants alter neuronal transmission. Indeed, ionotropic glutamate receptor
distribution is altered in cocaine-sensitized rats, and such changes may
contribute to the neuropathology of addictive behaviors. However, stimulantinduced effects on intracellular distribution of metabotropic receptors are not
well known. The current study fills this gap by adapting the
bis(sulfosuccinimidyl)suberate (BS3) cross-linking technique, which has been
successfully employed to measure changes in ionotropic receptor distribution, to
assess surface and intracellular components of metabotropic glutamate for the
first time. Metabotropic glutamate receptor subtype 5 (mGluR5) is involved in
the behavioral effects of stimulants; including conditioned place preference and
motor sensitization.
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The current report evaluated if mGluR5 sub-cellular distribution is regulated in
the limbic brain regions of rats conditioned with methamphetamine (Meth).
Repeated Meth conditioning (1mg/kg) resulted in a significant preference for the
Meth-paired context as well as a sensitized motor response. The medial
prefrontal cortex (mPFC), nucleus accumbens (NAc) and ventral pallidum (VP)
were subsequently assayed for changes in receptor distribution. Methconditioned rats demonstrated a significant decrease in the surface to
intracellular ratio of mGluR5 in the mPFC, but not the NAc or the VP. This study
demonstrates the utility of the BS3 cross-linking technique to generate an ex vivo
snapshot of metabotropic glutamate receptor systems after repeated stimulant
administration.

Introduction
Receptors located at the neuronal surface serve as targets for
extracellularly released neurotransmitters. Internalization renders the receptors
unavailable to these transmitters, and this is an important means to regulate
neurotransmission. Understanding stimulant-induced changes in receptor
distribution may provide insight into neuropathology of stimulant abuse.
Ionotropic glutamate receptor subunit surface and intracellular expression can be
detected ex vivo using the membrane impermeable cross-linking reagent
bis(sulfosuccinimidyl)suberate (BS3). This technique, pioneered by Boudreau
and Wolf (Boudreau and Wolf 2005), was utilized to define the role of AMPA
receptor subunit surface expression in the synaptic plasticity that occurs
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subsequent to repeated cocaine (Boudreau et al. 2007;Boudreau et al.
2009;Ferrario et al. 2010) or amphetamine (Nelson et al, 2009) administration.
Metabotropic receptors provide an important means to fine tune excitatory
ionotropic transmission and thus likely regulate the maladaptations that occur
after repeated stimulant administration.
The behavioral role of these metabotropic receptors has been a topic of
great interest, and selective ligands have been used in various rodent models,
including conditioned place preference (CPP) and motor sensitization. CPP is a
well-established method of measuring the rewarding attributes of abused drugs
by assessing the preference for environmental contextual cues previously
associated with drug administration (Childs and deWit H. 2009;Tzschentke
1998;Tzschentke 2007). Motor sensitization is the augmentation in motor
activity that occurs with repeated administration of a drug, and the brain
adaptations associated with this simple behavioral readout may model some of
the brain adaptations that occur in the human stimulant abuser (Robinson and
Berridge 1993;Stewart and Badiani 1993). Metabotropic glutamate receptors are
critical for stimulant-mediated reward (Carroll 2008;Kenny and Markou
2004;Olive 2009;Xi and Gardner 2008) as well as learning and memory
processes (Anwyl 1999;Conn and Pin 1997). Specifically, group I subtype 5
metabotropic glutamate receptors (mGluR5), are necessary for the development
of Meth- (Miyatake et al. 2005) and expression of amphetamine-induced
associative learning (Herzig et al. 2005). These findings underscore that mGluR5
represent a receptor system engaged during stimulant-induced behaviors, and
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thus it was selected for our assessments of surface expression following Methinduced CPP and/or motor sensitization.
Trafficking of mGlu5 receptors is a dynamic process, and a variety of in
vitro methods have been used to detect surface expression of mGluR5 (Ango et
al. 2002;Kumpost et al. 2008;Lee et al. 2008). However, none of these methods
allow for the resolution of both surface and intracellular components of
metabotropic receptors within the same sample nor had the methods been
adapted for ex vivo tissue samples. These are important assay attributes for
understanding changes imposed by behaviorally relevant treatments of Meth, as
well as for future evaluations of the potential of these receptor systems as targets
for anti-addiction pharmacotherapies. To fill this gap, we modified the Boudreau
and Wolf assay developed for AMPA receptors (Boudreau and Wolf 2005) to
provide assessments of metabotropic glutamate receptors. With this assay, the
membrane impermeable cross-linking agent, BS3, binds to extracellular basic
residues (via an amide bond) of proteins inserted into the membrane, resulting
in a high molecular weight aggregate that is easily differentiated from the
intracellular protein by using an antibody for protein detection targeted to the
carboxy-terminal region of the receptor (Mattson et al. 1993). This high
molecular weight aggregate makes up the surface component, and the
intracellular component is resolved at the normal molecular weight for the
protein of interest within the same lane of the SDS-PAGE gel. The mGluR5 are
well suited for this assay since they are part of the group C G-protein coupled
receptor family characterized by a large extracellular, amino-terminal domain
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where there are many basic amino acids to which the BS3 agent can bind
(Hermans and Challiss 2001;Pin et al. 2003). This assay is also efficient, since
ample signal detection is attained without pooling brain tissue samples from
multiple animals. These features make this assay ideal for a high through-put,
rapid determination of metabotropic receptor distribution that may occur with
stimulant reward-mediated behaviors.
The goals of this study were two fold: First, was to adapt the BS3 crosslinking technique to resolve surface versus intracellular pools of mGluR5 within
the same ex vivo tissue sample. Second, was to apply this assay to test the
hypothesis that changes in these receptors would occur in brain regions
important for reward and memory taken from rats that exhibit Meth-induced
CPP and/or motor sensitization.
Materials and Methods
Animals
A total of 32 male Sprague-Dawley rats weighing between 250-275g at the
start of experimentation were used. Rats were acclimated to handling procedures
and to the housing vivarium (Rush University Medical Center, accredited
through the Association for Assessment and Accreditation of Laboratory Animal
Care) for at least one week prior to the start of behavioral testing. The vivarium
was maintained at 23-25°C temperature on a 12hour light cycle (7AM lights on:
7PM lights off) and rats had ad libitum access to food and water.
Experimentation took place during the light cycle of the rats. During this time,
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rats have been shown to produce the most robust CPP performance to
amphetamine (Webb et al. 2009). All procedures were approved by the Rush
University Institutional Animal Care and Use Committee and were carried out in
accordance with the National Institutes of Health Guide for the Care and Use of
Laboratory Animals (National Research Council, 1996).
Drugs
(+)Methamphetamine hydrochloride (Meth; Sigma-Aldrich, St. Louis,
MO) was administered at a dose of 1mg/kg as the base in a 0.9% sterile saline
solution. Meth or its vehicle was administered intraperitoneally (i.p.) in a volume
of 1ml/kg.
Test Apparatus
Conditioned place preference (CPP) and motor behaviors were quantified in
activity boxes that consisted of two large conditioning chambers (25cm x 30cm x
30cm) and a small center chamber (13cm x 30cm x 30cm) (Accuscan
Instruments, Inc., Columbus, OH). Behavior in each chamber was measured via
two banks of photo-beams (24 horizontal and 12 vertical) so as to measure the rats’
motor movements in three dimensional space. Beam counts were analyzed with
Versamax analyzer and software (Accuscan Instruments, Inc., Columbus, OH).
The two large conditioning chambers each had distinct visual (horizontal vs.
vertical stripes) and tactile (textured floor) cues. One chamber had vertical
stripes on the walls and a randomly patterned floor with an overturned paint dish
glued in the center (termed Chamber A); the other chamber (i.e., Chamber B) had
horizontal stripes on the walls with a square patterned floor and a flat,
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rectangular piece of Plexiglas glued in the center; center chamber had solid color
walls with a flat, smooth floor. The chambers were separated from each other by
removable Plexiglas doors.

Conditioned Place Preference Procedure
Rats were transported from the vivarium to the behavioral testing room for
habituation at least 30min prior to experimentation. The testing room was dimly
lit with white noise continuously present (White noise generator, San Diego
Instruments, San Diego, CA). The behavioral paradigm consisted of three
phases: pre-test, conditioning, and CPP test (Fig. 8A). For the pre-test, rats were
placed in the center chamber; and doors were immediately removed to allow
access to the entire CPP box for 15min (900s). Time spent in Chamber A was
348±26s and time spent in Chamber B equaled 459±24s. As time spent in the
two conditioning chambers differed (t(31)=2.215, p=0.0343), treatment
assignments were counterbalanced as follows: half the rats were assigned to
receive Meth or saline (day 1) in the chamber in which they spent the greatest
amount of time during the pre-test and the other half were assigned to received
Meth or saline (day 1) in the chamber in which they spent the least amount of
time during the pre-test. Rats were assigned to one of two treatment groups:
Meth-conditioned (n=16; Meth administered on days 1, 3, & 5 and saline
administered on days 2, 4, & 6) or saline-conditioned (n=16; saline administered
on days 1-6). During conditioning (protocol days 1-5, Fig. 8A), rats received the
appropriate injection (Meth 1mg/kg or saline 1ml/kg) and were immediately
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placed into the appropriate chamber of the CPP box for 45min. Motor activity
was assessed throughout the session. To test for the expression of the preference
(i.e., CPP test on day 9), drug-free rats were placed in the center chamber; and
doors were immediately removed to allow access to the entire CPP box for 15min.
Time spent as well as motor activity in each chamber was determined.
Tissue Preparation and Immunoblotting
Rats were decapitated without anesthesia, and mPFC, VP, and NAc tissues
(Fig. 10) were harvested within approximately 4min of decapitation one day after
the CPP test. The tissue preparation and surface receptor cross-linking
methodology was adapted from that of Boudreau and Wolf (Boudreau and Wolf
2005). After being dissected, each brain region was chopped into 400µm slices
with a McIlwain tissue chopper (Mickle Laboratory Engineering Co. LTD, Goose
Green, UK) and immediately placed into artificial cerebrospinal fluid (aCSF) with
2mM Bis(sulfosuccinimidyl)suberate (BS3; Thermo Scientific, Rockford, IL). The
cross-linking reaction took place for 30min with gentle agitation at 4°C;
administration of 100mM glycine terminated the cross-linking reaction (10min at
4°C). The supernatant was separated from the tissue pellet by centrifugation at
14000rpm for 2min (4oC), and the supernatant was removed and the tissue pellet
was re-suspended in lysis buffer (25mM HEPES, 500mM NaCl, 2mM EDTA,
20mM NaF, 0.1% Nonidet P-40 (v/v), 1mM DTT, 1mM PMSF, 1 x protease
inhibitor cocktail (Calbiochem, La Jolla, CA), phosphatase inhibitor cocktail I
(Sigma-Aldrich) and phosphatase inhibitor cocktail II (Sigma-Aldrich). To
disrupt the cellular membrane, tissues were sonicated and subsequently
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aliquoted and frozen at -80°C for future use. Tissue homogenate samples were
prepared with in 1:1 dilution of Laemmli sample buffer (Bio-Rad, Hercules, CA)
with β-mercaptoethanol.
For control experiments (Fig. 11), two separate saline treated rats of the same
weight from a separate pilot study were prepared without cross-linking (NonXlink). Brain regions (Fig. 10) were hand dissected and immediately fast-frozen
on dry ice then kept at -80°C until tissue preparation. For tissue preparation,
brain regions were Dounce homogenized and sonicated in lysis buffer (25mM
HEPES, 1mM EGTA, 1mM EDTA, 100nM okadaic acid, 1mM sodium
orthovanadate, 100uM PMSF, 10µg/ml of pepstatin, leupeptin & aprotinin in
cocktail form). Protein concentrations were determined via the Bradford method
(Bradford 1976) and samples were prepared with sample buffer (NuPAGE LDS
Sample Buffer, Invitrogen, Carlsbad, CA) and reducing agent (NuPAGE Sample
Reducing Agent, Invitrogen), aliquoted and frozen until use at -80°C.
To allow for immunoblotting, protein samples (20µg) were loaded into 415% Tris-HCl gradient gels (Bio-Rad) and electrophoresed at 200V for 45min.
The gels were then transferred to a Hy-Bond PVDF membrane (GE Healthcare
Limited, Buckinghamshire, UK) for 1.5hr at a current of 1.25A. Nonspecific
binding was blocked by incubation of the membrane with TBST (0.05% Tween
20, Sigma-Aldrich), 1% normal goat serum, and 5% non-fat dry milk for at least
1hr. Membranes were then incubated with mGluR5 (1:15,000 in TBS; Upstate,
Temecula, CA), or actin (1:20,000 in TBST and 5% non-fat dry milk, Santa Cruz
Biotechnology, Inc.) overnight at 4°C. Membranes were washed repeatedly with
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TBST and then incubated with the appropriate HRP-conjugated secondary
antibody for mGluR5 (goat anti-rabbit 1:15,000 in TBST; Jackson
ImmunoResearch, West Grove, PA) and actin (goat anti-rabbit 1:20,000 in TBST
and 5% non-fat dry milk; Santa Cruz Biotechnology, Inc.). Membranes were
subsequently washed with TBST, TBS, and distilled water.
Chemiluminescent substrate (SuperSignal West Pico, Thermo Scientific,
Rockford, IL) was applied to the membrane to visualize the protein of interest on
autoradiography film (HyBlot CL, Denville Scientific, Inc., Metuchen, JN).
Optical density was determined via densitometric analysis with Un-Scan-It
Software (Silk Software,Inc., Orem, Utah).
To detect protein levels of Homer1b/c and actin (loading control), the Snap
I.D. system (Millipore, Billerica, MA) was used for antibody incubation and
washing. After samples were electrophoresed on 10% acrylamide Tris gels and
transferred onto PVDF membranes as stated above, membranes were blocked for
nonspecific binding with filtered 0.5% non-fat dry milk in TBS-T (0.1% Tween20) then vacuumed through the Snap I.D. Primary antibody for mGluR5
(0.5µl/ml; Upstate), Homer 1b/c (2.67µl/ml; Millipore) or actin (0.33 µl/ml,
Santa Cruz Biotechnology) was then applied and incubated on the membranes for
10min and subsequently vacuumed through the Snap I.D. system. Membranes
were incubated with the appropriate HRP-conjugated IgG secondary antibody:
goat anti-rabbit (actin 0.33µl/ml; Jackson) and rabbit anti-rat (Homer1b/c
1.33µl/ml, Millipore). After vacuuming through the secondary antibody,
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membranes were washed and exposed to chemilumenescent substrate as
described above.
For pre-absorption assays, immunoblotting was conducted as stated above.
The PVDF membrane was cut in half and antibody plus the blocking peptide
(pre-incubated for 1hr at room temperature) was applied to half the other half
was processed as described previously; membranes were incubated overnight at
4°C. The mGluR5 synthetic blocking peptide (1:500 in 1xTBS; Neuromics
Antibodies, Edina, MN) used was specific to the epitope of the anti-mGluR5
rabbit immunoaffinity purified IgG primary antibody (1:15,000 in 1xTBS;
Upstate). Immunoblots were subsequently washed, incubated with the
appropriate secondary antibody, and developed as described previously.
Statistics
CPP: Preference was considered to have been achieved when a significantly
greater amount of time was spent in the Meth-paired compared to the salinepaired chamber during the CPP test; paired t-test, (α=0.025). Development of
motor sensitization was determined by a significant increase in activity between
the first (conditioning day 1) and last (conditioning day 5) injection of drug;
paired t-test (α=0.05). Immunoblotting: Optical density of the entire smear of
surface signal component (as pictured in Fig. 12, denoted S) and intracellular
component (I) were determined and a ratio was calculated (S/I ratio) by dividing
the S by I. Total protein was calculated by adding the S and I components and
dividing this value by the actin loading control. The individual S and I
components were calculated by dividing the optical density of S and I by the
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loading control, actin. The S/I ratio, total protein, S and I values were
normalized to the average saline treatment groups within each gel and multiplied
by 100 to determine Optical Density (% Average Saline) as shown in Fig. 11.
Student’s t-tests (α=0.05) were used to determine differences between Meth and
saline treatment groups in surface/intracellular (S/I) ratio, total protein, surface
(S) component and intracellular (I) component for mGluR5. All data are
represented as mean ± standard error of the mean (SEM). Statistical outliers
were determined as more than two standard deviations above or below the mean
for any data set. For the immunoblotting data, 95 out of 720 data points were
removed. Four out of 128 data points were removed in the motor sensitization
data, and no outliers were removed from the CPP data.

Results
The conditioning protocol (Fig. 8A) successfully induced a preference for
the Meth-paired chamber in rats that were Meth-conditioned (t(15)=4.489,
p=0.0004; Fig. 8C) that was not evident in rats that were treated with saline
(t(15)=1.063, p=0.3044, Fig. 8B). The repeated administration of Meth (1mg/kg)
lead to a significant increase in horizontal activity (t(15)=2.611, p=0.0197), and
vertical time (t(15)=2.250, p=0.0399) between the first (conditioning day 1) and
last (conditioning day 5) administration (Fig. 9A,B). Rats treated repeatedly with
saline (1ml/kg), however, demonstrated a significant decrease in horizontal
activity (t(13)=3.027, p=0.0097) and vertical time (t(13)=5.160, p=0.0002) to the
fifth compared to the first injection (Fig. 9C,D). These data indicate that rats
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given repeated, intermittent Meth developed motor sensitization, while rats given
saline habituated to the environment in which it was administered.
A pre-absorption assay validated antibody specificity for the mGluR5
primary antibody used for the immunoblotting experiments (Fig. 11A-C). In this
experiment, pre-absorption with the respective blocking peptide completely
inhibited binding of the antibody in tissue with (Xlink) and without (Non-Xlink)
the BS3 cross-linking reagent (Fig. 11B). Shown in Fig. 11 is NAc for mGluR5.
Comparison of Xlink and Non-Xlink tissue demonstrated that the high molecular
weight aggregate (which corresponds to the BS3 bound receptor inserted into the
surface of the membrane) was not present in the Non-Xlink tissue and that the
molecular weights of the intracellular components for the mGluR5 (Fig. 11A)
were found at the expected molecular weight in both Xlink and Non-Xlink tissue
(mGluR5 molecular weight approximately 130kD). Thus, the cross-linking
procedure allows for the simultaneous detection of the high molecular weight
aggregate inserted into the membrane surface versus receptors that are located in
the intracellular compartment of the cell. To validate that BS3 did not permeate
the cell membrane, we used cross-linked tissue to evaluate Homer 1b/c, a protein
that is located exclusively in the intracellular compartment. Immunoblots of
Homer 1b/c resulted in a discrete band at approximately 47kD which correctly
corresponds with the molecular weight of Homer 1b/c and no high molecular
weight aggregate was detected (Fig. 11C).
Evaluation of distribution of mGlu5 receptors revealed excellent detection
levels in all brain regions tested (i.e., mPFC, NAc and VP). While no changes
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were observed for the mGluR5 receptor in the NAc (S/I ratio, t(28)=0.346, p=
0.731; total

protein, t(29)=1.96, p=0.059; surface, t(29)=1.342, p=0.190;

intracellular, t(29)=0.2235, p=0.8247, Fig. 12B) or the VP (S/I ratio, t(29)=1.33,
p=0.195; total protein, t(29)=0.265, p=0.793; surface, t(29)=0.7878, p=0.4372,
intracellular, t(28)=1.635, p=0.1133, Fig. 12C), Meth-conditioning significantly
reduced the mPFC mGluR5 S/I ratio (t(28)=3.14, p= 0.004) and increased the
intracellular component (t(30)=2.98, p=0.005) without altering total protein
(t(29)=0.11, p= 0.909) or the surface component (t(29)=0.3836, p=0.7041; Fig.
12A). Thus, brain and receptor specific changes were observed in the S/I ratio of
the mGluR5 in the mPFC of Meth-conditioned rats.

4. Discussion
We demonstrated for the first time that ex vivo BS3 cross-linking
methodology can be applied to metabotropic glutamate receptors. We also
revealed that this methodology can detect brain region-selective differences in
responding to Meth in behaviorally relevant doses. That is, in the mPFC, the S/I
ratio and intracellular levels of mGluR5 was significantly reduced after repeated
Meth administration that induced CPP and motor sensitization.
Distribution of mGluR5 can be determined using a variety of techniques.
Biotinylation has been successfully employed in vitro (Lee et al. 2008); however,
this technique may produce highly variable results because intracellular and
surface components are quantified in separate gels. Synaptosomal fractionation
has also been used to determine the distribution of mGluR5 receptors ex vivo
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(Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b;Shaffer et al. 2010);
however, this technique does not specifically determine levels of receptor protein
inserted into the surface of the cellular membrane. The technique used in the
current study, pioneered by Boudreau and Wolf (Boudreau and Wolf 2005) to
evaluate the surface expression of AMPA receptor subunits, provides several
advantages. The membrane impermeable cross-linking agent BS3 binds to
extracellular basic residues of proteins inserted into the membrane resulting in a
high molecular weight aggregate that is easily differentiated from the
intracellular protein by using an antibody for protein detection targeted to the
carboxy-terminal region of the receptor. We validated the lack of intracellular
BS3 binding using Homer 1b/c as an intracellular control since this is a
scaffolding protein is important for trafficking of the mGluR5 receptor (Ango et
al. 2002;Roche et al. 1999). This finding is in keeping with the work of Boudreau
and Wolf who demonstrated discrete, monomeric banding of tyrosine
hydroxylase in BS3 cross-linked tissue (Boudreau and Wolf 2005). It is
important to note that although this assay has been used to monitor changes in
the expression and distribution of mGluR5, AMPA receptors (Boudreau et al.
2007;Boudreau and Wolf 2005;Conrad et al. 2008;Mickiewicz et al. 2006;Nelson
et al. 2009), and now dopamine receptors (Conrad et al. 2010), it does not work
for all proteins inserted into the surface of the membrane. BS3 binds to basic
amino acid residues in the N-terminal region, and there must be an adequate
amount of these residues to allow for differentiation of the surface and
intracellular components. The mGluR5 are part of the class C family of
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metabotropic receptors that have very large extracellular domains, which each
contain many basic amino acid residues (Hermans and Challiss 2001;Pin et al.
2003). Another critical technical consideration relates to the fact that BS3 binds
to the amino (N)-terminal of the receptor. Consequently, it can mask antibody
binding sites located in the N-terminus; and so an antibody that binds to the
intracellular carboxy-terminal region of the receptor must be used.
In the current study, we observed that in the mPFC of rats showing Methinduced CPP, the mGluR5 S/I ratio was decreased compared to saline control
tissue, but the total mGluR5 protein between Meth and saline groups was not
different. This outcome indicated a redistribution of mGluR5 to the intracellular
pool of the cell, which is in accord with the significant increase in the intracellular
pool of mGluR5 receptors that we observed for the mPFC. Thus, it appears that
cells within the mPFC have adapted to the Meth conditioning treatment such that
there are fewer mGluR5 on the surface and more in the intracellular pool.
The decreased S/I ratio and increase in intracellular levels of the mGluR5
receptor in the mPFC may be a compensatory mechanism to counteract the
hyperexcitable state after repeated Meth administration. Meth administration
increases extracellular glutamate levels in the mPFC (Shoblock et al. 2003) and
this effect is enhanced by repeated pairing of Meth with environmental cues (Qi
et al. 2009). Also, mGluR5 receptors are desensitized with prolonged agonist
exposure (Catania et al. 1991). Shaffer and colleagues found that an acute
treatment of amphetamine increases synaptosomal mGluR5 in the mPFC
(Shaffer et al. 2010) whereas glutamate levels are unchanged in this region
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following amphetamine treatment (Shoblock et al. 2003). One day after repeated
cocaine, a time frame at which glutamate levels are increased in response to an
additional cocaine injection (Williams and Steketee 2004), an increase in
mGluR5 in the mPFC is observed in the synaptosomal fraction (Ghasemzadeh et
al. 2009b). The divergent outcomes found in the current study may reflect drugspecific effects (Meth vs. cocaine), withdrawal time specific effects (four days vs.
one day) or dissection-dependent effects (ventral vs. dorsal mPFC). This change
may also reflect the response to re-exposure to conditioning cues 24hr before the
tissue was collected. The current study adds to the literature to demonstrate that
repeated Meth administration, which was sufficient to induce CPP and MSn, may
be important for some of the adaptations that contribute to the addiction
phenomenon.
No other significant changes in the expression or distribution of the
mGluR5 receptor were identified in the NAc or VP. This was an unexpected
result, as there are a few examples of dynamic effects of mGluR5 expression in
the NAc in response to other stimulants, cocaine and amphetamine (the VP had
not been previously studied). For example, a repeated, sensitizing amphetamine
administration results in a decrease in mGluR5 mRNA in the NAc that occurs 3hr
after drug administration and persists up to 28 days (Mao and Wang 2001). A
potential explanation for this disparate finding from our study is that there is an
increase in extracellular glutamate levels in the NAc following amphetamine but
not Meth administration (Shoblock et al. 2003). Therefore, mGluR5 receptors
may have internalized in response to repeated glutamate exposure after repeated
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amphetamine which would not occur with Meth administration. In response to
repeated cocaine administration, on the other hand, synaptosomal protein levels
of mGluR5 are unchanged at early, and increased following extended (3 week)
withdrawal (Ghasemzadeh et al. 2009a). Yet, Swanson and colleagues
demonstrate a decrease in total mGluR5 protein and its associated scaffolding
protein Homer 1b/c at the same withdrawal time from repeated cocaine
(Swanson et al. 2001). Thus, it appears that glutamate receptor adaptations are
differentially altered by the various stimulant drugs. There is precedence for this
conclusion as Wolf and colleagues found differential adaptations in the surface
expression of AMPA receptor subunits to repeated cocaine (increase in
GluR1surface expression) and amphetamine (no change in GluR1 levels)
administration in the NAc using the BS3 cross-linking assay (Boudreau et al.
2007;Nelson et al. 2009). As little is known about sub-cellular dynamics of
mGluR5, following behaviorally relevant Meth administration, our results will aid
in a more thorough characterization of mGluR5 expression in the NAc in
response to stimulants. We have also extended the literature by including the VP
in our assessments. Though mGluR5 levels in the VP were unaltered in the
current study, these findings are an important step in the characterization of a
brain region known to be involved in motivation to action and incentive salience.
The current study has demonstrated the application of the BS3 crosslinking technique to assess surface expression of mGluR5 which provides an ex
vivo snapshot of the brain of in vivo Meth-induced processes. We have identified
brain region specific alterations in surface expression of mGlu5 receptor and
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exciting potential of this work would be to determine if this receptor
redistribution is functionally relevant in electrophysiological assays.
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Figure 8. Meth-induced CPP. A) Time-line of behavioral protocol. For the
pre-test (day -2), drug-free rats were allowed to explore the entire box for 15min.
Conditioning occurred for six days; for Meth conditioned rats, Meth (1mg/ml/kg,
i.p.) was paired with one chamber of the box on days 1, 3, & 5, and the saline
(1ml/kg, i.p.) was paired with the opposite chamber on days 2, 4, & 6). Saline
conditioned rats were treated in the same manner but saline was administered on
all days (days 1-6). Conditioning sessions were 45min in duration. Three days
later (day 9), rats were tested for the expression of Meth-induced CPP in a drugfree state (15min). Meth, methamphetamine, Sal, saline, Ø, no drug. B) Rats
conditioned with saline (n=16) did not demonstrate a preference for either
chamber on the CPP Test day (Paired t-test, p>0.025). C) Rats conditioned with
Meth (n=16) spent significantly more time in the Meth-paired (dark bar) vs. the
saline-paired (white bar) chamber during the CPP Test (Paired t-test,
***p<0.001).
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Figure

9.

Repeated

administration

of

methamphetamine

was

sufficient to induce the development of motor sensitization. Horizontal
Activity (number of horizontal beam breaks) in A) Saline (n=14)- and B) Meth
(n=16)-conditioned rats. Vertical Time (sec spent breaking beams in the vertical
plane) in C) Saline-conditioned (n=14) and D) Meth-conditioned (n=16) rats.
Shown here are mean ± SEM for data obtained on conditioning day 1 and
conditioning day 5 of the behavioral paradigm (treatment protocol illustrated in
Fig. 1A). Paired t-test, *p<0.05, **p<0.01, ***p<0.001.
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Figure 10. Stereotaxic brain maps indicating regions dissected. This
figure is modified from Paxinos and Watson (1998) with numbers indicating the
distance in millimeters from Bregma. The boxes indicate dissections from the
mPFC, medial prefrontal cortex, NAc, nucleus accumbens, and VP, ventral
pallidum.
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Figure 11. Validation of BS3 cross-linking technique applied to
mGluR5.

A) Cross-linked (Xlink) and non-cross-linked (Non-Xlink) NAc

tissues probed for mGluR5 demonstrated mGluR5 receptor protein at ~130kD,
corresponding to intracellular protein, and a high molecular weight aggregate at
>400kD, corresponding to surface receptor bound to BS3 which was present in
Xlink tissue only. An overexposed blot is pictured here as to demonstrate both
intracellular and surface proteins on the same exposure. Also, the same exposure
was demonstrated in B) for pre-incubation of the antibody with the blocking
peptide that inhibited all antibody binding, indicating antibody specificity
demonstrating no signal at longer exposures. C) A protein that is exclusively
located in the intracellular cell compartment, Homer1b/c (an intracellular
scaffolding protein) was detected at 47kD without any high molecular weight
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aggregate signal indicating that that BS3 cross-linker is not penetrating cellular
membranes.
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Figure 12. mGluR5 S/I ratio was decreased in the mPFC of Methconditioned rats. Treatment group is indicated by key: Sal=saline conditioned
(open bar), Meth=methamphetamine conditioned (filled bar). Representative
immunoblots are illustrated above each set of bar graphs. Data are shown for
surface to intracellular ratio (S/I Ratio), total protein (Total), surface and
intracellular receptor components. A) There was a significant reduction in the
S/I ratio of Meth-treated rats that expressed CPP in the mPFC. There was no
change in total mGluR5 or surface protein in the mPFC.

There was also a

significant increase in the intracellular component of mGluR5 in the mPFC.
There were no changes in mGluR5 S/I ratio, total protein, surface or intracellular
protein components in the B) NAc or C) the VP. Student’s t-test, **p<0.01.
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CHAPTER VI
DIFFERENTIAL DISTRIBUTION OF IONOTROPIC AND
METABOTROPIC GLUTAMATE RECEPTORS FOLLOWING
ACUTE AND REPEATED ADMINISTRATION OF
MORPHINE OR METHAMPHETAMINE: ROLE
OF mGluR5 IN EXPRESSION OF GluR2 AND
STEP61 PROTEINS

The current chapter is the result of collaboration with Dr. Amanda
Mickiewicz, a former student in the Napier laboratory. Dr. Mickiewicz, as a part
of her dissertation project, completed the work involving opiates. In alignment
with the body of this dissertation work, only results of this chapter dealing with
methamphetamine will be addressed in the General Discussion.

Abstract
The metabotropic glutamate group I subtype 5 receptor (mGluR5) is
critical for neuronal and behavioral effects of opiates and stimulants including
the progressive enhancement (sensitization) of motor activity in laboratory rats.
The mGluR5 also regulates surface expression of ionotropic AMPA receptor
subunits through the activation of striatal enriched tyrosine phosphatase isoform
61 (STEP61).
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To best study this phenomenon, we measured AMPA subunit and mGluR5
distribution levels in the same tissue samples harvested from rats after induction
of motor effects or after sensitized responding to the opiate morphine and the
stimulant methamphetamine (Meth). Application of the
bis(sulfosuccinimidyl)suberate (BS3) cross-linker to medial prefrontal cortex
(mPFC), nucleus accumbens (NAc) and ventral pallidum (VP) tissue collected
from rats one day after acute, or fourteen days after repeated morphine or Meth,
allowed for detection of AMPA receptor subunits (GluR1 and GluR2) and
mGluR5 surface expression as well as intracellular STEP61 protein via Western
blot analysis. Surface expression of GluR1 and GluR2 were decreased in the
mPFC following acute morphine. Fourteen days after a sensitizing regimen of
repeated morphine or Meth, the surface expression to intracellular protein ratio
of GluR2 in the mPFC and mGluR5 in the VP was increased. In repeated,
morphine-treated rats, mGluR5 surface expression decreased without a change in
STEP61 in the mPFC. In Meth treated rats, mGluR5 levels were not altered;
however, STEP61 was decreased. We hypothesized that function of mGluR5 was
responsible for the alterations that occurred in GluR2 and STEP61. After
administering an mGluR5-selective negative allosteric modulator, MTEP, prior to
Meth in a separate group of animals, levels of GluR2 and STEP61 were not altered
in the mPFC after fourteen days of withdrawal. These data give an excellent
comparison of glutamate receptor adaptations that occur subsequent to opiate
and stimulant sensitization. Furthermore we provide evidence that mGluR5 is
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functionally responsible for GluR2 and STEP61 alterations induced by
methamphetamine sensitization.

Introduction
Repeated administration of opiates and stimulants enhances motor
activity beyond that obtained with a single injection, a phenomenon often
referred to as sensitization. Drug-induced behavioral and neuronal sensitization
can persist long after the cessation of drug administration. The neuronal changes
associated with sensitized behaviors in rats may model some of the persistent
brain adaptations that occur in the abstinent, but drug-addicted human (Paulson
et al. 1991;Robinson and Berridge 1993;Sax and Strakowski 2001;Stewart and
Badiani 1993). The neuronal circuitry that undergoes sensitization to both
opiates and stimulants involves the limbic system, including glutamatergic
projections from the medial prefrontal cortex (mPFC), to the nucleus accumbens
(NAc) (Christie et al. 1985) and the ventral pallidum (VP) (Carnes et al.
1990;Fuller et al. 1987;Sesack et al. 1989). However, these brain structures are
involved in different phases of the sensitization processes. The mPFC is
implicated in the development of behavioral sensitization (Bjijou et al.
2002;Cador et al. 1999;Pierce et al. 1998;Wolf et al. 1995;Wolf and Xue 1999),
while the NAc mediates the maintenance and expression of the behavior (Pierce
and Kalivas 1997;Vanderschuren and Kalivas 2000). Studies from our laboratory
demonstrate that the VP is critical for the development, maintenance and
expression of sensitization (Dallimore et al. 2006;Johnson and Napier
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2000;McDaid et al. 2005;McDaid et al. 2006a;Mickiewicz et al. 2009).
Glutamatergic transmission in each of these brain regions is altered following
repeated treatment of opiates and stimulants, and most of the evaluations of
neuronal sensitization show that alterations in the mPFC occur during
development; the NAc is altered during maintenance and expression, whereas
glutamatergic enhancement occurs in the VP during all three phases of
sensitization (Chen et al. 2001;Hao et al. 2007b;Johnson and Napier
1997;LaLumiere and Kalivas 2008;McDaid et al. 2005;McDaid et al.
2006a;Pierce et al. 1996;Qi et al. 2009). Thus, to best understand the
complexities of drug-induced sensitization, an appreciation of the temporal (i.e.,
sensitization phase) and spatial (i.e., brain region) effects of the glutamatergic
processes need to be considered.
Group I subtype 5 metabotropic glutamateric receptors (mGluR5) are
located throughout the limbic circuitry (Lu et al. 1999;Romano et al. 1995;Testa
et al. 1994b), and these receptors are critical for both opiate- and stimulantmediated behaviors, including sensitization (Gass et al. 2009;Herzig et al.
2005;Herzig and Schmidt 2004;Kotlinska and Bochenski 2007;Miyatake et al.
2005). mGluR5 regulates release of glutamate and the functional state of the
ionotropic receptors. For example, activated mGluR5 induces internalization of
AMPA receptors containing the GluR1 and GluR2 subunits (Snyder et al. 2001)
via de-phosphorylation of AMPA receptor subunits by the striatal-enriched
protein tyrosine phosphatase, isoform 61 (STEP61) (Zhang et al. 2008). STEP61 is
expressed in CNS neurons, including those in striatal and cortical regions
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(Boulanger et al. 1995;Bult et al. 1996). Blockade of STEP was recently shown to
reduce the development of amphetamine-induced behavioral sensitization
(Tashev et al. 2009). Therefore, we considered that mGluR5 would be involved
in the regulation of AMPA receptor surface expression and STEP61 expression in
brain regions where these proteins were altered by opiates and/or stimulants.
Regulating the number of receptors available for transmitter activation is
an important means for regulating function, and processes involved in this
regulation are important underpinnings of drug-induced neuroplastictiy.
Increases in AMPA receptor surface expression enhance synaptic strength, which
promotes both the development and the maintenance of drug-induced
sensitization (Kauer and Malenka 2007;Wolf et al. 2004). Little is known about
these processes during opiate-induced sensitization, and the psychostimulant
most studied is cocaine. With repeated, once daily treatments of cocaine, one day
after the last injection (a time when the animal would be „expecting‟ a subsequent
cocaine treatment) there is little change in GluR1, GluR2 and mGluR5 levels in
the mPFC and NAc(Ghasemzadeh et al. 2009a;Ghasemzadeh et al. 2009b); the
VP was not assessed in these studies. Following extended (21 days) withdrawal
from repeated once-daily cocaine administration, there is an overall upregulation of these receptor proteins in synaptosomal membrane fractions in the
NAc and mPFC, as well as enhanced surface expression of GluR1 and GluR2/3
subunits (Boudreau and Wolf 2005;Ghasemzadeh et al. 2009a;Ghasemzadeh et
al. 2009b). Extended withdrawal from repeated amphetamine, on the other
hand, does not result in altered surface expression of GluR1 or GluR2 in the NAc
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(Nelson et al. 2009). These results indicate that the effects of one stimulant on
glutamate receptor trafficking cannot be generalized to all stimulants.
The current study was designed to determine if AMPA receptor surface
expression in limbic brain regions was commonly regulated by the opiates and
stimulants, if this co-varied with mGluR5 surface expression and STEP levels,
and if the apparent trafficking processes involved in induction of behavioral
sensitization were common to those involved in the maintenance. Furthermore,
we were able to determine if the mGluR5 receptor mediated these drug-induced
receptor adaptations via administration of an mGluR5 negative allosteric
modulator (NAM). Toward those objectives, we used a new methodology that
allows for ex vivo assessments of surface expression of receptor proteins in brain
samples taken from rats subjected to once-daily treatments of the opiate,
morphine and the stimulant, methamphetamine (Meth) (Mickiewicz & Napier,
under review; Herrold et al., under review). To provide a temporal and spatial
snapshot of maintenance, we harvested the mPFC, NAc and VP following 14 days
of withdrawal, a time frame that we have observed maintenance-related effects in
these brain regions in both morphine- and Meth-treated rats (McDaid et al.
2005;McDaid et al. 2006a;McDaid et al. 2006b;Mickiewicz et al. 2009). To
ascertain if similar changes in surface expression may be part of the induction
process, we also assayed ex vivo brain samples taken one day after a single drug
treatment (i.e., at a time when rats in the repeated treatment protocol received a
second drug treatment).
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The experimental outcomes significantly moved the field forward by filling
several gaps in the literature, include the following “firsts”: i) Characterization
of surface expression of both AMPA receptor subunits, as well as mGluR5,
following a sensitizing regimen of both an opiate and a stimulant. ii) Inclusion
of the VP in each of these assessments. iii) Determination of a mechanism for
mGluR5 regulation of AMPA receptor subunit surface expression subsequent to
drug-induced sensitization. iv) The ability of the negative allosteric modulator
MTEP to block both the behavioral and neuronal sensitization induced by Meth.
These data are particularly informative since surface expression of mGluR5 has
not been assessed following morphine administration, and the effects of Meth
administration on AMPA receptor proteins or surface expression of mGluR5 have
not been studied in ex vivo brain tissue samples.

Materials and Methods
Animals
Male Sprague-Dawley rats weighing 200-225g upon arrival (Harlan,
Indianapolis, IN) were housed in pairs under environmentally controlled
conditions (7:00AM/7:00PM light/dark cycle, temperature maintained at 2325oC) with ad libitum access to rat chow and water. The rats were habituated to
vivarium conditions for at least one week prior to experimentation. All
procedures were conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (National Research Council, Washington DC) and were
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approved by the Institutional Animal Care and Use Committees at Loyola and
Rush University Medical Centers.
Drugs
Morphine sulfate, obtained from the National Institute on Drug Abuse
(Bethesda, MD), was dissolved in 0.9% saline to yield a dose of 8mg/ml/kg as the
salt. Meth hydrochloride (Sigma, St. Louis, MO) was dissolved in saline to yield
a dose of 1mg/ml/kg as the salt. Control rats received the saline vehicle (1ml/kg).
Injections were given subcutaneously (sc). 3-((2-Methyl-1,3-thiazol-4yl)ethynyl)pyridine hydrochloride (MTEP, Tocris Bioscience, Ellisville, MO) was
dissolved in sterile water containing 20% w/v 2-hydroxypropyl-β-cyclodextrin
(Sigma) to yield a dose of 5mg/ml/kg as the salt. MTEP and its vehicle were
injected intraperitoneally (ip).

Behavioral Assessments and Treatment Protocols
Rats were transported across the hall from the housing room to the test
room at least 30min prior to the start of the experiment. The test room was
dimly lit (5 -10 foot candles) with white noise continuously present. Two days
prior to behavioral assessment, the rats were habituated to the activity boxes for
1hr, given sc saline injections, and motor activity was monitored for 2hr postinjection. The motor score obtained on the second day was used as baseline
activity. Drug treatments began one day after baseline collection; rats were
randomly assigned to receive saline, morphine or Meth. Motor activity was
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collected using Plexiglas activity chambers (25cm x 30cm x 30cm) equipped with
two sets of photobeams (AccuScan Instruments, Inc., Columbus, OH) that
allowed behavioral quantification in three dimensional space. Rats were allowed
to habituate to the motor boxes for 1hr, given a sc injection of the drug (saline,
morphine, Meth) and then immediately placed back into the motor box for 3hr of
behavioral monitoring. For the acute treatment protocol, On Day 1, 32 rats were
administered the drugs (morphine, Meth or the saline vehicle) and motor activity
was quantified. Rats were sacrificed the following day (Day 2) via rapid
decapitation to collect tissue for biochemical analysis (see below). For the
repeated treatment protocol, 64 rats were administered saline, morphine or Meth
once-daily for three days (Days 1-3), and motor activity was quantified.
Following a 14 day withdrawal (W/D) period, a subset of rats (n=32) was tested
for expression of sensitization after administration of morphine or Meth. Other
rats (n=32) were not given a drug challenge and were sacrificed via rapid
decapitation on W/D 14 to collect tissue for biochemical analysis.
To assess the effects of the mGluR5 NAM, MTEP on repeated Meth
treatments, rats were given vehicle (20% w/v 2-hydroxypropyl-β-cyclodextrin) or
the mGluR5 NAM, MTEP 10min before saline (n=12) or Meth (n=10),
respectively, once-daily for three days (Days 1-3) and motor activity was
quantified. On W/D day 14, rats were sacrificed via rapid decapitation to collect
tissue for biochemical analysis.
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Protein Cross-Linking with BS3
The brains were removed within 45-60sec after decapitation and
immediately chilled in ice-cold artificial cerebrospinal fluid. The mPFC, NAc,
and VP were dissected (see Fig. 13) and chopped into 400µm slices using a
McIlwain tissue chopper (The Vibratome Company, O‟Fallon, MO). Methods for
receptor cross-linking were based on Boudreau & Wolf (2005). Briefly, the slices
were quickly transferred to centrifuge tubes containing artificial CSF and 2mM
BS3 (Pierce, Rockford, IL) and incubated for 30min on a rocker at 4°C. The
cross-linking reaction was terminated by the addition of 100mM glycine for
10min at 4°C. The slices were pelleted by 2min of centrifugation and the
supernatant discarded. The pellets were re-suspended in ice-cold lysis buffer
[25mM HEPES, pH 7.4, 500mM NaCl, 2mM EDTA, 1mM DTT, 1mM PMSF,
20mM NaF, 1x phosphatase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), 1x
protease inhibitor cocktail (Calbiochem, La Jolla, CA), and 0.1% Nonidet P-40].
The samples were sonicated for 5sec, centrifuged for 2min, aliquotted, and stored
at -80°C until analysis. Total protein concentration of lysates was determined
according to the Bradford method (Bradford 1976).

Immunoblotting GluR1, GluR2, mGluR5 and STEP
Samples (20µg) were loaded and electrophoresed on 4-15% gradient TrisHCl gels (Bio-Rad, Hercules, CA) and transferred to PVDF membranes for
immunoblotting. Non-specific binding sites were blocked using 1% normal goat
serum and 5% nonfat dry milk in TBS-Tween 20 (TBS-T, Sigma), pH 7.4 for 1hr
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at room temperature. Membranes were incubated in primary antibody (GluR1,
1:1000, Millipore, Billerica, MA; mGluR5, 1:15,000, Millipore; GluR2, 1:4000,
Millipore; STEP, 1:4000, Millipore; actin, 1:20,000, Santa Cruz Biotechnology,
Santa Cruz, CA) overnight at 4oC with gentle shaking. Following six washes for
5min each in TBS-T, membranes were incubated in HRP-conjugated secondary
antibody (goat anti-rabbit; either 1:10,000 (Millipore, GluR1 and GluR2),
1:15,000 (Jackson ImmunoResearch, West Grove, PA, mGluR5), or 1:20,000
(Jackson, actin); rabbit anti-mouse, 1:4000 (Jackson, STEP)) for 1hr at room
temperature. Membranes were again washed in TBS-T (six x 5min), immersed in
enhanced chemiluminescent substrate (Pico, Pierce, Rockford, IL) for 5min, and
exposed to HyBlot CL film (Denville Scientific, Metuchen, NJ). Two bands were
visualized on film; a dense, high molecular weight band of ~400-600 kDa (crosslinked GluR1 or mGluR5 corresponding to the surface pool (S)) and a band at
~106 kDa (GluR1 and GluR2), ~135kDa (mGluR5), (i.e., unmodified GluR1,
GluR2 or mGluR5 corresponding to the intracellular pool (I)) or ~61kDa (STEP61
isoform). Densities of the immunoreactive bands were analyzed using Lab Works
(UVP, Upland, CA) or Un-Scan It (Silk Scientific, Orem, UT) software. Images
were captured using a BioChemi Imaging System (UVP) coupled to a CCD camera
or a scanner (Epson Electronics America, Inc., San Jose, CA) coupled to a PC
computer. All samples were run at least twice and averaged across runs.
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Data Summaries and Analyses
Behavior: For the acute treatment study, a Student‟s t-test was used to
compare total session counts on Day 1 between saline and drug treatment. For
the repeated treatment study, development of sensitization was determined using
a one-way repeated measures analysis of variance (rmANOVA) comparing motor
activity on Day1 and Day 3 between treatment groups with a post hoc Newman
Keuls test for multiple comparisons. To determine expression of sensitization, a
Student‟s t-test was used to compare motor responses between treatment groups.
All data are presented as mean ± SEM. Significance was a priori set at α=0.05
Immunoblots: The surface/intracellular ratio (S/I) of GluR1, GluR2, and
mGluR5 was calculated by dividing the optical densities of the surface band by
the intracellular band. Total GluR1, GluR2, and mGluR5 were determined by
adding the optical densities of the surface and intracellular bands and dividing by
the loading control actin. The portion of GluR1, GluR2, or mGluR5 on the
surface was calculated by dividing the optical density of the surface band by actin;
intracellular GluR1 or mGluR5 was similarly determined by dividing the optical
density of the intracellular band by actin. Results from morphine-and Methtreated rats were normalized to saline-treated (control) values for each brain
region. All data are presented as mean + SEM. A Student‟s t-test was used to
compare between saline control and drug treatment groups, with a Bonferroni
correction for comparing the same control group to each of the two treatment
groups, setting α=0.025 for accepting significance.
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Results
Behavioral Response to Acute Drug Administration
Rats treated with a single morphine injection (8mg/kg sc) demonstrated a
significant decrease in horizontal activity (t(14)=4.438, p<0.001) and repetitive
beam breaks (t(14)=4.682, p<0.001) compared to rats given saline (Table 2A). In
contrast, a single injection of Meth (1mg/kg sc) resulted in a significant increase
in horizontal activity (t14=5.700, p<0.001) and vertical time (t(14)=3.099, p<0.01)
compared to saline treated rats (Table 2B).

Behavioral Response to Repeated Drug Administration
The behavioral responses to repeated drug administration are illustrated
in Fig. 14 and 15. The development of morphine-induced sensitization was
demonstrated by comparing motor activity on Days 1, 2 and 3. Horizontal beam
breaks (Fig. 14A; F(2,14)=7.94, p=0.005) and repetitive beam breaks (Figure 14B;
F(2,14)=6.49, p=0.009) were significantly increased with repeated morphine
treatments. Similarly, motor sensitization developed following three injections of
Meth. When motor activity was compared on Days 1, 2, and 3, vertical beam
breaks (Fig. 15A; F(2,14)=5.49, p=0.02) and vertical time (Figure 15B; F(2,14)=4.67,
p=0.03) were significantly increased. The sensitization was maintained for at
least 14 days, for a between treatment group analysis showed that responding to
an acute morphine challenge (8mg/kg sc; given on protocol Day 17) was greater
in rats with a morphine history compared to those that received morphine for the
first time (horizontal beam breaks: t(13)=2.77, p=0.02; repetitive beam breaks:
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t(14)=2.76, p=0.02). When challenged with Meth 14 days later (Day 17), rats with
a treatment history of Meth also had higher counts of activity compared to those
with a saline treatment history (vertical beam breaks: t(14)=2.45, p=0.03; vertical
time: t(14)=2.68, p=0.02), indicating that sensitization was maintained in the
Meth-treated animals.
A separate group of animals was subjected to the same treatment protocols
for Days 1-3, but on Day 17, brain tissue was harvested for biochemical analyses.
As in the previous experiments, drug-treated rats demonstrated increased motor
activity on Day 3 compared to Day 1. For morphine, horizontal beam breaks,
F(2,16)=13.68; repetitive beam breaks, F(2,18)=11.35 (p<0.001).
For Meth, vertical beam breaks F(2,18)=6.68, p=0.007; and vertical time,
F(2,16)=7.27, p=0.006. Thus, the biochemical results obtained on Day 17 for both
morphine and Meth-treated rats represent neuronal adaptations that occur in the
sensitized brain.

Effects of mGluR5 Negative Allosteric Modulator on development of motor
sensitization
Miyatake has demonstrated that mGluR5 are involved in the development
of Meth-induced CPP(Miyatake et al. 2005). We extended this literature by
testing if these receptors were critical for the development of Meth-induced
motor sensitization. As shown in Fig. 15, there was no effect of repeated vehicle
and saline treatment (open triangles) or MTEP and Meth treatment (filled
triangles) on vertical beam breaks (F(1,17)=0.718, p=0.409) or vertical time
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(F(1,16)=0.002, p=0.964). Vertical beam breaks did not show an effect of repeated
treatment day (F(1,34)=1.849, p=0.173) or an interaction between treatment and
day of testing (F(2,34)=2.042, p=0.145, Fig. 15C). Vertical time also did not shown
an effect of repeated treatment day (F(2,32)=1.33, p=0.278) nor was there a
significant interaction between treatment and day of motor testing (F(2,32)=1.01,
p=0.376; Fig. 15D). These data indicate that development of motor sensitization
did not occur after repeated treatment with Meth in rats pre-treated with the
mGluR5 NAM, MTEP (5mg/kg, ip).

Effect of a single administration of morphine or Meth on the distribution of
glutamate receptors.
There were minimal changes observed in the NAc (Table 3A&B) and VP
(Table 3 A&B) one day after an acute morphine and Meth. Only the GluR1 S/I
ratio was significantly decreased in the NAc of morphine compared to saline
treated rats (Table 3A); yet, total, surface and intracellular GluR1 protein levels
remained unchanged between treatment groups. There were no changes in S/I
Ratio or total GluR2 or mGluR5 proteins in the NAc between saline and
morphine treated rats (Table 3A). Furthermore, there were no changes in the S/I
ratio or total GluR1, GluR2 or mGluR5 protein in the NAc between saline and
Meth treated rats (Table 3B) or in the VP between saline and morphine (Table
4A) or saline and Meth treated rats (Table 4B).
Evaluations of immunoblots from tissue harvested on one day after
morphine administration showed that the GluR1 S/I ratio was decreased in the
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mPFC (t(19)=2.853, p=0.0102). The decrease in the S/I ratio reflects the slight
(but not significant) increase in the amount of intracellular GluR1 (t(20)=1.996,
p=0.0597), decrease in surface GluR1(t(20)=2.182, p=0.0412), and decrease in
total GluR1 (t(20)=2.187, p=0.0408) in morphine treated rats (Fig. 16B) (Note a
Bonferroni correction was implemented for comparing the same control group to
each of the two treatment groups, setting α=0.025 for accepting significance).
In the mPFC from morphine-treated rats, the amount of surface GluR2
was decreased (t(18)=2.523, p=0.0213, Fig. 16D). However, there was not a
significant change between saline and morphine treatment groups in total GluR2
(S+I, t(18)=1.839, p=0.0825), S/I ratio (t(18)=0.8660, p=0.3979) or intracellular
protein (t(18)=0.2862, p=0.7780). There was no change in the mPFC between
saline and morphine treated rats in mGluR5 S/I ratio (t(17)=1.476, p=0.1582),
total protein (S+I, t(17)=1.315, p=0.2059), surface protein (t(17)=1.294, p=0.2130),
or intracellular protein (t(16)=1.423, p=0.1739, Fig. 16F). There also was no
difference between saline and Meth treated rats in mPFC tissues with any
glutamate receptor protein assayed (Table 5).
Effect of 14day withdrawal from repeated morphine or Meth administration on
distribution of glutamate receptors.
No changes resulted in the NAc for GluR1, GluR2, or mGluR5 proteins
following 14 days of withdrawal from repeated morphine (Table 6A) or Meth
(Table 6B) treated rats (Student‟s t-test, p>0.025). Therefore, no STEP61 protein
levels were assessed in the NAc.
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In VP tissue collected from rats treated with either morphine (t(18)=2.653,
p=0.016, Fig. 17B) or Meth (t(19)=3.040, p=0.007, Fig. 17D), there was an
increase in mGluR5 S/I ratio compared to the saline treatment group. This
statistically significant increase in the mGluR5 S/I ratio reflected the nonsignificant trends in individual components: a slight increase in the surface
component and a modest decrease in the intracellular mGluR5 pool. However,
there was no change in any other mGluR5 protein component measured
(Student‟s t-test, p>0.025, Fig. 17B and D). Moreover, no changes were detected
in GluR1, GluR2 or STEP61 proteins in the VP between saline and morphine
(Table 7A) or Meth (Table 7B) (Student‟s t-test, p>0.025).
mPFC tissue collected 14 days after repeated morphine (8mg/kg), showed
a significant increase in GluR2 S/I ratio of (t(18)=2.997, p=0.008) compared to
saline treated rats (Fig. 18C). Of note, is that the GluR2 I component
demonstrated a non-significant trend towards a decrease (t(19)=2.146, p=0.045)
(Fig. 18C). There was no difference between treatment groups in the amount of
GluR2 total protein (t(19)=0.476, p=0.640) or S component (t(19)=0.752, p=0.462)
in mPFC tissues (Fig. 18C). Decreased in the amount of total mGluR5
(t(19)=3.062, p=0.006) and S protein (t(19)=2.691, p=0.014) were obtained in the
mPFC of morphine-treated rats compared to saline controls (Fig. 18F). However,
there was no change in the mGluR5 S/I ratio (t(19)=2.057, p=0.054) or I protein
(t(19)=0.476, p=0.640) in this brain region (Fig. 18F). There was no change in any
component of the GluR1 subunit of the AMPA receptor in the mPFC (Student‟s ttest, p>0.025, Fig. 18B) nor the STEP61 protein (Fig. 18H).
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Similar to what was observed subsequent to morphine treatment, after 14
days withdrawal from repeated Meth (1mg/kg), GluR2 S/I ratio was increased in
the mPFC (t(19)=3.475, p=0.002) (Fig. 19D). There was also a non-significant
trend towards a decrease in the GluR2 I component of Meth-treated rats
(t(20)=2.385, p=0.027, Fig. 19D). However, there was no difference between
treatment groups in total (t(20)=0.086, p=0.932) or the S component (t(20)=0.534,
p=0.599) of GluR2 in the mPFC. Unlike what was detected after morphine
treatment, there was a decrease in the level of STEP61 protein in the mPFC of
Meth- treated rats (t(19)=2.504, p=0.022, Fig. 19H), but no change, in the protein
components of mGluR5 (Fig. 19F) or GluR1 (Fig. 19B) (Student‟s t-test, p>0.025).

Effects of mGluR5 blockade on distribution of GluR2 and STEP61 subsequent to
Meth withdrawal.
To determine if mGluR5 signaling was responsible for the changes in
GluR2 surface expression and STEP61 seen in the mPFC following repeated Meth,
the mPFC was harvested after 14 days withdrawal from rats where the mGluR5
NAM, MTEP was shown to block the development of Meth-induced motor
sensitization (motor data shown in Figure 15C and D). The changes that occurred
subsequent to 14 days withdrawal from Meth in the mPFC were no longer present
in GluR2 (Fig. 20B) and STEP61 (Fig. 20D) of MTEP and Meth treated rats
compared to vehicle and saline treated controls (Student‟s t-test, p>0.025).
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Discussion
These studies demonstrate that administration of morphine (8mg/kg, sc)
or Meth (1mg/kg, sc) produced an increased motor responding to a single
injection. A progressive enhancement in motor behavior between the first and
last of three, daily morphine or Meth administrations of morphine or Meth also
occurred. Thus, harvesting tissue one day after the first injection, i.e., a time that
equaled the inter-dosing interval used for the repeated injection, provided a
temporal snapshot of the processes that occur during development of
sensitization. The expression of motor sensitization was validated in a subset of
rats behaviorally tested at fourteen days of withdrawal, suggesting that the brain
was in a sensitized state at the time when tissue was harvested for biochemical
analysis. We also determined that the mGluR5 NAM, MTEP (5mg/kg, ip),
administered prior to Meth during development, precluded sensitization. This
finding concurs with prior demonstration that mGluR5 is necessary for the
development of Meth-induced conditioned place preference (Miyatake et al.
2005).
Several studies have reported changes in AMPA receptor and mGluR5
distribution in the NAc associated with cocaine treatment, a region important for
the expression of sensitization. Cell surface and synaptic AMPA receptor levels
are increased in the NAc after 2-3 weeks, but not one day of withdrawal from a
sensitizing regimen of cocaine (Boudreau et al. 2007;Boudreau and Wolf
2005;Ghasemzadeh et al. 2009a). A single administration of amphetamine
transiently decreases synaptosomal mGluR5 levels in the NAc one hour after

114
administration, an effect that is normalized five hours later (Shaffer et al. 2010).
As with the AMPA receptors, synaptosomal mGluR5 levels remain unchanged
one day after repeated cocaine administration; yet, these levels are also upregulated following long-term (3 weeks) withdrawal in the NAc (Ghasemzadeh et
al. 2009a). Supporting our negative findings in the NAc following repeated Meth
treatment, Nelson and colleagues report that AMPA receptor S/I ratio is
unchanged in the NAc of rats that are sensitized to amphetamine; however, acute
amphetamine treatment slightly decreased surface levels of GluR1 after 24hr
(Nelson et al. 2009). Therefore alterations in AMPA receptor subunits GluR1 and
GluR2 appear to be unchanged following repeated Meth or amphetamine
treatment in the NAc. Here we show that acute morphine treatment did not alter
surface levels of GluR1; changes in the ratio were due to a non-significant
increase in the intracellular levels of GluR1. Interpreted in the sense that surface
AMPA receptors are the functional receptors, we would predict that AMPA
receptor function in the NAc would not be affected by acute morphine treatment.
This does not conflict with the role of NAc in the long-term effects of repeated
drug exposure. AMPA receptors are clearly important for cue and drug-induced
heroin seeking behavior at the withdrawal time examined in the current study
(LaLumiere and Kalivas 2008); however, these receptors do not have to be upregulated on the cell surface to produce these effects.
Our results indicate that specific up-regulation of mGluR5 S/I ratio is a
common feature of withdrawal from a sensitizing regimen of both the opiate
morphine and the stimulant Meth in the VP. Here we demonstrated that 14 days
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after repeated morphine treatment, there was an increase in the mGluR5 S/I
ratio due to a slight increase in the surface component of this receptor. Our lab
has demonstrated that the VP is a critical mediator in the development (Johnson
and Napier 2000;Mickiewicz et al. 2009), and maintenance (Dallimore et al.
2006;McDaid et al. 2006a) of opioid-induced motor sensitization. We have also
shown that in VP neurons of morphine sensitized rats there is a significantly
increased ability to enter depolarization block subsequent to local glutamate
application (McDaid et al. 2006a). The activation of mGluR5 influences
excitability in many ways, including the augmentation of ionotropic glutamate Nmethyl-D-aspartic acid receptor (NMDAR) currents as well as suppression of
after-hyperpolarization potassium currents (Ireland and Abraham
2002;Mannaioni et al. 2001). Therefore, it is possible that augmented mGluR5
S/I ratio could reduce recovery of VP neurons leading to increased excitability
and depolarization inactivation in the presence of glutamate agonist. At this time
point, however, we saw no alterations in the surface expression of GluR1 or
GluR2 subsequent to morphine treatment in the VP. Alternative explanations for
the observed increase in VP neuronal functionality include posttranslational
modifications of AMPA receptors to alter the conductance of these channels
(Derkach et al. 1999), changes in the cellular distribution of other AMPA receptor
subunits (e.g. GluR3) or NMDA receptors. Electrophysiological studies with local
application of selective agonists and antagonists for AMPA and NMDA receptors
are needed to verify which receptor is functionally up-regulated. In the present
study, we also observed an increase in the mGluR5 S/I ratio in the VP of rats 14
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days after repeated Meth administration due to a decreased shift in the mGluR5
intracellular component. Therefore, mGluR5 levels are likely maintained on the
cell surface while intracellular receptors are degraded, perhaps due to the lack of
agonist-induced desensitization of mGluR5. VP neurons are also important for
coding incentive motivational properties of drug cues following amphetamine
sensitization (Tindell et al. 2005) and neuronal markers for activity as well as
synaptogenesis in VP neurons are up-regulated following the expression of
amphetamine-induced associative learning (Rademacher et al. 2006). Future
electrophysiological assessments would help determine the role of mGluR5 on
the excitability of VP neurons following withdrawal from repeated morphine and
Meth.
We demonstrated here that acute morphine treatment significantly
reduced the GluR1 S/I in the mPFC, and we propose this is a result of decreases
in surface expression and increases in intracellular levels of GluR1, suggesting
that GluR1 was redistributed from the surface to the intracellular compartment.
These results are consistent with role of the mPFC in the development, but not
expression, of morphine sensitization (Hao et al. 2007a;Tzschentke and Schmidt
1999). Long-term withdrawal from morphine treatment returned GluR1 levels to
baseline. These results suggest that a decrease in responsiveness to excitatory
inputs occurs within the inter-dosing interval timeframe of the treatments (24hr
after acute or repeated treatment, Mickiewicz & Napier, under review) and prior
to a long-term withdrawal period (14 days). In contrast to the observed effects
following a single morphine treatment, there was no change in AMPA receptor
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subunits in the mPFC after a single Meth injection. A recent study by Simoes and
colleagues (Simoes et al. 2008) showed an increase in GluR2 in the frontal cortex
24hr after a single administration of meth. One possible explanation for the
contrasting results was the dose of Meth, 30 mg/kg in the Simoes study
compared to 1mg/kg used here.
At the long-term withdrawal period, both surface and total mGluR5
protein levels are decreased. Therefore, less mGluR5 was available to be
activated in the mPFC of morphine-treated rats. Since mGluR5 activation results
in internalization of AMPA receptor subunits (Snyder et al. 2001), it follows that
the GluR2 S/I ratio was significantly increased after 14 days of withdrawal from
repeated morphine. Though STEP61 is a key mediator in mGluR5-dependent
internalization of GluR2 (Zhang et al. 2008), this protein remained unchanged
fourteen days after repeated morphine. However, the brain state of the mPFC
following withdrawal from repeated morphine is adapting in such a way as to
reduce neuronal calcium levels by favoring AMPA receptor subunit composition
for the calcium-impermeable GluR2 (Liu and Zukin 2007) as well as decreasing
mGluR5 surface and total protein which would reduce calcium release from
intracellular stores (Sladeczek et al. 1985). Similarly, the GluR2 S/I ratio is
increased following 14 days of withdrawal from repeated Meth due to a decreased
shift in the intracellular GluR2 pool. No alterations occurred in mGluR5 levels in
the mPFC. Since STEP61 protein levels were significantly decreased, it appears
that less phosphatase is available to internalize GluR2 receptors and levels
increase on the membrane surface. We determined that this effect was mediated
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through activation of mGluR5 receptors, as a pre-treatment of MTEP prior to
Meth administration precluded any changes in mPFC GluR2 or STEP61 levels at
14 days of withdrawal. Therefore, the up-regulation of GluR2 S/I ratio and the
decrease in STEP61 protein likely reflected activation of mGluR5 through Methinduced increases in glutamate transmitter in the mPFC (Qi et al. 2009;Shoblock
et al. 2003).
The current study characterized glutamate receptor adaptations induced
by two drugs of separate classes: the opiate morphine and the stimulant Meth.
Overlaps for the two drugs included the up-regulation of mGluR5 S/I ratio in the
VP and GluR2 surface expression in the mPFC after long-term withdrawal. This
suggests that there are common glutamatergic mechanisms between the
adaptations that underlie sensitization.
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Tables
Table 2A. Motor Activity evoked by a single injection of morphine.
Saline

Morphine

Horizontal Activity

1306±50

555±126***

Repetitive Beam Breaks

822±46

339±74***

Table 1B. Motor activity evoked by a single injection of
Methamphetamine.
Saline

Methamphetamine

Vertical Activity

113±32

1924±385**

Vertical Time

70±20

651±143***

(A) Rats given a single administration of morphine (8mg/kg, sc, n=6)
demonstrated a significant decrease in both horizontal activity and repetitive
beam breaks compared to rats treated with saline (1ml/kg, sc, n=10). Behavioral
assessments occurred over 90min post-injection. Student‟s t-test, ***p<0.001
(B) Rats given a single administration of Meth (1mg/kg sc; n=10) demonstrated
a significant increase in both vertical activity and vertical time compared to rats
treated with saline (1ml/kg sc; n=6).

Behavioral assessments occurred over

60min post-injection. Student‟s t-test, **p<0.01,***p<0.001
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Table 3A. NAc: 1 Day After Morphine.
Protein: Component
GluR1

GluR2

mGluR5

Saline

Morphine

S/I

103.1±10.6

68.3±7.3

t(18)=2.581, p=0.019*

Total

100.3±6.9

102.2±4.0

t(19)=0.238, p=0.814

S/I

97.6±5.2

113.7±10.7

t(17)=1.394, p=0.181

Total

115.9±7.6

112.5±6.6

t(18)=0.335, p=0.741

S/I

100.0±7.8

101.7±16.0

t(18)=0.103, p=0.919

Total

98.7±10.2

114.8±11.3

t(19)=1.061, p=0.302

Table 3B. NAc: 1 Day After Methamphetamine.
Protein: Component
Saline
Meth-

Statistics

Statistics

amphetamine
GluR1

GluR2

mGluR5

S/I

103.1±10.6

142.4±28.3

t(18)=1.405, p=0.177

Total

100.3±6.9

112.1±6.4

t(19)=1.251, p=0.226

S/I

97.6±5.2

97.3±4.5

t(18)=0.047, p=0.963

Total

115.9±7.6

108.1±12.7

t(18)=0.550, p=0.589

S/I

100.0±7.8

103.5±12.1

t(20)=0.246, p=0.808

Total

98.7±10.2

106.5±8.8

t(20)=0.577, p=0.570

Shown are the mean ± SEM optical density values as percent average saline
control for each treatment group and corresponding Student‟s t-test statistics.
S/I ratio and Total (S+I) protein were assessed for GluR1, GluR2, and mGluR5 in
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VP tissues after one day of a single injection of Saline (1ml/kg, sc), (A) morphine
(8mg/kg, sc) or (B) Meth(1mg/kg, sc). There was a significant decrease in the
GluR1 S/I ratio in the NAc of morphine-treated rats *p<0.025. However, there
were no other differences between saline and Meth treatment groups for any
glutamate receptor protein component assayed. Shown are mean ± SEM optical
density values as percent average saline control for each treatment group and
corresponding Student‟s t-test statistics, with Bonferroni correction as saline
groups were used for morphine and Meth comparisons, α=0.025.
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Table 4A. VP: 1 Day After Morphine.
Protein: Component
Saline
Morphine
GluR1

GluR2

mGluR5

Statistics

S/I

100.9±12.2

133.6±21.8

t(20)=1.370, p=0.186

Total

99.6±5.7

111.5±7.0

t(20)=1.328, p=0.199

S/I

100.0±7.1

115.0±8.8

t(18)=1.340, p=0.197

Total

100.0±4.5

96.0±3.9

t(18)=0.649, p=0.525

S/I

100.0±9.7

131.4±22.1

t(20)=1.381, p=0.182

Total

95.6±5.14

118.2±12.5

t(19)=1.729, p=0.100

Table 4B. VP: 1 Day After Methamphetamine.
Protein: Component
Saline
Meth-

Statistics

amphetamine
GluR1

GluR2

mGluR5

S/I

100.9±12.2

108.7±16.0

t(20)=0.397, p=0.696

Total

99.6±5.7

101.9±6.3

t(20)=0.279, p=0.783

S/I

100.0±7.1

105.3±11.4

t(18)=0.412, p=0.685

Total

100.0±4.5

98.3±6.2

t(18)=0.222, p=0.827

S/I

100.0±9.7

97.8±14.6

t(19)=0.129, p=0.898

Total

95.6±5.1

135.1±18.3

t(19)=2.164, p=0.043

S/I ratio and Total (S+I) protein were assessed for GluR1, GluR2, and mGluR5 in
the VP tissues after one day of acute Saline (1ml/kg, sc), (A) morphine (8mg/kg,
sc) or (B) Meth (1mg/kg, sc) treatment. There were no differences between
saline and morphine treatment groups for any glutamate receptor protein
component assayed. Shown are mean ± SEM optical density values as percent
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average saline control for each treatment group and corresponding Student‟s ttest statistics, α=0.025.
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Table 5. mPFC: 1 Day After Methamphetamine.
Protein: Component

Saline

Meth-

Statistics

amphetamine
GluR1

GluR2

mGluR5

S/I

100.9±17.2

81.5±19.6

t(18)=0.733, p=0.473

Total

100.7±3.7

92.4±4.9

t(19)=1.376, p=0.185

S/I

100.4±9.7

95.4±14.3

t(17)=0.296, p=0.770

Total

101.5±6.7

88.6±5.8

t(17)=1.285, p=0.216

S/I

101.5±10.3

136.2±27.6

t(16)=1.281, p=0.218

Total

100.1±6.7

100.2±8.4

t(16)=0.008, p=0.994

S/I ratio and Total (S+I) protein were assessed for GluR1, GluR2, and mGluR5 in
the mPFC tissues after one day of acute Saline (1ml/kg, sc) or Meth (1mg/kg, sc)
treatment. There was no difference between treatment groups for any glutamate
receptor protein assayed. Shown are mean ± SEM optical density values as
percent average saline control for each treatment group and corresponding
Student‟s t-test statistics, α=0.025 (Bonferroni correction).
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Table 6A. NAc: 14 Days After Morphine.
Protein: Component
Saline
Morphine
GluR1

GluR2

mGluR5

Statistics

S/I

99.9±7.5

154.2±32.9

t(19)=1.844, p=0.081

Total

106.4±7.2

111.1±7.3

t(20)=0.447, p=0.659

S/I

99.6±9.0

113.6±16.6

t(19)=0.762, p=0.455

Total

99.5±4.5

91.2±8.8

t(19)=0.855, p=0.403

S/I

101.3±11.7

129.2±10.8

t(20)=1.726, p=0.099

Total

100.9±3.6

101.5±6.3

t(20)=0.079, p=0.938

Table 6B. NAc: 14 Days After Methamphetamine.
MethProtein: Component
Saline
Statistics
amphetamine

GluR1

GluR2

mGluR5

S/I

99.9±7.5

84.1±10.2

t(19)=1.278, p=0.217

Total

106.4±7.2

113.7±7.1

t(20)=0.716, p=0.482

S/I

99.6±9.0

101.2±13.5

t(18)=0.102, p=0.920

Total

99.5±4.5

84.9±9.4

t(17)=1.524, p=0.146

S/I

101.3±11.7

118.5±23.7

t(19)=0.706, p=0.489

Total

100.9±3.6

94.0±5.1

t(20)=1.141, p=0.267

There were no differences between (A) saline and morphine (8mg/kg sc, once
daily for 3 days) or (B) saline (1ml/kg sc, once daily for 3 days) and Meth
treatment (1mg/kg sc for 3 days) groups for any glutamate receptor protein
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component assayed.

Shown are the mean ± SEM optical density values as

percent average saline control for each treatment group and corresponding
Student‟s t-test statistics, α=0.025 (Bonferroni correction).
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Table 7A. VP: 14 Days After Morphine.
Protein:

Component

Saline

Morphine

Statistics

GluR1

S/I

99.1±9.0

123.1±23.4

t(19)=1.057, p=0.304

Total

99.7±5.6

99.4±8.6

t(20)=0.037, p=0.970

S/I

98.9±6.3

99.6±11.0

t(20)=0.058, p=0.954

Total

101.1±5.7

102.0±10.3

t(20)=0.075, p=0.941

100.0±8.3

94.1±8.2

t(20)=0.503, p=0.621

GluR2

STEP61

Table 7B. VP: 14 Days After Methamphetamine.
MethProtein: Component
Saline
Statistics
amphetamine

GluR1

GluR2

S/I

99.1±9.0

114.5±15.2

t(20)=0.906, p=0.376

Total

100.6±5.8

109.6±3.6

t(20)=1.258, p=0.223

S/I

98.9±6.3

88.8±13.4

t(19)=0.735, p=0.471

Total

101.1±5.7

130.0±12.6

t(20)=2.262, p=0.035

100.0±8.3

107.3±9.6

t(19)=0.573, p=0.574

STEP61

There were no differences between (A) saline and morphine (8mg/kg sc, once
daily for 3 days) or (B) saline (1ml/kg sc, once daily for 3 days) and Meth
treatment (1mg/kg sc for 3 days) groups for any glutamate receptor protein
component assayed.

Shown are the mean ± SEM optical density values as
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percent average saline control for each treatment group and corresponding
Student‟s t-test statistics, α=0.025 (Bonferroni correction).
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Figure 13. Stereotaxic maps of brain regions assayed. Illustrations of
stereotaxic maps of rodent brain were modified from Paxinos and Watson (1998).
The bold outlines correspond to dissections of the medial prefrontal cortex
(mPFC), nucleus accumbens (NAc) and ventral pallidum (VP) brain tissues
assayed in the current study. Numbers indicate distance in millimeters of the
respective brain section from bregma.
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Figure 14. Development and expression of morphine sensitization.
Data were collapsed for 90min after administration of morphine. A) Horizontal
Beam Breaks, B) Repetitive beam breaks. There was no statistical difference
between days 1, 2 or 3 of the saline treatment (open symbols, n=6-8). In the
morphine-treated groups, there were significant differences between treatment
days (filled circles=animals used for biochemistry; filled squares=animals used
for behavioral verification). A challenge injection of morphine was administered
on day 17 (14 days withdrawal) to rats with a saline (open square, n=7-8) or
morphine (filled square, n=8) treatment history; rats with a morphine treatment
history expressed sensitization. One-way rmANOVA with post hoc NewmanKeuls, ## p<0.01 (biochemistry group), †† p<0.01 (behavior group); Student‟s ttest, * p<0.05.
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Figure 15. Development and expression of Meth sensitization. Data
were collapsed for 60min after administration of Meth. A) Vertical Beam Breaks,
B) Vertical Time. There was no statistical difference between days 1, 2 or 3 of the
saline treatment (open symbols, n=6-8). In the Meth-treated groups, there were
significant differences between treatment days (filled diamonds = animals used
for biochemistry; filled triangles = animals used for behavioral verification). A
challenge injection of Meth was administered on day 17 (14 days withdrawal) to
rats with a saline (open triangle, n=8) or Meth (filled triangle, n=8) treatment
history; rats with a Meth treatment history expressed sensitization. There was no
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development of motor sensitization from Day 1 to Day 3 assessed by Vertical
Beam Breaks C), or Vertical Time D), in rats treated with MTEP and Meth (solid
triangles) or Vehicle and saline (open triangles). There was also no difference
between treatment groups in either motor activity parameter on Day 1 of drug
administration. One-way rmANOVA with post hoc Newman-Keuls, ## p<0.01
(biochemistry group), † p<0.05 (behavior group); Student‟s t-test, * p<0.05.
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Figure 16. Decreased surface expression of GluR1 and GluR2
occurred in the mPFC of rats treated acutely with morphine.
Representative immunoblots for A. GluR1, C. GluR2, and E. mGluR5 in mPFC
tissues harvested one day after a single injection of saline (SAL, 1ml/kg, sc) or
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morphine (MOR, 8mg/kg, sc) treatment. Distinct surface and intracellular
components are labeled for each protein on each representative immunoblot with
corresponding molecular weight of the intracellular component quantified. B.
GluR1 S/I ratio was decreased in MOR treated rats, but Total, S and I
components remain unchanged. D. GluR2 S component was decreased in MOR
treated rats but S/I ratio, Total and I GluR2 protein did not change. F. mGluR5
S/I ratio, Total, S and I protein did not change between SAL and MOR treated
rats in the mPFC. White bars represent saline (SAL) and white bars with
horizontal lines represent morphine (MOR) treated rats. Numbers within bars
represent sample number (N). Unpaired t-test, *p<0.025.
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Figure 17. Increased mGluR5 surface expression occurred in the VP 14
days after morphine or Meth treatment. Representative immunoblots
probed for mGluR5 in the VP 14 days after morphine (MOR, 8mg/kg, sc) A. or
Meth (METH, 1mg/kg, sc) C. treatment. Distinct surface and intracellular
components are labeled for each protein on each representative immunoblot with
corresponding molecular weight of the intracellular component quantified. B.
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The mGluR5 S/I ratio was increased in MOR treated rats but Total, S and I
components remained unchanged. D. The mGluR5 S/I ratio was also increased
in the VP of METH compared to saline treated rats. However, mGluR5 Total, S
and I protein components were not altered by treatment history. White bars
represent saline (SAL), white bars with horizontal lines represent morphine
(MOR), and filled black bars represent Meth (METH) treated rats. Numbers
within bars represent sample number (N). Student‟s t-test, *p<0.025.
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Figure 18. Surface expression of GluR2 is increased in the mPFC 14
days after morphine administration. Representative immunoblots for A.
GluR1, C. GluR2, E. mGluR5, and G. STEP61 in mPFC tissues harvested 14 days
after repeated injections of saline (SAL, 1ml/kg, sc) or morphine (MOR, 8mg/kg,
sc) treatment. B. The GluR1 S/I ratio, Total, S and I protein components
remained unchanged between saline and morphine treatment groups in the
mPFC 14 days after morphine administration. C. There was a significant
increase in the GluR2 S/I ratio of morphine compared to saline treated rats in the
mPFC without a change in Total, S or I GluR2 protein components. F. There
was a significant decrease in mGluR5 Total and S components of morphine
treated rats without a change in the mGluR5 S/I ratio or I component between
saline and morphine treatment groups. H. There was no difference between
saline and morphine treatment groups in the level of STEP61 after 14 days in the
mPFC. White bars represent saline (SAL) and white bars with horizontal lines
represent morphine (MOR) treated rats. Numbers within bars represent sample
number (N). Unpaired t-test, *p<0.025.

139

140
Figure 19. GluR2 surface expression is increased and STEP61 levels
were decreased 14 days after repeated Meth administration in the
mPFC. Representative immunoblots for A. GluR1, C. GluR2, E. mGluR5, and
G. STEP61 in mPFC tissues harvested 14 days after repeated injections of saline
(SAL, 1ml/kg, sc) or Meth (METH, 1mg/kg, sc) treatment. B. There was no
difference in GluR1 S/I ratio, Total, S or I components in the mPFC between rats
with a saline or Meth treatment history. D. The GluR2 S/I ratio was elevated in
Meth compared to saline treated rats 14 days after drug administration.
However, GluR2 Total, S and I components remained unchanged. E. mGluR5
S/I ratio, Total, S and I components remain unchanged 14 days after saline and
Meth in mPFC tissue. H. STEP61 was significantly reduced in the mPFC of rats
14 days after Meth compared to saline. White bars represent saline (SAL) and
filled black bars represent Meth (METH) treated rats. Numbers within bars
represent sample number (N). Student‟s t-test, *p<0.025.
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Figure 20. Levels of GluR2 and STEP61 remain unaltered 14 days
following repeated treatment with mGluR5 antagonist, MTEP, and
Meth in the mPFC. Representative immunoblots for A. GluR2 and C. STEP61
in mPFC tissues harvested 14 days after a repeated injections of vehicle and saline
(VEH/SAL; 1ml/kg, ip; 1ml/kg sc) or MTEP and Meth (MTEP/METH; 5mg/kg,
ip; 1mg/kg, sc) treatment. B. There are no GluR2 S/I ratio, Total protein, S or I
protein component differences between VEH/SAL and MTEP/METH treated rats
in mPFC. D. There are no differences in STEP61 levels between VEH/SAL and
MTEP/METH treated rats in the mPFC. White bars with slanted black lines
represent vehicle and saline treated rats (VEH/SAL) and filled black bars with
slanted white lines represent MTEP and Meth (MTEP/METH) treated rats.
Numbers within bars represent sample number (N). Student‟s t-test, p>0.025.

CHAPTER VII
PHARMACOLOGICAL AND DEVELOPMENTAL MODELS OF
SCHIZOPHRENIA: DIFFERENCES IN SENSORIMOTOR
GATING, AND RESPONDING TO METHAMPHETAMINE
AND AN mGluR5 POSITIVE ALLOSTERIC
MODULATOR
Abstract
Schizophrenia patients have a higher incidence of substance use disorders than
the general population. Amphetamines including methamphetamine (Meth)
exacerbate symptoms of psychosis in schizophrenia patients. Our objective was
to study the detrimental effects of stimulants on deficits associated with
schizophrenia and the underlying sensitivity of this population to stimulant
addiction. We chose to induce a schizophrenia-like brain state via
pharmacological and developmental means with two well-established models of
this neuropathology: repeated, escalating amphetamine (Amph) (Peleg-Raibstein
et al. 2008) and isolation rearing (Geyer et al. 1993). Both of these models are
known to produce deficits in sensorimotor gating assessed by prepulse inhibition
(PPI) of the acoustic startle response. Therefore, we measured PPI deficits in
both models and compared these assessments with the rewarding and motor
responses to Meth via conditioned place preference (CPP) and motor
sensitization, respectively.
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CPP implements reward and associative learning, both of which are associated
with negative symptoms of schizophrenia; thus, we hypothesized that
sensorimotor gating deficits would be inversely correlated with Meth-induced
CPP. Because motor sensitization in rodents is hypothesized to parallel the
course of psychosis in humans and positive symptoms of schizophrenia, we
hypothesized that PPI deficits would be positively correlated with Meth-induced
activity and motor sensitization. We found that PPI deficits in both
pharmacological and developmental schizophrenia models negatively correlated
with Meth-induced CPP. Both schizophrenia-like rodent models also
demonstrated enhanced sensitivity to the hypermotoric effects of Meth. By
strengthening the signal of associative learning with the addition of the Meth cue
or by enhancing the glutamatergic system, Meth-induced CPP was enhanced.
These novel findings demonstrate that schizophrenia-like rodents are less
sensitive to the rewarding and more sensitive to the hypermotoric properties of
Meth. Sensorimotor gating deficits can predict both of these Meth-induced
behaviors. Therefore, this work provides pre-clinical rationale for the use of PPI
as a predictor for Meth addiction in schizophrenia patients.

Introduction
A diagnosis of schizophrenia increases the likelihood of a substance abuse
disorder by approximately five times over that of the general United States
population (Regier et al. 1990). A recent clinical assessment demonstrated that
25% of schizophrenia patients also meet criteria for psychostimulant dependence
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(Compton et al. 2005). This dual diagnosis is particularly problematic for
stimulants because these abused drugs exacerbate symptoms in schizophrenia
patients (Angrist et al. 1980;Janowsky and Davis 1976). Methamphetamine
(Meth) is a powerful stimulant with high abuse liability and remains the third
most widely used illicit drug world-wide (United Nations Office on Drugs and
crime 2009). It is well documented the Meth abuse can induce a psychotic state
similar to that of schizophrenia (Harris and Batki 2000;McKetin et al. 2006;Scott
et al. 2007). Therefore, elucidating correlations between behaviors associated
with the schizophrenia brain state and Meth-abuse would provide insight into
each disorder as well as the dual diagnosis.
Behavioral overlaps between laboratory animals and humans provide a
powerful means to model, and thus study, the human condition. Sensorimotor
gating deficits measured by prepulse inhibition (PPI) occur in human
schizophrenia patients and in rodent models of this disorder, illustrating the
cognitive fragmentation that occurs with this neuropathology (Braff et al.
2001;Swerdlow and Geyer 1998). Acoustic startle response PPI refers to a
normal suppression of the startle reflex that occurs when a strong startling
stimulus is preceded by a weaker stimulus (i.e., a warning signal, termed the „prepulse‟) (Graham 1975;Hoffman and Searle 1968;Ison et al. 1973;Swerdlow and
Geyer 1998). Deficits in this behavior can be induced by pharmacological or nonpharmacological means. Acute (Swerdlow et al. 2003) and repeated (PelegRaibstein et al. 2008) amphetamine administration induce PPI deficits in the
acoustic startle response in rodents and humans. These deficits are reversed by

145
antipsychotic drugs (Geyer et al. 2001), which supports the value of this measure
as an indicator of the schizophrenia-like brain. Early environmental stressors,
such as rearing young rats in isolation, result in sensorimotor gating deficits that
are also reversed by antipsychotic medication (Bakshi et al. 1998;Geyer et al.
1993). Both Amph treatment and isolation rearing in laboratory rats are widely
used to model aspect of the human schizophrenia brain. Since these two models
are produced by vastly different means, with differential effects on the adult
brain, we sought to compare them in terms of modeling the co-morbidity of
schizophrenia and stimulant abuse.
Human stimulant abuse is modeled in rodents via a wide variety of
paradigms and outcome measures. Key to the phenomenon of drug addiction is
the neuronal adaptations that are imposed by repeated drug exposure.
Behavioral outcomes of such adaptations that are easily measured in laboratory
rats include stimulant-induced motor activity and associative learning. The
augmentation of motoric responses to stimulants that occurs after repeated
treatment is termed motor sensitization (Stewart and Badiani 1993). The acute
effects of Amph (e.g., euphoria, hyper-vigilance) appear to “sensitize” with
repeated exposure and can result in psychotic state that is akin to the positive
symptoms of schizophrenia (Angrist et al. 1980;Strakowski et al. 1996).
Developmental rodent models of schizophrenia, including isolation rearing,
render rodents more sensitive to the motor stimulating effects of cocaine,
nicotine, Amph, and Meth (Berg and Chambers 2008;Chambers and Taylor
2004;Dai et al. 2004;Smith et al. 1997). Thus, motor sensitization appears to be
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an excellent outcome measure that mirrors the clinical evidence for an increased
propensity for substance abuse in schizophrenia. Self-administration of cocaine
and Meth are also enhanced in developmental, rodent models of schizophrenia,
indicating that these drugs are more reinforcing in a schizophrenia brain state
(Brady et al. 2008;Chambers and Self 2002). Associative learning underlies the
well-described phenomenon wherein environmental cues associated with drug
administration take on the salience of the drug, and exposure to these cues can
evoke drug craving in drug-withdrawn addicts (Hartz et al. 2001;Hogarth et al.
2010;Mucha et al. 1998;Panlilio et al. 2005;Tolliver et al. 2010). Conditioned
place preference (CPP) is a classical conditioning paradigm that can assess
salience attributed to drug-associated contextual cues in both rodents and
humans (Childs and deWit H. 2009;Tzschentke 1998;Tzschentke 2007). In the
CPP paradigm, unique contextual cues (the conditioned stimulus) are temporally
paired with a reward (e.g., a stimulant; the unconditioned stimulus), and once an
association is formed between the context and the stimulant, the subject tends to
spend more time in that context (or place) even in a drug-free state. The CPP
procedure involves components of reward as well as associative learning, both of
which are deficits associated with the negative symptoms of schizophrenia (i.e.,
anhedonia and working memory deficits). Schizophrenia-like rodents fail to
demonstrate drug-induced CPP subsequent to conditioning with morphine or
amphetamine (Le et al. 2002;Wongwitdecha and Marsden 1995;Wongwitdecha
and Marsden 1996). These studies demonstrate that CPP paradigms serve as a
useful index of negative symptoms of schizophrenia such as anhedonia and
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working memory deficits, whereas motor sensitization may be more analogous to
the positive symptoms. The objective for the current study was to compare
behavioral outcomes associated with schizophrenia in both pharmacological and
developmental models of the disorder and to correlate these outcomes with
Meth-induced CPP and motor sensitization in the same animal. We hypothesized
that sensorimotor gating deficits would be inversely related to Meth-induced CPP
and positively related with motor sensitization.
The brain state that is reflected schizophrenia and stimulant addiction
includes a dysregulation in glutamate transmission (Bardo 1998;Carlsson et al.
1999;Goff and Coyle 2001;Tzschentke 1998). One regulator of glutamate
transmission is the group I subtype 5 metabotropic glutamate receptor
(mGluR5). This receptor is highly expressed in brain regions important for
stimulant reward and associative learning including the nucleus accumbens,
medial prefrontal cortex and hippocampus (Kerner et al. 1997;Lu et al.
1999;Testa et al. 1994b). The mGluR5 is critical for the acquisition of Methinduced CPP (Miyatake et al. 2005), expression of Amph-induced CPP (Herzig et
al. 2005), as well as Meth self-administration (Osborne and Olive 2008) and the
cue-induced reinstatement of this behavior (Gass et al. 2009). Alternatively,
augmenting mGluR5 activity through the use of a selective positive allosteric
modulator (PAM) facilitates extinction learning of cocaine-induced CPP (Gass
and Olive 2009). Schizophrenia-like rats demonstrate that Meth is, in fact,
reinforcing in self-administration paradigms. Thus, by enhancing the
glutamatergic signal during the acquisition or expression process of CPP,
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schizophrenia-like rodents may be better able to make Meth-induced
associations. We therefore hypothesized that administration of an mGluR5 PAM
during conditioning would enhance Meth-induced associative learning in rodent
models expressing a deficit in this behavior.
This novel study demonstrated for the first time a direct correlation
between sensorimotor gating deficits and drug-induced associative learning in
the same subject. Furthermore, we revealed that the two, distinct schizophrenialike models demonstrate divergent sensitivities to the rewarding and incentive
motivational properties of Meth. Finally, we determined that augmenting the
mGluR5 system altered Meth-induced associative learning in a rodent model of
schizophrenia.

Methods
Animals
Male Sprague-Dawley rats were used for all experiments. Rats from the
acute (Experiment 1) and repeated, escalating amphetamine studies (Experiment
2) were habituated to the vivarium at Rush University Chicago for one week
prior to experimentation and were handled at least three times prior to the onset
of behavioral experimentation. Rats in the isolation rearing experiment
(Experiments 3 and 4) arrived at post natal day 21, which was one day after
weaning. Isolation-reared rats were housed alone and social-reared rats were
housed in groups of 4 per cage until rats reached approximately 225g, then social
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reared rats were housed in groups of 2 per cage prior to behavioral testing. The
vivarium was maintained at a constant temperature between 23-25°C. All rats
were given access to food and water ad libitum and were tested during the light
cycle (7:00AM to 7:00PM). Experimentation took place during the light cycle of
the rats. During this time, rats have been shown to produce the most robust CPP
performance to amphetamine (Webb et al. 2009). All studies were conducted
with approval by the Rush University Institutional Animal Care and Use
Committee in accordance with NIH Guide for the care and use of laboratory
animals.

Drugs
(+)Methamphetamine hydrochloride (Meth, NIDA, Bethesda, MD and
Sigma Aldrich, St. Louis, MO) and amphetamine sulfate (Amph, Sigma Aldrich)
were dissolved in sterile 0.9% saline. Meth was given at a dose of 1mg/kg (as the
base). Amph dosage varied between 1 to 8mg/kg (as the base), based on
treatment protocol of Peleg-Raibstein and colleagues described below (PelegRaibstein et al. 2008). Meth, Amph, and saline vehicle were given at a volume of
1ml/kg and injected intraperitoneally (i.p.). The mGluR5 positive allosteric
modulator, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB; Tocris
Bioscience, Ellisville, MO) was given in a suspension of 20% w/v 2hydroxypropyl-β-cyclodextrin (Sigma Aldrich) in sterile water at a dose of
3mg/kg. The dose of CDPPB used (3mg/kg) most efficiently facilitated extinction
learning subsequent to cocaine CPP without affecting motor activity (Gass and
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Olive 2009). CDPPB and its vehicle (20% 2-hydroxypropyl-β-cyclodextrin) were
given at a volume of 1ml/kg subcutaneously (s.c.).

Behavioral Equipment
Conditioned Place Preference
Small animal activity boxes (Accuscan Instruments, Inc., Columbus, OH)
were used for the CPP and motor sensitization evaluations. The boxes (63cm x
30 cm x 30 cm) consisted of two large chambers (25cm x 30cm x 30cm) and one
smaller center chamber (13cm x 30cm x 30cm). The two large chambers had
unique yet neutral contextual cues of horizontal or vertical white wall stripes
(visual cue) and patterned floor with overturned paint dish and grid floor with
flat Plexiglas dish (tactile cues). The center chamber had a smooth white floor
and white opaque walls. Removable sliding doors separated the compartments.
The CPP boxes were equipped with photosensors (24 which measure horizontal
movements and 12 which measure vertical movements) and particular patterns in
the beam breaks were used to assess motor activity and time spent in each
chamber.

Acoustic Startle
Acoustic startle boxes (SR-Lab, San Diego Instruments, San Diego, CA)
were equipped with Plexiglas cylinder animal enclosures attached to piezoelectric
sensors. A speaker for delivery of acoustic pulses was located above the
enclosure. A digital sound level meter (RadioShack, Fort Worth, TX) was used to
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assess sound levels using the dB(A) weighted scale and all sound measurements
for these studies used this scale.

Experimental Procedures
Thirty min prior to the start of behavioral testing, all rats were habituated
to testing room, located in the same suite as the animal vivarium. Background
white noise of 65dB was present throughout CPP and acoustic startle testing
(white noise generator, San Diego Instruments).

Experiment 1.
Timeline for behavioral experiments illustrated in Fig. 21A. Rats were
acclimated to startle testing with a baseline startle session. This session included
a total of 38 trials presented in a pseudo-random order, including 16 „Pulse
Alone‟ (120dB), six of each 68, 71, and 77dB „Prepulse + Pulse‟ trials, and four „No
Stimulus‟ trails. Four Pulse Alone trials were given at the beginning and end of
the test session to allow for a comparison of stable responding and eliminate
initial habituation of startle response in each test session (Geyer et al. 1990).
These data were not included in the data analysis. Outcomes from the baseline
acoustic startle data were used to assign treatment groups. On protocol day 5,
half of the rats (n=12) received saline (1ml/kg) and the other half received Amph
(3mg/kg) (n=12) 30min prior to the first PPI Test. Each test session consisted of
88 trials, presented in a pseudo-random order, including 24, 120dB Pulse Alone
trials, 16 of each 68, 71 and 77dB Prepulse + Pulse trials, and 16 No Stimulus
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trials. Again, the four 120dB Pulse Alone trials at the start and end of the test
session were excluded from data analysis. A second PPI test was conducted four
days later (protocol day 9), wherein the pretreatment was reversed, rats that
previously received saline, received Amph and rats that previously received
Amph, received saline. Subsequently, rats were tested for Meth-induced CPP. To
do so, drug-free rats were first allowed to explore the entire activity box (pretested) and time spent in each chamber was determined. As a group, rats had no
preference for one chamber over the other (t-test, p>0.05). However, individual
rats demonstrated preference and thus rats were paired with Meth in the
chamber in which they spent the least amount of time on the pre-test. Half of the
rats were then conditioned with Meth (1mg/kg) on days 14, 16, and 18 by placing
rats in the chamber where the least amount of time was spent during pre-test
their initially non-preferred side immediately after the Meth injection. On days
15, 17, and 19 rats were placed into the opposite chamber immediately following
saline (1ml/kg) administration. The other half of rats were paired with saline on
days 14, 16, and 18 and Meth on days 15, 17, and 18. Conditioning lasted for
45min and motor activity was continuously monitored. Three days after the last
conditioning session, rats were tested for context preference. The CPP test was
conducted by placing untreated rats into the center chamber with the sliding
doors shut. The doors were then immediately removed to allow access to the
entire CPP box for 30min. Time spent in each chamber and motor activity was
monitored. See Fig. 21A for timeline of behavioral procedures.
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Experiment 2.
Timeline for behavioral experiments illustrated in Fig. 22A. The 16 rats
used for this experiment went through the same acclimation, baseline, and saline
pre-treatment startle sessions as in Experiment 1. Four days later, rats were
subjected to six days of Amph treatment using the escalating dosing protocol
described by Peleg–Raibstein and colleagues (Peleg-Raibstein et al. 2008). On
day 1, rats were injected with 1mg/kg Amph at 7AM, 2mg/kg at 1PM and 3mg/kg
at 7PM. On day 2, rats received 4mg/kg of Amph at 7AM, 5mg/kg at 1PM and
6mg/kg at 7PM. On day 3, rats were administered 7mg/kg of Amph at 7AM,
8mg/kg at 1PM and 8mg/kg at 7PM. On days 4-6, rats received 8mg/kg of Amph
at 7AM, 1PM, and 7PM. PPI test sessions took place 30min after the fifth (second
to last) Amph injection (8mg/kg) on the sixth day of injections in order to test
rats during the light cycle and to keep time of day for startle sessions consistent.
To determine the enduring effects of the escalating Amph treatment on deficits,
an additional PPI test was conducted six days after the last Amph treatment. The
same test session design was used as in the acute study for each PPI test session.
Following PPI testing, Meth-induced CPP was conducted to determine the effects
of escalating Amph on reward-mediated learning. Rats were conditioned with
Meth and tested for preference (see Fig. 22A, protocol days 25-36) as described
in the acute study, however all rats were paired with Meth on the first
conditioning day and saline on the second day of conditioning.
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Experiment 3.
The protocol timelines for this study are illustrated in Fig. 23A and 24A.
After 8 weeks of isolation (n=12) or social (n=12) rearing, rats were subjected to
an acoustic startle session (as described for Experiments 1 and 2) after a 30min
pretreatment of saline (1ml/kg). This determined the sensorimotor gating
deficits associated with rearing conditions. The startle session was repeated on
protocol days 56 and 59. This retesting for startle responding was based on
reports that isolation reared rats may need to be tested repeatedly in order for a
rearing-induced deficit (as indicated by %PPI) to be present (Bakshi et al. 1998).
Following these initial startle sessions, three startle sessions (protocol days 70, 78
and 82) were completed after pre-treatment of 0.5, 1.0, or 1.0mg/kg Amph. The
conditioned place preference procedure involves components of reward as well as
associative learning. Subsequent to Amph startle sessions, rats were subjected to
Meth-CPP (protocol days 83-98) as described above for Experiments 1 and 2.
One day after the CPP test (protocol day 99), rats were tested again for acoustic
startle response after a 30min pretreatment of saline (1ml/kg) to determine the
effects that Meth-conditioning had on gating deficits. After 12 days of withdrawal
from Meth, rats received Meth (1mg/kg) and then placed in their drug-paired
chamber to test for the expression of Meth-induced motor sensitization (see Fig.
24A, protocol day 106). Finally, after 41 days from the original CPP test, rats
were tested again for preference immediately after administration of Meth
(1mg/kg) (protocol day 139 in Fig. 24A) to test for state-dependent expression of
associative learning.
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Experiment 4.
Protocol timeline for this study is illustrated in Fig. 25A. After 8 weeks of
isolation, 24 rats were tested for sensorimotor gating deficits in two separate
startle sessions (protocol days 56 and 59) as in the isolation rearing study. Rats
were then subjected to Meth-induced CPP protocols on day 60-71, wherein they
received a pre-treatment of the mGluR5 PAM CDPPB (3mg/kg; n=12) or its
vehicle (20% 2-hydroxypropyl-β-cyclodextrin, 1ml/kg; n=12) 20min prior to each
conditioning session (i.e., before both the Meth and saline pairings). To
determine the effects of CDPPB treatment on subsequent sensorimotor gating
and motor activity, 24 hr after the CPP Test, rats were subjected to another
acoustic startle session (PPI Test 3; protocol day 72). On day 79, rats were given
an acute challenge of Meth (1mg/kg) and placed in the chamber where Meth was
administered during conditioning (Motor Test). To determine the effects of
acutely enhancing mGluR5 signaling on expression of Meth context preference, a
second CPP test was conducted on day 85 wherein 20min prior to testing, rats
that received CDPPB during conditioning were administered vehicle, and rats
that received vehicle during conditioning received CDPPB.

Statistics
%PPI was calculated by the following equation: %PPI = 100 - (Average
Startle Magnitude on Prepulse + Pulse Trials / Average Startle Magnitude on
Pulse Alone Trials ) x 100. Data were analyzed with a two-way repeated
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measures analysis of variance (rmANOVA) with post hoc Newman Keuls test,
α=0.05. An Amph effect score was calculated by averaging the %PPI scores
across prepulse intensities per rat and the group average with Amph was
subtracted from that of saline pretreatment. CPP was evaluated by comparing
time spent in the Meth-paired chamber compared to time spent in the same
chamber during the pretest. Preference was defined as a significant increase in
time spent in the Meth-paired chamber from during the pre-test to the CPP test
using a paired t-test, α=0.05. The development of motor sensitization was
determined by a paired t-test between motor activity during the first and last
Meth injection, α=0.05. Motor parameters of horizontal activity, total distance
traveled, vertical activity, vertical time, stereotypy count and stereotypy time
were chosen to analyze as they reliably represent the motor profile induced by
low doses of Meth. Pearson correlation was used to compare %PPI Amph effect
score to time spent on the Meth-paired chamber on the CPP test or motor activity
ratio (activity on last day of Meth injection / activity on first day of Meth
injection). Data are presented as the mean + the standard error of the mean
(SEM).

Results
Experiment 1.
As shown in Fig. 21B, 3mg/kg i.p. Amph produced deficits in PPI. There
was no difference in %PPI response based on the order of Amph administration
at any pre-pulse intensity (69, 71 or 77dB) (unpaired t-test between rats given
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saline on PPI Test 1 and PPI Test 2, p<0.05; unpaired t-test between rats given
Amph on PPI Test 1 and PPI Test 2, p<0.05); thus, PPI data under each pretreatment condition were pooled.
Deficits in %PPI were observed at all pre-pulse intensities tested (68, 71
and 77dB, Fig. 21B) when rats (n=24) were given a 30min pretreatment with
Amph (3.0mg/kg) compared to saline (1ml/kg). A two-way rmANOVA resulted
in a significant Treatment effect F(1, 46)=30.504, p<0.001, Pre-pulse Intensity
effect F(2, 92)=34.771, p<0.001 and Treatment x Pre-pulse Intensity interaction F(2,
92)=10.847,

p<0.001 (post-hoc Newman Keuls test significance shown in Fig.

21B). Thus, as pre-pulse intensity increased, the %PPI deficit decreased.
Subsequent Meth-conditioning (conducted on protocol days 11-22)
revealed that rats (n=22) demonstrated a significant preference for the Methpaired compartment on the CPP test compared to the pre-test (t(21)=4.481,
p<0.001, Fig. 21C). Since Meth pairing on the first or second day of conditioning
did not influence the magnitude of time spent in the Meth-paired chamber
during the CPP test (unpaired t-test, t(22)=0.036, p=0.972) Fig. 21C results are the
pooled data from both pairing paradigms. To assess whether the magnitude of
PPI deficits correlated with the magnitude of CPP, the %PPI Amph effect score
(determined from protocol day 5 and 9 data) and time spent on the Meth paired
side on the CPP Test (protocol day 22) were compared in the same rat. There was
not a correlation between %PPI Amph effect score and CPP Test time spent in the
Meth-paired chamber (Pearson correlation, r=0.081, p=0.721, Fig. 21D). These
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data show that responding to a single dose of Amph did not induce sensorimotor
gating deficits that predicted responding to Meth-induced CPP.
The conditioning procedure also resulted in the development of motor
sensitization to Meth in horizontal activity (t(21)=3.227, p=0.004) and stereotypy
count (t(22)=2.376, p=0.027) parameters (Table. 8). To determine the correlation
between sensorimotor gating deficits and subsequent sensitization to Meth, the
horizontal motor activity ratio (activity on the last / first Meth injection) was
compared to the %PPI Amph effect score. There was a significant, positive
correlation between horizontal motor activity ratio and %PPI Amph effect score
(Pearson correlation, r=0.433, p=0.044, Fig.21E) indicating that rats with larger
deficits in sensorimotor gating exhibited more robust sensitized motor response
to Meth. Correlation assessments were also performed on stereotypy count data,
as this parameter demonstrated sensitization in this cohort of rats. However,
there was not a significant correlation for the stereotypy count data set (data not
shown).

Experiment 2.
Testing for Amph (8mg/kg i.p.)-induced PPI deficits on the last day of the
repeated, escalating Amph administration protocol (PPI Test 2 on protocol day
14; Fig. 22A) revealed deficits in %PPI as compared to saline (PPI Test 1) at 71
and 77dB pre-pulse intensities. Two-way rmANOVA revealed a significant
Treatment effect F(1, 30)=4.396, p=0.045, a significant Pre-pulse Intensity effect
F(2,60)=60.801, p<0.0001 and no Treatment x Pre-pulse Intensity interaction
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F(2,60)=2.519, p<0.089 (post hoc Newman Keuls test, p<0.01, Fig. 22B).
Subsequent Meth conditioning revealed that rats had a significant preference for
the Meth-paired chamber (paired t-test, t(15)=3.936, p<0.01, Fig. 22C). Based on
the PPI results generated on protocol day 5 and 14 and CPP results from protocol
day 36, there was a significant correlation between %PPI Amph effect score and
CPP Test time spent in the Meth-paired chamber (Pearson correlation, r=-0.588,
p=0.017, Fig. 22D). That is, the rats that had low sensorimotor gating deficits
had a greater preference for the context associated with the rewarding effects of
Meth. Additionally, these data indicate that repeated administration of Amph
induces PPI deficits that inversely correlate with the strength of Meth-induced
CPP.
Development of motor sensitization, determined by comparing the first
and last Meth injection, did not occur during conditioning to any parameter
measured, due to the repeated Amph treatment history (paired t-test, p>0.05;
Table 9). There was also no correlation between the horizontal motor activity
ratio (activity on day of last / activity on day of first Meth injection) and %PPI
Amph effect score (Pearson correlation, r=-0.027, p=0.919, Fig. 22E).

Experiment 3.
After eight weeks of isolation or social rearing, rats were tested for deficits
in %PPI with saline pretreatment (PPI Tests 1-3, Fig. 23A). No differences were
observed between isolation and social reared groups (two-way rmANOVA,
p>0.05, data not shown). Amph administered 30min prior to the startle test
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session did not induce sensorimotor gating deficits that distinguish isolation (PPI
Tests 3-6, two-way rmANOVA with post-hoc Newman Keuls test, p>0.05, data
not shown). Rats were subsequently conditioned with Meth (see Fig. 23A).
Motor sensitization was assessed during conditioning and place preference was
subsequently assessed three days later in a drug-free state. On conditioning day
1, isolation compared to social reared rats demonstrated an increase in horizontal
activity (paired t-test, t(20)=2.268, p=0.035) and total distance (unpaired t-test,
t(20)=3.962, p=0.001) (Table 10). Therefore, rearing history plays a role in the
acute motoric response to Meth. Furthermore, it can be seen that the motor
responses subsequent to the initial Meth injection in the repeated, escalating
Amph treated rats (Experiment 2, Table 9) are heightened compared to social
reared rats (Table 10). Though different treatment conditions were employed to
induce a schizophrenia-like brain state, common outcomes, such as enhanced
response to an acute treatment of Meth, can occur. Both social and isolation
reared rats developed motor sensitization to Meth over the course of conditioning
sessions (Table 10). There is not a difference between social and isolation reared
rats in the magnitude of motor sensitization development.
Social but not isolation-reared rats demonstrated a significant preference
for the Meth-paired chamber after conditioning compared to the amount of time
spent in the same chamber during the pre-test (unpaired t-test, t(11)=2.756,
p<0.05, Fig. 23B&C). The data were similar to those obtained from the Amph
models of schizophrenia (compare with Fig. 21C and 22C).
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To determine if rearing history in conjunction with Meth conditioning
differentially influenced PPI, rats were tested for acoustic startle response after
the CPP test (i.e., on day 99; see Fig. 23A). For this PPI test, all rats were
subjected to a 30min pretreatment with saline. Isolation reared rats had a lower
%PPI score at the 71 and 77dB pre-pulse intensity. A two-way rmANOVA
resulted in a Rearing Condition effect that was close to significance F(1,19)=4.313,
p=0.052, a significant Pre-pulse Intensity effect F(2,38)=51.172, p<0.0001 , and no
effect of Rearing Conditioning x Pre-pulse Intensity interaction F(2,38)=0.215,
p=0.807. Because the Rearing effect demonstrated a trend and there was a
significant effect of Pre-pulse Intensity, a post hoc test was conducted (post-hoc
Newman Keuls test, p<0.05, Fig. 23D).
On day 106 (which was 12 days after the last Meth conditioning session;
refer to Fig. 24A), all rats were habituated to the Meth-paired chamber, then
given a Meth injection (1mg/kg), and immediately placed back into the Methpaired chamber. Because of the significant effect of rearing condition to the acute
response of Meth demonstrated by the total distance parameter (Table 10), a time
course evaluation of motor expression was conducted. For total distance, a twoway rmANOVA resulted in a no Rearing Condition effect F(1,19)=3.547, p=0.075,
and significant Time effect F(8,152)=7.950, p<0.0001 and Rearing Condition x
Time interaction F(8,152)=2.345, p=0.021. A post-hoc Newman Keuls test revealed
condition differences at 5, 30, and 35min after Meth injection (p<0.05, Fig. 24B).
As rats are injected (i.p.) and immediately placed in the activity box, the
hyperactivity that resulted at 5min in the isolation reared rats is likely due to a
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heightened conditioned motor response and/or rearing condition alone. Rats
reared in isolation for at least four weeks demonstrate increased motor activity,
in general, compared to social reared counterparts (Bakshi and Geyer 1999).
Also, these data demonstrate that during the time of peak Meth effects (3035min), the rearing condition may have also influenced the expression of Methinduced motor sensitization.
In contrast to the rearing condition differences in motor responding to an
acute challenge of Meth, place preference measure during an acute Meth
challenge did not distinguish the two groups. That is, on day 139 (Fig. 24A),
when rats were tested for preference immediately after an administration of Meth
(1mg/kg), both the social-reared (unpaired t-test, t(20)=4.72,p<0.001, Fig. 24D)
and the isolation-reared (unpaired t-test, t(20)=5.01, p<0.001, Fig. 24E) rats
demonstrated a preference for the Meth paired side. These data demonstrate
that isolation reared rats were able to express Meth-induced associative learning
after they were primed with the drug cue.

Experiment 4.
Comparing findings from Experiment 3 and 4 (i.e., data from Fig. 23C and
Fig. 24D) indicated that isolation-reared rats can acquire CPP tasks and this is
expressed if a drug cue (i.e., the unconditioned stimulus) was present during
testing for the salience of the paired context (i.e., the conditioned stimulus). This
suggested that if the salient signal strength is enhanced during conditioning,
isolation-reared rats should be able to express preference in a drug-free state. As
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augmenting mGluR5 activity with a PAM facilitates extinction learning of
cocaine-induced CPP (Gass and Olive 2009), we hypothesized that a mGluR5
PAM should be able to boost association learning during Meth conditioning, and
in so doing, aid isolation-reared rats to acquire the task. Therefore, as shown in
Fig. 25A, isolation reared rats were administered the mGluR5 PAM, CDPPB
(3mg/kg, n=11) or its vehicle (1ml/kg, n=11) prior to conditioning and then
subsequently tested for preference (CPP Test 1, Fig. 25A). Here, as we
hypothesized, isolation-reared rats demonstrated preference for the Meth-paired
context when tested in the drug free state (Fig. 25B, gray bars). To determine if
acute mGluR5 activation altered the expression of Meth-induced CPP, these rats
were retested (see Fig. 25A, CPP Test 2; protocol day 85) 20min after CDPPB
(3mg/kg, n=11) or vehicle (1ml/kg, n=11) administration. CDPPB enhanced
preference for the Meth-paired chamber in rats that received vehicle pretreatment during conditioning (Fig. 25B, left set of gray and black bars) and this
enhancement reached the level obtained in rats that received CDPPB during
conditioning.
Rats were tested for sensorimotor gating deficits one day following CPP
Test 1 in a drug free state (protocol day 72, see Fig. 25A). It was determined that
there was no difference in %PPI between isolation reared rats given a treatment
of CDPPB or its vehicle prior to conditioning sessions (protocol days 63-68) on
PPI Test 3 in a drug-free state (two-way rmANOVA, non significant effect of
Treatment: F(1,17)=0.005, p=0.942, a significant effect of Pre-Pulse F(2,34)=45.052,
p<0.0001, and a non significant Interaction F(2,34)=1.154, p=0.327; Fig. 25C).
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Therefore, while CDPPB enhanced development and expression of Meth-induced
CPP, it had no effect on sensorimotor gating deficits. It was also determined that
there was no difference between CDPPB or vehicle treatments during
conditioning on motor activity to a challenge administration of Meth (1mg/kg,
i.p.) after extended withdrawal on protocol day 79 (two-way rmANOVA with post
hoc Newman Keuls, p>0.05, data not shown). Therefore, while CDPPB enhanced
development and expression of Meth-induced CPP, it had no effect on
sensorimotor gating deficits or on motor activity induced by Meth in isolation
reared rats.

Discussion
The current study provides several novel findings, including the following:
1) Both pharmacological and developmental rodent models of schizophrenia
demonstrated deficits in Meth-induced associative learning. 2) Isolation-reared
rats were able to express Meth CPP in a state-dependent manner. 3) The
mGluR5 system was critical for the acquisition and expression of Meth-induced
associative learning in isolation-reared rats.

Enhanced motor activity occurs in schizophrenia-like rodent models.
Results from Experiments 1 through 3 demonstrated that schizophrenialike rodents were more sensitive to the motoric properties of Meth. In
Experiment 1, sensorimotor gating deficits induced by an acute administration of
Amph correlated positively with Meth-induced motor sensitization.
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Demonstrated in Experiment 3, isolation reared rats showed greater motor
activation to an acute administration of Meth compared to their social reared
counterparts. Rats administered with repeated, escalating Amph (Experiment 2)
were also hyperactive in response to the first Meth injection compared to social
reared control animals. Furthermore, the level of sensitized motor responding to
an acute Meth challenge following withdrawal from repeated exposure to Meth
was greater in Isolation reared rats compared to social reared rats (Experiment
2). Hyperactivity in response to Amph and Meth administration is a welldocumented feature of post-weaning isolation in rodents (Dai et al. 2004;Smith
et al. 1997). Because the isolation-reared rats used in the current study did not
display initial deficits in %PPI, (note: PPI deficits do not occur 100% of the time
in these animals (Fone and Porkess 2008)) it was important to demonstrate this
sensitivity to acute administration of Meth,. These findings are in alignment with
the neonatal ventral hippocampal lesion (NVHL), schizophrenia model in which
enhanced cocaine- and nicotine-induced motor sensitization occurs (Berg and
Chambers 2008;Chambers and Taylor 2004). An increased sensitivity to the
motoric properties of Meth also parallels the human condition in which
amphetamines exacerbate psychosis in schizophrenia patients (Angrist et al.
1980;Janowsky and Davis 1976).
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Sensorimotor gating deficits predict magnitude of Meth-induced associative
learning.
Results from the repeated, escalating Amph treatment (Experiment 2) and
isolation rearing experiments (Experiment 3) converge to demonstrate that
schizophrenia-like rats show deficits in Meth-induced associative learning. We
revealed that sensorimotor gating deficits induced pharmacologically (PelegRaibstein et al. 2008) inversely correlated with Meth-conditioned contextual
preference. These results suggest that schizophrenia-like rats are less sensitive to
the rewarding properties of Meth.
Because of the potential confound of cross-sensitization between Amph
and Meth (Hall et al. 2008), we chose to validate the repeated, escalating Amph
findings using the developmental rodent model of schizophrenia, isolation
rearing. We determined that isolation-reared rats failed to express Meth-induced
associative learning (Experiment 3). This finding is in keeping with our results
for the repeated, escalating Amph experiment and the literature in which
isolation reared rats and NVHL rats fail to express Amph-induced CPP (Le et al.
2002;Wongwitdecha and Marsden 1995). There are two likely explanations for
these findings due to the nature of the CPP assessment: 1) schizophrenia-like rats
are deficient in the ability to perceive reward, or 2) schizophrenia-like rats have
deficits in mnemonic processes that result in a failure to express learned
associations between contextual cues conditioned with Meth.
Another novel finding of the current study is that %PPI was decreased in
isolation-reared rats compared to social-reared rats after Meth conditioning.
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Prior work demonstrated that isolation-reared rats have increased sensorimotor
gating deficits in response to a sensitizing regimen of Meth (Dai et al. 2004). We
extended this finding to reveal that these deficits occur in drug-free, Methconditioned rats thus supporting our hypothesis that Meth-induced CPP is
negatively associated with sensorimotor gating deficits.
Reward and associative learning are both measured in Meth-induced CPP.
These properties are also associated with negative symptoms of schizophrenia
(i.e., anhedonia, cognitive fragmentation, and working memory deficits). NVHL
rodents will expend more effort than unlesioned controls in order to receive the
Meth reinforcer (Brady et al. 2008). This suggests that schizophrenia-like
rodents are more motivated by the reinforcing properties of Meth. Therefore, it
may be hypothesized that schizophrenia-like rodents are capable of experiencing
Meth reward but may be less sensitive to these properties. There are conflicting
reports on spatial learning and memory abilities in rodent models of
schizophrenia including isolation rearing. Isolation-reared rats show an
enhanced ability to locate a submerged platform in the Morris water maze
experiment demonstrating superior acquisition of spatial learning over socialreared counterparts (Wongwitdecha and Marsden 1995). However, others report
no differences in acquisition in Morris water maze training (Quan et al.
2010;Schrijver et al. 2002), or that isolation-reared rats take longer to find the
platform indicating deficits in multiple phases of the learning process (Dai et al.
2004;Hellemans et al. 2004). Results for spatial memory retention are also
varied, with reports demonstrating no difference between rearing conditions
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(Hellemans et al. 2004;Schrijver et al. 2002) or a deficit in isolation reared rats
(Quan et al. 2010). There results suggest that isolation rearing rodents may
exhibit working memory deficits in the acquisition or expression phase of
mnemonic processes. Therefore, spatial working memory necessary to associate
an environmental context with the rewarding properties of a stimulant may be
compromised in schizophrenia-like rats. Cognitive assessments in non-human
primates given repeated, escalating doses of Amph show deficits in some aspects
of working memory but not in acquisition of visual discrimination tasks that
assess associative learning between contextual cues and food reward (Castner et
al. 2005). Working memory deficits and anhedonia in schizophrenia patients are
well documented (Driesen et al. 2008;Park and Holzman 1992). Therefore, these
negative symptoms may be assessed in the CPP task in schizophrenia-like
rodents.

Meth and mGluR5 PAM administration enhances associative learning
performance in isolation- reared rats.
We observed that when isolation-reared rats were administered Meth
prior to a CPP test, the animals were capable of expressing a preference for the
context previously paired with Meth (Experiment 3). These novel findings
suggest that isolation-reared rats can demonstrate that associative learning had
occurred when they were tested in the presence of the unconditioned stimulus.
The addition of the drug cue during the CPP Test replicates the physiological
state that occurred during conditioning and increases the ability of the
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schizophrenia-like rodent to express the previously acquired association.
Therefore, schizophrenia patients experiencing negative symptoms including
anhedonia and working memory deficits may be less sensitive to the rewarding
properties of stimulants, but when conditions are appropriate, they may be able
to make stimulant-induced associations.
The mGlu5 receptor is critical for the development of Meth-induced
associative learning (Miyatake et al. 2005) and for the facilitation cocaineinduced place preference extinction learning (Gass and Olive 2009). Our
findings demonstrate that mGlu5 receptors were also critical for both the
acquisition and expression of Meth-induced CPP in a rodent model of
schizophrenia. Our results also suggest that the magnitude of preference for the
Meth-paired context was more enhanced by pre-conditioning treatment with the
mGluR5 positive allosteric modulator, as rats that were administered CDPPB
prior to conditioning spent more time on the Meth-paired chamber compared to
rats that were administered CDPPB on the CPP Test day. One explanation for
our findings is that CDPPB administration compensated for a deficient mGluR5
system in isolation-reared rats. Isolation rearing decreases levels of mGluR5 in
the prefrontal cortex (Gregory and Szumlinski 2008;Melendez et al. 2004) a
brain region essential for working memory and executive function. The mGluR5
PAM is also known to enhance acquisition of extinction learning of cocaineinduced place preference (Gass and Olive 2009). These evidences converge to
indicate that mGlu5 receptors contributed to the positive results obtained with
the Meth „state-dependent‟ CPP test in the isolation-reared rats pre-treatment in
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the current study. This possibility was corroborated by the ability of isolationreared rats to demonstrate Meth-induced CPP following treatment with the
mGluR5 NAM, CDPBB during conditioning. Therefore, when associative
learning signals are strengthened in schizophrenia-like rats via Meth or an
mGluR5 PAM, a preference for cues previously paired with Meth can be
subsequently expressed.
In summary, the results of the current study converged to demonstrate
that sensorimotor gating deficits are inversely correlated with Meth-induced
associative learning, whereas sensitivity to motor activity is enhanced in
schizophrenia-like rats. We further demonstrated isolation reared rats could
express state-dependent CPP and that mGluR5 is a critical mediator for both
acquisition and expression of Meth-induced associative learning. Both working
memory and anhedonia predict substance abuse likelihood in schizophrenia
patients (Potvin et al. 2008a;Potvin et al. 2008b). Thus, the results of the
current study suggest that sensorimotor gating deficits may predict the
propensity of schizophrenia patients to for Meth-induced associative memories.
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Tables
Table 8. Motor responses to Meth after acute Amph treatment.
Motor
Parameter
Horizontal
Activity
Total Distance
(cm)
Vertical
Activity
Vertical Time
(sec)
Stereotypy
Count
Stereotypy
Time (sec)

First
Injection
4991±254

Last
Injection
6106±285**

1095±54

1314±127

1622±178

1468±165

689±86

656±87

3006±188

3748±254*

526±35

631±44

For this study, Amph was given on protocol days 5 or 9; the first and last Meth
injections were given on protocol days 14 or 15 and 18 or 19, respectively. Data
are number of beam breaks, distance (cm) or time (sec) detected by photobeams
in the small animal activity box used for CPP. Data represent mean ± SEM.
n=20-23. Paired t-test, *p<0.05, **p<0.01.
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Table 9. Motor responses to Meth after repeated, escalating Amph
treatment.
Motor
Parameter
Horizontal
Activity
Total Distance
(cm)
Vertical
Activity
Vertical Time
(sec)
Stereotypy
Count
Stereotypy
Time (sec)

Meth Conditioning
First
Last
Injection
Injection
7416±416
7981±374
1546±121

1678±130

1696±103

1616±156

566±48

735±146

4981±369

5369±367

804±53

846±62

For this experiment, Amph was given in an escalating dosing paradigm (1 to 8
mg/kg, i.p.) on protocol days 9 to 14. The first and last Meth injections were
administered on protocol days 28 and 32, respectively. Data are number of beam
breaks, distance (cm) or time (sec) detected by photobeams in CPP box. Data
represent mean ± SEM. n=13-16. Paired t-test, p>0.05.
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Table 10. Motor responses to Meth following social or isolation
rearing.
Motor
Parameter
Horizontal
Activity
Total Distance
(cm)
Vertical
Activity
Vertical Time
(sec)
Stereotypy
Count
Stereotypy
Time (sec)

Social Rearing
First
Last
Injection
Injection
4365±250
5460±339*

Isolation Rearing
First
Last
Injection
Injection
5305±308†
6136±411

924±53

1223±123*

1416±106††

1780±162

1459±116

1709±199

1840±262

1363±144*

559±54

670±87*

748±116

574±64

2487±226

3399±311**

2900±179

3893±279**

417±40

567±55**

477±27

701±56**

For this experiment, the first and last Meth injections were administered on
protocol days 90 and 94, respectively. Data are number of beam breaks, distance
(cm) or time (sec) detected by photobeams in CPP box. Data represent mean ±
SEM. Social n=11-12, Isolation n=11. Paired t-test within Social or Isolation
Rearing groups, *p<0.05, **p<0.01. Unpaired t-test between Social and Isolation
Rearing groups, †p<0.05, ††p<0.01.
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Table 11. Motor responses to Meth by rats reared in isolation
following pre-treatment of CDPPB or its vehicle.
Motor
Parameter
Horizontal
Activity
Total
Distance (cm)
Vertical
Activity
Vertical Time
(sec)
Stereotypy
Count
Stereotypy
Time (sec)

Vehicle

CDPPB

First
Injection
4282±282

Last
Injection
5285±315**

First
Injection
4256±289

Last
Injection
5619±293***

1131±105

1401±167*

1097±106

1301±134*

1639±134

1760±197

1528±124

1959±181*

642±76

695±94

642±75

1080±246

2283±568

2976±249**

2193±174

3145±208***

391±28

492±39**

381±31

513±33**

For this experiment, the first and last Meth injections were administered on
protocol days 63 (Day 1) and 67 (Day 5), respectively. Data are number of beam
breaks, distance (cm) or time (sec) detected by photobeams in CPP box. Data
represent mean ± SEM. Vehicle (1ml/kg, s.c.) n=11-12, CDPPB (mGluR5 PAM,
3mg/kg, s.c.) n=11-12. Paired t-test within Social or Isolation Rearing groups,
*p<0.05, **p<0.01, ***p<0.001.
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Figure 21. Deficits in sensorimotor gating induced by acute
administration of Amph predict motor but not reward responses to
Meth.
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A) Timeline of behavior/treatment protocol for Amph-induced deficits in
prepulse inhibition (PPI) assessments (protocol days 1-11) and Meth-induced
conditioned place preference (CPP; protocol days 14-22). On day 1, all rats
(n=22) were tested with a baseline startle session. On days 5, half of the rats
were given a 30min pretreatment with saline (1ml/kg, i.p.) and the other half
were given Amph (3mg/kg, i.p.) and then subjected to the startle session. On day
9 the treatment groups were switched and rats that previously received saline
received Amph prior to the startle session. Rats were then pre-tested (protocol
day 11) and conditioned with Meth every other day for six days (protocol days 1419). Rats were tested for place preference on protocol day 22. B) PPI Test 1 and
2 (protocol days 5 and 9). Data represented here are pooled based on pre-PPI
Test treatment history. Rats demonstrated a significant deficit in %PPI 30min
after a pre-treatment of Amph compared to saline at 68, 71 and 77dB prepulse
intensities (two-way rmANOVA with post hoc Newman Keuls test, *p<0.05,
**p<0.01). C) CPP Test (protocol day 22). Rats showed a significant increase in
time spent in the Meth-paired chamber after conditioning compared to the pretest (unpaired t-test, ##p<0.01). D) There was no correlation for CPP
magnitude (i.e., Time spent in the Meth-paired compartment) vs. the %PPI
Amph Effect Score. E) There was a significant correlation between the
development of motor sensitization and the %PPI Amph Effect Score (Pearson
correlation, r=0.433, p=0.044). Motor sensitization as assessed by a ratio of
horizontal activity on the first over the last injection of Meth during the
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conditioning phase. Sal = saline, 1ml/kg, i.p.; Amph = amphetamine, 3mg/kg,
i.p.; Meth= methamphetamine, 1mg/kg, i.p.
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Figure 22. Deficits in sensorimotor gating induced by a repeated,
escalating administration of Amph predict reward, but not sensitized
motor, responses to Meth.
A) Timeline of behavior/treatment protocol for Amph-induced deficits in
prepulse inhibition (PPI) assessments (protocol days 1-20) and Meth-induced
conditioned place preference (CPP; protocol days 25-36). On day 1, all rats
(n=16) were tested with a baseline startle session. On protocol day 5, rats were
subjected to an acoustic startle session. On protocol days 9-14, rats received 3
once-daily injections of Amph that escalated from 1-8mg/kg. On the last day of
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Amph treatment, rats were tested for acoustic startle response and on protocol
day 20 in a drug-free state. Rats were pre-tested on protocol day 25 then
conditioned with Meth or saline on protocol days 28-33. On protocol day 36, rats
were tested for place preference. B) PPI Test 1 (protocol day 5). Rats
demonstrated a significant decrease in %PPI when given a 30min pretreatment
of Amph (8mg/kg, i.p., day 14, PPI Test 2) compared to a saline (1ml/kg, i.p.)
pretreatment at 71 and 77dB (two-way rmANOVA, with post hoc Newman Keuls
test, *p<0.05, **p<0.01). C) CPP Test (protocol day 36). Rats demonstrated a
significant preference for the Meth-paired chamber after conditioning (unpaired
t-test, ##p<0.01). D) There was a significant correlation between amount of
time spent on the Meth-paired compartment during the CPP Test and the %PPI
Amph effect score (Pearson Correlation, p<0.05, r2=0.3451). E) There was no
correlation between the development of motor sensitization as assessed by a ratio
of horizontal activity on the first over the last injection of Meth and the %PPI
Amph Effect Score (Pearson correlation, p>0.05, r2=0.001). Sal = saline, 1ml/kg,
i.p.; Amph = amphetamine, 1-8 mg/kg, i.p.; Meth= methamphetamine, 1mg/kg,
i.p.
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Figure 23. Isolation rearing produced sensorimotor gating and
associative learning deficits following Meth conditioning.
A) Timeline of behavior/treatment protocol. After 8 weeks of isolation or social
rearing (protocol days 1-56), all rats were tested for acoustic startle response
30min following a saline pretreatment (1ml/kg, i.p.; protocol days 56 and 59).
On days 70, 78, and 82, rats were tested for startle 30min after an Amph (0.1, 1
and 1mg/kg, i.p., respectively) pretreatment. Rats were tested for initial
preference on protocol day 83, conditioned with Meth (1mg/kg, i.p.) on protocol
days 90, 92, and 94, and saline (1ml/kg, i.p.) on protocol days 92, 93, and 95.
Rats were subsequently tested for preference on protocol day 98 (CPP Test 1).
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Rats were tested for acoustic startle response after a saline (1ml/kg)
administration on day 99 (PPI Test 7). B) Social reared rats demonstrated a
significant preference for the Meth-paired CPP chamber after conditioning
compared to the CPP pre-test (unpaired t-test, #p<0.05). C) Isolation reared
rats did not demonstrate a preference for the Meth-paired environment in a
drug-free state on CPP Test 1. D) After Meth conditioning, isolation reared rats
demonstrated a significant deficit in %PPI compared to social reared rats at the
71 and 77dB prepulse intensity (two-way rmANOVA with post hoc Newman Keuls
test, *p<0.05). Sal = saline, 1ml/kg, i.p.; Amph = amphetamine, 0.1-1mg/kg, i.p.;
Meth= methamphetamine, 1mg/kg, i.p.
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Figure 24. Isolation reared rats demonstrated enhanced
hyperactivity and associative learning in response to Meth
administration.
A) Timeline of behavior/treatment protocol; days 1-99 are similar to that
described in Fig. 3. On protocol day 106, all rats were given a Meth injection
(1mg/kg, i.p.) on the Meth-paired chamber and motor activity was monitored
(Motor Test). Finally, rats were tested for state-dependent CPP (CPP Test 2;
protocol day 139) immediately following an injection of Meth (1mg/kg, i.p.). B)
Isolation reared rats demonstrated an increase in total distance traveled (cm) at
5, 30 and 35min post-Meth (1.0mg/kg, i.p.) injection (two-way rmANOVA with
post hoc Newman Keuls test, *p<0.05, **p<0.01) compared to social reared rats.
Both social C) and isolation D) reared rats demonstrated a significant preference
for the Meth-paired compartment post- compared to pre-conditioning when
given an injection of Meth (1.0mg/kg, i.p.) immediately before CPP Test 2
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(unpaired t-test, ##p<0.01). Sal = saline 1ml/kg, i.p.; Meth = methamphetamine,
1mg/kg, i.p.
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Figure 25. Activation of mGluR5 enhances development and
expression of Meth-induced CPP in isolation reared rats without an
effect on subsequent sensorimotor gating deficits.
A) Timeline of behavior/treatment protocol. Rats were reared in isolation for 8
weeks and subsequently tested for sensorimotor gating deficits on protocol days
56 and 59 (PPI Tests 1 and 2). Rats were pre-tested on protocol day 60 in a drugfree state. During conditioning, rats were given a 20min pre-treatment with
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CDPPB (3mg/kg, s.c.; n=11) or its vehicle (1ml/kg, s.c.; n=11) prior to Meth
(1mg/kg, i.p.) on days 63, 65, and 67, or saline (1ml/kg, i.p.) on days 64, 66, and
68. Rats were tested for Meth-induced preference on day 71 in a (CPP Test 1) in a
drug-free state and sensorimotor gating deficits on day 72 (PPI Test 3) 30min
after a saline (1ml/kg, i.p.) injection. Rats were given an injection of Meth
1mg/kg and immediately placed in the Meth-paired chamber as in conditioning
on the Motor Test (day 79). Rats administered CDPPB (3mg/kg, s.c.) prior to
conditioning were given vehicle (1ml/kg, s.c.) and rats that had a preconditioning treatment of vehicle (1ml/kg, s.c.) were injected with CDPPB
(3mg/kg, s.c.) prior to CPP Test 2 on protocol day 85. B) CPP (protocol days 71
and 85). Rats administered CDPPB during conditioning demonstrated greater
amount of time spent on the Meth-paired chamber compared to rats given preconditioning vehicle. Rats administered CDPPB prior to CPP Test 2 spent more
time on the Meth-paired side on this test day compared to CPP Test 1. Rats
administered CDPPB prior to conditioning demonstrated an increase in time
spent in the Meth-paired side on compared to rats that were administered
CDPPB prior CPP Test 2 on this test day (two-way rmANOVA with post hoc
Newman Keuls test, *p<0.05, **p<0.01). C) There was no difference between
rats given CDPPB or vehicle prior to conditioning on %PPI in the acoustic startle
response session on day 72 (PPI Test 3) (two-way rmANOVA with post hoc
Newman Keuls test, p>0.05).

CHAPTER VIII
GENERAL DISCUSSION
The overall goal of this dissertation project was to expand our knowledge
of the role of the mGluR5 system in Meth addiction and in the co-morbidity of
schizophrenia and Meth substance use disorder. Towards that end, we
characterized the function and expression of mGluR5 following both short
(Chapters III and V) and extended (Chapters IV and V) periods of withdrawal
after repeated Meth administration. We determined that mGluR5 was necessary
for the maintenance of Meth-induced place preference (Chapter IV) and that
mGluR5 expression was differentially regulated by Meth in various rewardrelated brain regions (Chapters V and VI). We found that sensorimotor gating
deficits associated with schizophrenia were negatively correlated with Methinduced associative learning in both pharmacological and developmental rat
models of schizophrenia (Chapter VII). Both models also showed hyperactive
motor responses to Meth compared with controls (i.e., social rats; Chapter VII).
Finally, we determined that activating mGluR5 augmented the development and
expression of Meth-induced CPP in a developmental model of schizophrenia
(Chapter VII). These novel findings contribute to our understanding of the
dynamics of mGluR5 system in multiple phases of Meth addiction and reward
mediated behaviors, and in the co-morbid stimulant-abusing schizophrenia
patient.
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Phases of Meth addiction
The addiction phenomenon is a complex and dynamic process. The
neurobiology of this process is dictated by many factors, including the nature of
the abused drug, the dose and frequency of exposure, the drug experience of the
individual, and the involvement of associated behaviors. For purposes of this
dissertation project, we adapted a commonly used set of time-related descriptors
or phases to categorize our investigations as follows: induction,
acquisition/development, maintenance, and expression. The induction phase
simply refers to the initial administration of Meth and the behavioral response.
The consequences of this initial or acute administration may persist long after
Meth is administered. We have assessed two behaviors which occur subsequent
to the repeated treatment of Meth, CPP and motor sensitization. During
acquisition, Meth is repeatedly paired with a context and the rewarding
properties of Meth then become associated with these environmental cues.
Repeated Meth treatment also results in a progressive enhancement in motor
activity and we will refer to the phase between the first and last repeated
treatment as the development of motor sensitization. Neuronal adaptations that
are induced and acquired/developed are then maintained after Meth is no longer
administered. Behaviors are then expressed under the appropriate conditions
where Meth or Meth-related cues are present. Each of these phases provides
valuable information as to how neuronal adaptations occur throughout the
addiction process.
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Induction
The initial Meth administration serves as a stimulus that induces
behavioral and neurotransmission responses. The consequences of this stimulus
can persist beyond the lifetime of the stimulus itself, and with repeated exposures
these consequences can summate. For example, a single treatment with
psychostimulants including cocaine, amphetamine, and Meth increases motor
function and, with repeated intermittent administration, e.g., once daily, these
responses are enhanced or „sensitized‟. We are interested in the mGluR5
neurobiology that is associated with development of sensitization, and so we
studied outcomes measured during the induction period and soon after
sensitization had been achieved. To study effects during induction, we have
assessed changes in Meth-induced behaviors and the mGluR5 system within the
inter-dosing interval used in our behavioral paradigms.
When rats are given an acute injection of Meth, motor activity is increased
compared to saline treated animals. This hyperactivity was observed in normal
rats and was reduced with the mGluR5 NAM, MTEP (Chapter VI). Our
laboratory also shows that a single administration of Meth can induce CPP that
can persist and be expressed 3 days later (Herrold et al. 2009). Meth therefore,
serves as a strong stimulus which induces neuronal and behavioral changes that
persist after the drug is withdrawn from the system.
Hyperactivity in response to stimulants is a common feature of
schizophrenia. Our results agree with this clinical assessment as both repeated,
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escalating Amph treated as well as isolation reared rats displayed increased
motor activity to an initial Meth injection compared to social reared control
animals. The implication of these data in the model of co-morbidity,
schizophrenia and Meth addiction will be discussed later.
To fully understand how the mGluR5 system may adapt within the interdosing interval used in our behavioral paradigms, we assessed mGluR5 surface
expression levels 24hrs after Meth administration. This assessment tells us if
basal levels of glutamate receptors are changed as a result of drug injection. We
determined that mGluR5 receptors were unchanged 24hr after a single Meth
injection, but down-regulation of these receptors with mGluR5 NAM treatment
prior to Meth administration reduced the acute hyperactive response to Meth
(Chapter VI). Thus, while the function of mGluR5 is necessary for the induction
of Meth behavior, changes in protein levels of these receptors are not. Shaffer
and colleagues report that mGluR5 protein levels are increased in the membrane
fraction of mPFC tissue 1hr after acute Amph (5mg/kg). However, these changes
are transient and mGluR5 protein levels are normalized by 5hrs post-Amph
treatment (Shaffer et al. 2010). It is therefore possible that mGluR5 levels
assessed in the current study would have been initially up-regulated, had tissue
been assessed at an earlier time-point. To determine if the acute Meth treatment
employed in our study truly replicated the findings of Shaffer and colleagues, rats
must be sacrificed and mGluR5 surface expression assessed 5hrs following Meth
(1mg/kg) administration.
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Acquisition/Development
With repeated treatment, the context associated with Meth becomes
significant or salient to the individual. We are interested in the neuronal
adaptations that occur during this salience attribution, i.e., how the association
between the reward of Meth and the Meth context is acquired. Meth-induced
motor hyperactivity can also progressively enhance with repeated administration
such that the activity induced by the last Meth administration is larger than
activity induced by the first, i.e., development of motor sensitization. The
administration of the mGluR5 NAM, MTEP, prior to repeated Meth
administration blunted the development of Meth-induced motor sensitization, a
novel finding of the current dissertation project (Chapter VI). The findings from
the current studies with CPP and motor sensitization align with the established
role of mGluR5 in the acquisition phase of other addiction models. It is known
that mGluR5 regulates the development of Meth-induced CPP (Miyatake et al.
2005) and the acquisition of Meth self-administration (Osborne and Olive 2008).
Furthermore, mGluR5 knock-out mice fail to develop cocaine-induced motor
sensitization. So it is clear that mGluR5 is involved in the development of motor
sensitization and this action is not stimulant-specific. We extended this work to
ascertain if the role of mGluR5 in Meth-induced behaviors in rat was altered in
models of schizophrenia. In the isolation rearing model, where initial deficits in
Meth-induced CPP were found, the administration of the mGluR5 PAM, CDPPB,
enhanced task acquisition (Chapter VII). Showing that the agonist can promote
other forms of learning, CDPPB also facilitates the acquisition of extinction
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learning in cocaine CPP treated rats (Gass and Olive 2009). Further discussion
of these data in co-morbidity models will follow.

Anatomy and cell biology of induction / acquisition behaviors
The acquisition process of associative learning is thought to involve the
transfer of sensory information from the cortex to the NAc, VP and the
hippocampus via glutamatergic afferents (Christie et al. 1985;Fuller et al.
1987;Sesack et al. 1989). All of these regions also receive dopaminergic input
from the VTA and project to motor output regions regulating activity levels.
When Meth is administered, extracellular glutamate concentration levels increase
in the mPFC and dopamine increases in the NAc (Shoblock et al. 2003).
Activation of mGluR5 and dopamine D1 receptors results in an array of
transduction cascades which can converge to enhance common secondary and
tertiary messengers such as intracellular calcium (Abe et al. 1992;Surmeier et al.
1995) and the phosphorylation of cAMP response element binding protein
(CREB) (Dudman et al. 2003;Mao et al. 2007;Roberson et al. 1999;Voulalas et al.
2005). For example, mGluR5 activation results in phosphoinositide hydrolysis
and subsequent activation of phospholipase C (PLC) and protein kinase C (PKC)
(Abe et al. 1992;Joly et al. 1995), which ultimately can increase intracellular
calcium. Activity of PLC and PKC both regulate the development of CPP (Aujla
and Beninger 2003;Cervo et al. 1997;Narita et al. 2004). Activation cAMPdependent protein kinase (PKA) via dopamine D1 receptor activation leads to
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enhance calcium influx through cAMP-dependent protein kinase (PKA)
phosphorylation of ionotropic NMDA receptors (Das et al. 1997). This D1R
process plays a role in the acquisition of stimulant-induced associative learning
(Beninger and Gerdjikov 2004;Gerdjikov et al. 2007). Activation of both D1 and
mGluR5 can increase cAMP-response element binding protein (CREB) (Dudman
et al. 2003;Mao et al. 2007;Roberson et al. 1999;Voulalas et al. 2005). CREB
phosphorylation can increase protein synthesis and enhance cellular indices of
memory, e.g., long term potentiation (LTP) (Bourtchuladze et al. 1994). In the
NAc and hippocampus, mGluR5 is necessary for LTP (Bikbaev et al.
2008;Schotanus and Chergui 2008). High frequency stimulation induced LTP in
NAc slice preparations is dependent upon mGluR5 and dopamine D1 receptors
(Schotanus and Chergui 2008). Induction of LTP in the NAc and dentate gyrus
subfield of the hippocampus is inhibited by mGluR5 blockade (Bikbaev et al.
2008;Schotanus and Chergui 2008); both regions are important for the
induction of stimulant-induced CPP. Bikbaev and colleagues also revealed that
in vivo (i.c.v.) treatments of the mGluR5 NAM, MPEP, inhibit acquisition of
spatial/working and reference memory in rats, and reduce LTP in ex vivo
hippocampal slices (Bikbaev et al. 2008). Our data and the literature, concur
with the idea that Meth administration indirectly enhances glutamate
transmission, and via mGluR5 activation in limbic brain regions, promotes the
association between the rewarding properties of drugs and the context in which
they are administered.
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Maintenance
After the acquisition of stimulant-induced associative learning, the
stimulant-related memories are maintained for protracted periods. Memory
maintenance is a dynamic process. This dissertation project contributed to the
understanding the role of mGluR5 in the maintenance of Meth-context
associations. We found that mGluR5 was necessary for the long-term (Chapter
IV), but not short-term (Chapter III) maintenance of Meth-induced CPP. There
are two likely explanations for these findings. First, the mGluR5 system has
adapted and perhaps up-regulated over the two week withdrawal from Meth
conditioning. Second, the memory of Meth-associations has become more
vulnerable to deterioration over time. We included a vehicle control to account
for the second factor, and we have biochemical evidence to support that an upregulation in reward related brain regions occurred 14 days after repeated Meth
administration.
Our behavioral and biochemical findings converge upon an important role
for mGluR5 in the VP in the maintenance of stimulant-mediated behaviors. We
found that 14 days after a sensitizing treatment regimen of Meth, the mGluR5 S/I
ratio was up-regulated in the VP without a change in surface. This change in the
ratio was likely due to a modest decrease within the intracellular pool (Chapter
VI). When mGluRs are removed from the membrane surface they are generally
either desensitized and rapidly recycled back to the membrane surface, slowly
recycled and kept within the endosome of the cell or trafficked to the lysosome
and degraded (Dhami and Ferguson 2006). Therefore in the current study,
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mGluR5 levels are sustained within the membrane surface of VP cells, while the
intracellular mGluR5 proteins are removed or degraded. VP neurons appear to
be adapting to the changing glutamate environment to maintain surface levels of
mGluR5; yet, surface levels are not scaled up. Interestingly, administration of
mGluR5 NAMs blunt Meth-induced CPP at the same withdrawal period that the
mGluR5 S/I ratio was up-regulated in the VP. Though levels of the surface
mGluR5 component were unaltered, this does not preclude changes in the
function of mGluR5 in the VP at the level of downstream signaling mechanisms,
for example. Our laboratory has demonstrated that ionotropic glutamate
receptors in the VP are necessary for the expression of morphine-induced CPP
and motor sensitization (Dallimore et al. 2006), and the work in the current
dissertation project suggests that mGluR5 in the VP may be critical for the
expression of Meth-induced CPP and motor sensitization as well. In Amphsensitized rats, VP neurons increase in firing during the presentation of an
Amph-associated cue (Tindell et al. 2005). These converging data suggest that
modulation of VP neuronal activity by mGluR5 may play an important role in the
maintenance and subsequent expression of stimulant-induced associative
learning. Exciting future studies with intra-VP injections of an mGluR5 NAM
would verify the necessity of mGluR5 during long-term maintenance to express
Meth-induced CPP.
Pre-clinical electrophysiological and biochemical experiments (for review,
see (Kalivas and Hu 2006)) and human brain imaging studies (Ernst and Chang
2008) suggest that the PFC becomes hypoactive during extended withdrawal
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from stimulants. Our data provide one mechanism by which this may occur
following repeated Meth administration. We found that 14 days after repeated
Meth treatment, surface to intracellular ratio levels of the GluR2 AMPA receptor
subunit were increased. This increase corresponded with a decrease in the
STEP61 protein, while GluR1 AMPA receptor subunits remained unchanged
(Chapter VI). We determined that the alterations in GluR2 and STEP61 levels
were a result of mGluR5 activation during repeated Meth administration
(Chapter VI). These findings demonstrate that though mGluR5 surface
expression levels were not changed after an initial Meth injection, the activity of
these receptors during induction of Meth-induced sensitization likely influences
persistent molecular events resulting in alterations in ionotropic glutamate
receptor distribution. An increase in the surface expression of GluR2 AMPA
receptor subunit without an alteration in the GluR1 subunit would lead to a
decrease in calcium permeability and inward rectification of mPFC neurons,
known characteristics of GluR2 subunits (Buldakova et al. 1999). Levels of GluR1
and GluR2 mRNA and protein are expressed throughout the layers of the cerebral
cortex(Martin et al. 1993;Sato et al. 1993). However, GluR2 levels are generally,
modestly higher than GluR1 in the cortex (Sato et al. 1993). Therefore, an
increase in the S/I ratio of GluR2 alone would not change overall excitability.
GluR2 receptors In conclusion, after 14 days from Meth conditioning, mPFC
neurons are likely in a calcium-impermeable state that is regulated by mGluR5.

Expression and biochemical response to Meth-related cues
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After Meth-associated memories have been acquired and maintained, they
can be expressed under the appropriate conditions, such as the presentation of
salient contextual cues previously paired with the rewarding properties of Meth.
Activity of mGluR5 necessary for the expression of Amph-induced CPP (Herzig et
al. 2005) and cue as well as Meth-induced expression of Meth-seeking behavior
(Gass et al. 2009). In the current dissertation project, we also demonstrated that
augmenting mGluR5 signaling enhanced expression of Meth-induced CPP in
isolation reared rats (Chapter VII, further discussed in following sections).
Therefore, mGluR5 protein surface expression levels were assessed 24hr after
Meth-induced CPP was expressed. We determined that mGluR5 surface to
intracellular ratio was decreased in the mPFC of Meth-conditioned rats. This
outcome may reflect internalization of receptors 24hr after CPP expression
during short-term withdrawal (Chapter V). Upon exposure to stimulantassociated cues, extracellular glutamate levels in the mPFC are increased
(Hotsenpiller et al. 2001;Hotsenpiller and Wolf 2002). Cellular activation also
occurs in limbic structures subsequent to drug-associated cues, measured by
increases in the immediate early gene fos expression (Brown et al. 1992;Rhodes
et al. 2005). With prolonged agonist exposure and cellular activation, the
mGluR5 system must adapt, and these receptors are phosphorylated and
desensitized via PKC (Gereau and Heinemann 1998;Lee et al. 2008). Therefore,
the internalization of mGluR5 shown after short-term withdrawal and
subsequent to drug-related cue re-exposure is likely reflective of cellular
homeostasis.
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Activation of mGluR5 enhanced Meth addiction behaviors associated with
negative symptoms in schizophrenia-like rats
The addiction behaviors assessed in the current dissertation project, i.e.,
motor sensitization and CPP, were chosen since they may measure positive and
negative symptoms of schizophrenia, respectively. We found that activation of
mGluR5 through the use of the mGluR5 PAM, CDPPB facilitated CPP but not
motor sensitization behaviors (at least at the dose tested). Therefore, mGluR5
may be involved in the negative symptoms of schizophrenia such as anhedonia,
cognitive fragmentation and working memory deficits they may lead to addiction
vulnerability in schizophrenia patients.
Our isolation rearing co-morbid model revealed that mGluR5 activation
can enhance the acquisition and expression of Meth-induced associative learning
in schizophrenia-like rodents, which show an initial deficit in this behavior
(current study Chapter VII and (Le et al. 2002;Wongwitdecha and Marsden
1995)). A common characteristic of schizophrenia is hypofrontality. The results
of the current dissertation support the proposition that mGluR5 is involved in
these dynamics that contribute to the ability of schizophrenia-like rodents to
acquire stimulant-induced associative learning. The mPFC is a critical brain
region for the induction of stimulant-mediated behaviors, and the isolation
rearing model used in this project is characterized by decreased levels of mGluR5
in the mPFC (Melendez et al. 2004) as well as reduced mPFC volume (DayWilson et al. 2006). There is clinical evidence to support the role of the mPFC in
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anhedonia experienced by schizophrenia patients. Recently, it was shown that
metabolic activity in the mPFC is negatively correlated with self reports of
anhedonia in schizophrenia patients (Harvey et al. 2010;Park et al. 2009).
Therefore, by increasing mGluR5 function in the mPFC via CDPPB
administration, the ability to experience Meth-induced reward may be increased
in isolation-reared rodents. There is also pre-clinical data that support the value
of enhancing mGluR5 for treating anhedonia; administration of CDPPB increases
sucrose consumption in animals that show a deficit in this behavior induced by
the NMDA channel blocker, MK-801 (Vardigan et al. 2010). Our findings are
congruent with the pre-clinical and clinical literature suggesting that
schizophrenia-like individuals have decreased capacity to experience or respond
to reward, and we furthered these concepts to demonstrate that mGluR5 activity
is important for this phenomenon.
Though isolation reared rats did not express Meth-induced CPP in a drugfree state, the addition of the Meth cue resulted in a positive preference for the
Meth-paired context (Chapter VII). These data demonstrate that while
schizophrenia-like rats may be less sensitive to the rewarding properties of Meth
or perhaps less able to make an association between Meth and the context in
which it was administered, they are capable of making the association when in
the same physiological state as the conditioning period. Meth increases
extracellular glutamate overflow in the mPFC (Shoblock et al. 2003). Cues
previously paired with Meth also increase mPFC glutamate and this is enhanced
when Meth is given during cue exposure (Qi et al. 2009). Thus, increased mPFC
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glutamate may have contributed to the ability of Meth administration during CPP
test to promote place preference in the current study.
The CPP procedure involves components of reward as well as associative
learning. Another negative symptom, along with anhedonia, central to mPFC
abnormalities of schizophrenia which may contribute to the deficit in Meth CPP
is working memory deficits (Goldman-Rakic and Selemon 1997). Moreover,
working and recognition memory deficits show improvement with by mGluR5
PAMs such as CDPPB (Uslaner et al. 2009). Our data also demonstrate, for the
first time, that though schizophrenia-like rodents demonstrate initial deficits in
Meth-induced CPP, this behavior was acquired and then was expressed when
„salient signaling‟ was amplified. That is, when the drug-cue, Meth, is
administered prior to the CPP test, all of the signals present during the
acquisition phase are present and under these conditions, the isolation reared
rats were capable of expressing CPP. CDPPB co-administered with Meth during
conditioning, enhances mGluR5 signaling, and this strengthened the acquisition
of Meth-induced associative learning so that preference was expressed by
isolation reared rats in a drug-free state. Therefore, the glutamate system may
contribute to the state-dependency of Meth-induced CPP in isolation reared rats
and enhances the neuronal signaling important for associative learning.

Critical discussion of co-mobidity behavioral models
Though repeated, escalating Amph administration and isolation rearing
are two very different means of inducing a schizophrenia-like brain state and
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sensorimotor gating deficits, we demonstrate that in both pharmacological and
developmental models of schizophrenia, sensorimotor gating deficits associated
with schizophrenia were negatively related to Meth-induced associative learning.
The isolation reared rats and those subjected to repeated, escalating Amph
treatments showed PPI deficits. These behavioral responses to Meth are
consistent with deficits in sensory processing and cognitive fragmentation in
schizophrenia patients. Thus, PPI deficits may serve as a predictor for stimulantmediated dysregulation. And so doing, PPI deficits may provide a means of
screening for potential vulnerability to substance use disorders as well as
schizophrenia itself. We also found that Amph- and isolation rearing-induced
deficits in PPI are related with an enhancement in Meth-induced hyperactivity.
Our findings are supported by the literature that indicates schizophrenia-like
rodents show an enhanced response to stimulant-induced motor sensitization
(Berg and Chambers 2008;Chambers and Taylor 2004) but a deficit in stimulantinduced associative learning (Le et al. 2002;Wongwitdecha and Marsden 1995).
Another developmental rodent models of schizophrenia, which implements
neonatal hippocampal lesions (NVHL) is also characterized by an increase in
drug-taking behavior measured in self-administration paradigms (Brady et al.
2008;Chambers and Self 2002). Though not directly correlated with stimulant
seeking or taking behavior, NVHL rats show PPI deficits (Lipska et al. 1995).
These data call into question what aspects of addiction are modeled by CPP,
motor sensitization, and self administration and how these addictive behaviors
manifest and contribute to substance use disorders in the c0-morbid
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schizophrenia patient. The addiction model of CPP utilizes reward and
associative learning mechanisms, both of which relate to negative symptoms of
schizophrenia. Therefore, it is logical that our data demonstrate a negative
correlation between sensorimotor gating deficits and Meth-induced place
preference. The self-administration completed in the laboratories of Chambers
and O‟Donnell stress that schizophrenia-like rodents are motivated to perform an
operant task for a stimulant reinforcer (Brady et al. 2008;Chambers and Self
2002). The use of a progressive ratio schedule for Meth self-administration
nicely demonstrates that schizophrenia-like rats are even motivated to work
harder than control animals to receive Meth reinforcement (Brady et al. 2008).
The acute effects of Amph (e.g., euphoria, hyper-vigilance) appear to “sensitize”
with repeated exposure and can result in psychotic state that is akin to the
positive symptoms of schizophrenia (Angrist et al. 1980;Strakowski et al. 1996).
Thus, it is also logical that with both models of schizophrenia used in the current
project, the motor responses to Meth were greater than (i.e., sensitized) that
observed in controls (i.e., social). Therefore, we have determined that deficits in
sensorimotor gating induced by two very different means (i.e., repeated,
escalating Amph and isolation rearing), produce a phenotype that negatively
correlate to the rewarding and positively correlate to the motor effects of Meth.
There are many hypotheses as to why schizophrenia patients take illicit
substances. One of which is that schizophrenia patients are “self medicating”,
perhaps due to a reduced capacity to feel reward, or anhedonia (Khantzian 1997).
Another hypothesis is that schizophrenia patients are more vulnerable to the
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rewarding effects of abused substances (Krystal et al. 1999;Tseng et al. 2009).
These two hypotheses may go hand-in-hand: that is, negative symptoms may
predict as well as play a causal role in stimulant use. Both working memory and
anhedonia occur and predict substance abuse likelihood in schizophrenia
patients (Potvin et al. 2008a;Potvin et al. 2008b). Therefore, it may be
hypothesized that schizophrenia patients must take more stimulants in order to
experience their rewarding or reinforcing effects. Our studies also demonstrate
that the mGluR5 system may be critical in fine tuning the signaling necessary to
amplify the effects of stimulants in schizophrenia-like rats. Therefore,
modulation of mGluR5 may be a potential therapeutic target not only for Meth
addiction but also Meth addiction in the co-morbid schizophrenia patient.
In conclusion, the current dissertation project makes an important
contribution to the current understanding of mGluR5 function and expression in
the maintenance of Meth behaviors. Furthermore, these data and their
interpretation elucidate a role of mGluR5 in modulating rewarding signaling in
Meth abuse, schizophrenia co-morbidity.
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